<SEC-DOCUMENT>0001104659-22-030867.txt : 20220307
<SEC-HEADER>0001104659-22-030867.hdr.sgml : 20220307
<ACCEPTANCE-DATETIME>20220307073904
ACCESSION NUMBER:		0001104659-22-030867
CONFORMED SUBMISSION TYPE:	POSASR
PUBLIC DOCUMENT COUNT:		10
FILED AS OF DATE:		20220307
DATE AS OF CHANGE:		20220307
EFFECTIVENESS DATE:		20220307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scholar Rock Holding Corp
		CENTRAL INDEX KEY:			0001727196
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823750435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POSASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-254057
		FILM NUMBER:		22716262

	BUSINESS ADDRESS:	
		STREET 1:		301 BINNEY STREET
		STREET 2:		3RD FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		857-259-3860

	MAIL ADDRESS:	
		STREET 1:		301 BINNEY STREET
		STREET 2:		3RD FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>POSASR
<SEQUENCE>1
<FILENAME>tm228243-1_posasr.htm
<DESCRIPTION>POSASR
<TEXT>
<html>
  <head>
    <title>tm228243-1_posasr - none - 10.7656461s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-left:63pt;width:505.31pt;">
        <div style="text-align:center; width:505.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">As filed with the Securities and Exchange Commission on March&#160;7, 2022.</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="text-align:right; width:505.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Registration No. 333-254057</font>&#8203;</div>
        <div style="margin-top:2.5pt; width:505.31pt;">
          <div style="margin-left: 0pt; width: 505.31pt; margin-top: 2.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:505.31pt;">
          <div style="margin-left: 0pt; width: 505.31pt; margin-top: 3pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6pt; text-align:center; width:505.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">UNITED STATES </font>
          <br >
          <font style="letter-spacing:-0.28pt;">SECURITIES AND EXCHANGE COMMISSION</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:505.31pt; line-height:11pt;font-weight:bold;font-size:9pt;">
          <font style="letter-spacing:-0.18pt;">Washington, D.C. 20549</font><font style="font-weight:normal;letter-spacing:0.18pt;"> </font>
        </div>
        <div style="margin-top:6.5pt; text-align:center; width:505.31pt;">
          <div style="margin-left: 39.314%; margin-right: 39.314%; margin-top: 6.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6pt; text-align:center; width:505.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">POST-EFFECTIVE AMENDMENT NO. 1 </font>
          <br >
          <font style="letter-spacing:-0.28pt;">TO </font>
          <br >
          <font style="letter-spacing:-0.28pt;">FORM S-3</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:505.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">REGISTRATION STATEMENT </font>
          <br >
          <font style="letter-spacing:-0.16pt;">UNDER </font>
          <br >
          <font style="letter-spacing:-0.16pt;">THE SECURITIES ACT OF 1933</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:6.5pt; text-align:center; width:505.31pt;">
          <div style="margin-left: 39.314%; margin-right: 39.314%; margin-top: 6.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:8pt; text-align:center; width:505.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">SCHOLAR ROCK HOLDING CORPORATION</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="text-align:center; width:505.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">(Exact name of registrant as specified in its charter) </font>
        </div>
        <div style="margin-top:6.5pt; text-align:center; width:505.31pt;">
          <div style="margin-left: 39.314%; margin-right: 39.314%; margin-top: 6.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:505.31pt;height:26.17pt;margin-top:7.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:7.97999999999999pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:160.44pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Delaware</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:160.44pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:160.43pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">82-3750435</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:160.44pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">(State or other jurisdiction of </font>
                <br >
                <font style="letter-spacing:0.16pt;">incorporation or organization) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:160.44pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:160.43pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">(I.R.S. Employer </font>
                <br >
                <font style="letter-spacing:0.16pt;">Identification Number)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10pt; text-align:center; width:505.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">301 Binney Street, Cambridge, MA 02142</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:505.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">(Address of principal executive offices) </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:505.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">(857) 259-3860</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:505.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">(Registrant&#8217;s telephone number, including area code) </font>
        </div>
        <div style="margin-top:6.5pt; text-align:center; width:505.31pt;">
          <div style="margin-left: 39.314%; margin-right: 39.314%; margin-top: 6.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6pt; text-align:center; width:505.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Nagesh K. Mahanthappa </font>
          <br >
          <font style="letter-spacing:-0.16pt;">Interim President and Chief Executive Officer </font>
          <br >
          <font style="letter-spacing:-0.16pt;">301 Binney Street </font>
          <br >
          <font style="letter-spacing:-0.16pt;">Cambridge, MA 02142 </font>
          <br >
          <font style="letter-spacing:-0.16pt;">(857) 259-3860</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
          <br >
          <font style="font-weight:normal;letter-spacing:0.16pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </font>
        </div>
        <div style="margin-top:6.5pt; text-align:center; width:505.31pt;">
          <div style="margin-left: 39.314%; margin-right: 39.314%; margin-top: 6.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6pt; text-align:center; width:505.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">With copies to:</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <table style="width:505.31pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:160.44pt;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.16pt;">Kingsley L. Taft </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Laurie A. Burlingame </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Goodwin Procter LLP </font>
                <br >
                <font style="letter-spacing:-0.16pt;">100 Northern Ave. </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Boston, MA 02210 </font>
                <br >
                <font style="letter-spacing:-0.16pt;">(617) 570-1000</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:160.44pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:160.43pt;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.16pt;">Junlin Ho </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Scholar Rock Holding Corporation </font>
                <br >
                <font style="letter-spacing:-0.16pt;">301 Binney Street </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Cambridge, MA 02142 </font>
                <br >
                <font style="letter-spacing:-0.16pt;">(857) 259-3860</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:10pt; width:485.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective.</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: &#9746; </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&#160;462(e) under the Securities Act, check the following box. &#9746; </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&#160;413(b) under the Securities Act, check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </font>
        </div>
        <div style="margin-top:2pt; width:505.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">Large accelerated filer&#8199;&#9744; </font><font style="margin-left:52.55pt;letter-spacing:0.16pt;">Accelerated filer&#8199;&#9744; </font><font style="margin-left:52.55pt;letter-spacing:0.16pt;">Non-accelerated filer&#8199;&#9746; </font><font style="float:right;letter-spacing:0.16pt;">Smaller reporting company&#8199;&#9746; </font>
        </div>
        <div style="margin-left:20pt; margin-top:1pt; text-align:right; width:485.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">Emerging growth company&#8199;&#9746;</font>&#8203;</div>
        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9746;</font>
        </div>
        <div style="margin-top:6.5pt; text-align:center; width:505.31pt;">
          <div style="margin-left: 39.314%; margin-right: 39.314%; margin-top: 6.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:9.5pt; width:505.31pt;">
          <div style="margin-left: 0pt; width: 505.31pt; margin-top: 9.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:505.31pt;">
          <div style="margin-left: 0pt; width: 505.31pt; margin-top: 3pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-left:27pt;width:706pt;">
        <div style="width:706pt; line-height:9.5pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;">
          <font style="letter-spacing:-0.08pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPLANATORY NOTE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This Post-Effective Amendment No. 1 to the Registration Statement on <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000110465921033893/tm219041-1_s3asr.htm">Form S-3 (Commission File&#160;No. 333-254057)</a>, or the Automatic Shelf Registration Statement, of Scholar Rock Holding Corporation, or the Registrant, is being filed because the Registrant will no longer be a well-known seasoned issuer (as such term is defined in Rule&#160;405 of the Securities Act of 1933, as amended, or the Securities Act, when it files its Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021. This Post-Effective Amendment No. 1 is filed using EDGAR submission type POSASR and supplements disclosure to the Automatic Shelf Registration Statement required for a registrant other than a well-known seasoned issuer and makes certain other amendments. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This registration statement contains two prospectuses: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a base prospectus which covers the offering, issuance and sale by us of the securities identified above from time to time in one or more offerings with a total value of up to $300,000,000; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $150,000,000 of our common stock that may be issued and sold under a sales agreement with Jefferies LLC, or Jefferies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus other than the shares under the sales agreement will be specified in a prospectus supplement to the base prospectus. The specific terms of the securities to be issued and sold under the sales agreement are specified in the sales agreement prospectus that immediately follows the base prospectus. The common stock that may be offered, issued and sold under the sales agreement prospectus is included in the $300,000,000 of securities that may be offered, issued and sold by the registrant under the base prospectus. Upon termination of the sales agreement, any portion of the $150,000,000 included in the sales agreement prospectus that is not sold pursuant to the sales agreement will be available for sale in other offerings pursuant to the base prospectus.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lg_scholarrocknew-4clr.jpg" alt="[MISSING IMAGE: lg_scholarrocknew-4clr.jpg]" height="60" width="317" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:15pt;font-weight:bold;font-size:13pt;">
          <font style="letter-spacing:-0.26pt;">$300,000,000</font><font style="font-weight:normal;letter-spacing:0.26pt;"> </font>
        </div>
        <div style="margin-top:3pt; text-align:center; width:456pt; line-height:15pt;font-weight:bold;font-size:13pt;">
          <font style="letter-spacing:-0.26pt;">Common Stock </font>
          <br >
          <font style="letter-spacing:-0.26pt;">Preferred Stock </font>
          <br >
          <font style="letter-spacing:-0.26pt;">Debt Securities </font>
          <br >
          <font style="letter-spacing:-0.26pt;">Warrants </font>
          <br >
          <font style="letter-spacing:-0.26pt;">Units</font><font style="font-weight:normal;letter-spacing:0.26pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may from time to time offer and sell up to $300,000,000 in aggregate principal amount of, in one or more series or classes, our common stock, preferred stock, debt securities, warrants and/or&#160;units. We may offer these securities separately or together in&#160;units. We will specify in the accompanying prospectus supplement the terms of the securities being offered. We may sell these securities to or through underwriters and also to other purchasers or through agents. We will set forth the names of any underwriters or agents, and any fees, conversions, or discount arrangements, in the accompanying prospectus supplement. We may not sell any securities under this prospectus without delivery of the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should read this document and any prospectus supplement or amendment carefully before you invest in our securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;SRRK.&#8221; On March&#160;1, 2022, the closing price for our common stock, as reported on The Nasdaq Global Select Market, was $16.92 per share. Our principal executive offices are located at 301 Binney Street, Cambridge, MA 02142. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are an &#8220;emerging growth company&#8221; as defined by the Jumpstart Our Business Startups Act of 2012 and, as such, we are subject to reduced public company reporting requirements.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;</font><font style="font-style:italic;letter-spacing:-0.2pt;">Risk Factors</font><font style="letter-spacing:-0.2pt;">&#8221; contained in this prospectus beginning on page <a href="#tRIFA">2</a> and any applicable prospectus supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The date of this Prospectus is March&#160;7, 2022.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:357.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:233.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">About this Prospectus </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">1</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">Risk Factors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">2</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSRF"><font style="letter-spacing:0.2pt;">Cautionary Statement Regarding Forward-Looking Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSRF">3</a></font> <a href="#tCSRF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHCO"><font style="letter-spacing:0.2pt;">The Company </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHCO">5</a></font> <a href="#tTHCO"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">Use of Proceeds </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">7</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSWMO"><font style="letter-spacing:0.2pt;">Securities We May Offer </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSWMO">8</a></font> <a href="#tSWMO"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:0.2pt;">Description of Capital Stock </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOCS">9</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDODS"><font style="letter-spacing:0.2pt;">Description of Debt Securities </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDODS">16</a></font> <a href="#tDODS"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOW"><font style="letter-spacing:0.2pt;">Description of Warrants </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOW">30</a></font> <a href="#tDOW"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOU"><font style="letter-spacing:0.2pt;">Description of Units </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOU">31</a></font> <a href="#tDOU"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">Plan of Distribution </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">34</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">Legal Matters </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">36</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">Experts </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">36</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">Where You Can Find More Information </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">36</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIBR"><font style="letter-spacing:0.2pt;">Incorporation by Reference </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIBR">37</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:216pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of an automatic registration statement that we filed with the Securities and Exchange Commission, or the SEC, as a &#8220;well-known seasoned issuer&#8221; as defined in Rule&#160;405 under the Securities Act of 1933, as amended, using a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus provides you with a general description of the securities we may offer in one or more offerings for an aggregate offering amount of up to $300,000,000. Each time we sell securities, we will provide one or more prospectus supplements that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this prospectus and the accompanying prospectus supplement together with the additional information described under the heading &#8220;Where You Can Find More Information&#8221;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and the accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in the accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the context otherwise indicates, references in this prospectus to &#8220;Scholar Rock&#8221;, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221; and &#8220;the Company&#8221; refer, collectively, to Scholar Rock Holding Corporation and its subsidiaries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We own various U.S. federal trademark applications and unregistered trademarks, including &#8220;Scholar Rock&#8221; and our corporate logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the symbols </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> and </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#8482;</font><font style="letter-spacing:0.2pt;">, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:440pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. You should carefully consider the risks described in the documents incorporated by reference in this prospectus and any prospectus supplement, as well as other information we include or incorporate by reference into this prospectus and any applicable prospectus supplement, before making an investment decision. Our business, financial condition or results of operations could be materially adversely affected by the materialization of any of these risks. The trading price of our securities could decline due to the materialization of any of these risks, and you may lose all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks described below and in the documents incorporated herein by reference, including our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, which is on file with the SEC and is incorporated herein by reference, and other documents we file with the SEC that are deemed incorporated by reference into this prospectus. See &#8220;Where You Can Find More Information&#8221; for information about how to obtain a copy of these documents. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCSRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions, or the negative of these terms, or similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus, and in particular those factors referenced in the section &#8220;Risk Factors.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. These statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success, cost and timing of clinical trials for apitegromab, including the progress and completion of clinical trials for apitegromab, and the results, and the timing of results, from these trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success, cost and timing of preclinical studies and clinical trials for SRK-181, including, but not limited to, the results, progress and completion of our DRAGON Phase&#160;1 clinical trial for SRK-181, any future preclinical studies and future clinical trials for SRK-181, and the results, and the timing of results, from these trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success, cost and timing of our other product development activities, preclinical studies and clinical trials, and the results, and timing of results, from these studies and trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our success in identifying and executing a development program for additional indications for apitegromab, SRK-181 and in identifying product candidates from our other programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the clinical utility of our product candidates and their potential advantages over other therapeutic options; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to obtain, generally or on terms acceptable to us, funding for our operations, including funding necessary to complete further development and, upon successful development, if approved, commercialization of apitegromab, SRK-181 or any of our future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">risks associated with the COVID-19 pandemic, which may adversely impact our workforce, global supply chain, business, preclinical studies, clinical trials and financial results; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential for our identified research priorities to advance our proprietary platform, development programs or product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing, scope or likelihood of our ability to obtain and maintain regulatory approval from the U.S. Food and Drug Administration, or FDA, the European Commission and other regulatory authorities for apitegromab, SRK-181 and any future product candidates, and any related restrictions, limitations or warnings in the label of any approved product candidate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to continue to grow our organization, including our personnel, systems and relationships with third parties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to retain our executives and highly skilled technical and managerial personnel, which could be affected due to any transition in management, or if we fail to recruit additional highly skilled personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and the duration of such protection; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:192pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability and the potential to successfully manufacture our product candidates for clinical trials and for commercial use, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to establish or maintain collaborations or strategic relationships; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations relating to the potential of our proprietary platform technology; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to obtain additional funding when necessary; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets, either alone or in combination with others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations related to the use of our cash reserves; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact of new laws and regulations or amendments to existing laws and regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">developments and projections relating to our competitors and our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expected use of proceeds from this offering; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our estimates and expectations regarding cash and expense levels, future revenues, capital requirements and needs for additional financing, including our expected use of proceeds from our public offerings, and liquidity sources; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations regarding the period during which we qualify as an emerging growth company, or EGC, under the Jumpstart Our Business Startups Act. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have included important factors in the cautionary statements included in this prospectus and the documents we incorporate by reference herein, particularly in the &#8220;Risk Factors&#8221; sections of these documents, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. No forward-looking statement is a guarantee of future performance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should read this prospectus and the documents that we incorporate by reference in this prospectus completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements in this prospectus and the documents we incorporate by reference herein represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward- looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTHCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE COMPANY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following highlights information about the Registrant and our business contained elsewhere or incorporated by reference in this prospectus. It is not complete and does not contain all of the information that you should consider before investing in any of our securities. You should carefully read this prospectus together with the more detailed information incorporated by reference in this prospectus.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. By targeting the signaling proteins at the cellular level and acting in the disease microenvironment, we believe we may avoid the historical dose-limiting safety challenges associated with inhibiting growth factors for therapeutic effect. We believe our focus on biologically validated growth factors may facilitate a more efficient development path. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have a productive scientific platform and are building our portfolio of novel product candidates with the aim of transforming the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. We have discovered and progressed the development of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Apitegromab, an inhibitor of the activation of latent myostatin, for the treatment of spinal muscular atrophy (&#8220;SMA&#8221;). We also believe apitegromab could have potential in the treatment of other myostatin-related disorders. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (&#8220;TGF&beta;1&#8221;), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Potent and selective inhibitors of the activation of transforming growth factor beta (&#8220;TGF&beta;&#8221;) for the treatment of fibrotic diseases. We are advancing multiple antibody profiles toward product candidate selection including antibodies that selectively inhibit the activation of latent TGF&beta;1 in the context of fibrotic extracellular matrix and that avoid perturbing TGF&beta;1 presented by cells of the immune system. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Additional discovery and early preclinical programs related to the selective modulation of growth factor signaling including BMP6 and other growth factors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our first product candidate, apitegromab (formerly SRK-015), is a highly selective, fully human, monoclonal antibody, with a unique mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-directed therapy for the treatment of SMA. We are conducting SAPPHIRE, a pivotal Phase&#160;3 trial to evaluate the efficacy and safety of apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA (which is estimated to represent the majority of the current prevalent SMA patient population in the U.S. and Europe). Apitegromab was evaluated in our TOPAZ Phase&#160;2 proof-of-concept clinical trial for the treatment of patients with Type 2 and Type 3 SMA. Positive 12-month top-line results were announced in April&#160;2021 showing apitegromab&#8217;s transformative potential (see &#8220;TOPAZ Twelve-Month Analysis&#8221; below). The FDA granted fast track designation, rare pediatric disease designation and orphan drug designation to apitegromab for the treatment of SMA in May&#160;2021, August&#160;2020 and March&#160;2018, respectively. The European Medicines Agency (&#8220;EMA&#8221;) granted PRIority MEdicines (&#8220;PRIME&#8221;) designation in March&#160;2021 and the European Commission (&#8220;EC&#8221;) granted orphan medicinal product designation in December&#160;2018 to apitegromab for the treatment of SMA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our second product candidate, SRK-181, is being developed for the treatment of cancers that are resistant to checkpoint inhibitor therapies (&#8220;CPI therapies&#8221;), such as anti-PD-1 or anti-PD-L1 antibody therapies. SRK-181 is a highly selective inhibitor of the activation of latent TGF&beta;1 that is being investigated in our DRAGON Phase&#160;1 proof-of-concept clinical trial in patients with locally advanced or metastatic solid tumors that exhibit primary resistance to anti-PD-(L)1 antibodies. This two-part clinical trial consists of a dose escalation portion (Part&#160;A) and a dose expansion portion evaluating SRK-181 in combination with an approved anti-PD-(L)1 antibody therapy (Part&#160;B). Part&#160;B encompasses five cohorts, including urothelial carcinoma, cutaneous melanoma, non-small cell lung cancer, clear cell renal cell carcinoma and other solid </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:26pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">tumors and commenced in 2021. Initial clinical data from Part&#160;A were presented in November&#160;2021 at the Society for Immunotherapy of Cancer (&#8220;SITC&#8221;) 36th Annual Meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our approach and proprietary platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Beyond these programs, we continue to discover and develop highly specific monoclonal antibodies to selectively modulate growth factor signaling. Growth factors are naturally occurring proteins that typically act as signaling molecules between cells and play a fundamental role in regulating a variety of normal cellular processes, including cell growth and differentiation. Current therapeutic approaches to treating diseases in which growth factors play a fundamental role involve directly targeting the active form of the growth factor or its receptor systemically throughout the body. These approaches have suffered from a variety of shortcomings, including lack of pathway selectivity, lack of target selectivity, and non-localized target inhibition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our innovative approach is rooted in our structural biology insights into the mechanism by which certain growth factors are activated in close proximity to the cell surface. We integrate these insights with sophisticated protein expression, assay development and monoclonal antibody discovery capabilities. We believe our proprietary platform can address the challenges of treating diseases in which growth factors play a fundamental role by: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">targeting the natural activation mechanism to prevent activation of the growth factor rather than attempting to inhibit the growth factor after activation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">achieving heightened specificity for the targeted growth factor while minimizing interactions with structurally similar and related growth factors, thereby potentially reducing the risk of unintended systemic adverse events; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">targeting the disease microenvironment, where we believe we can interfere with the disease process while minimizing the effects on the normal physiological processes mediated by the same growth factors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Company information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We were incorporated in 2017 under the laws of the State of Delaware as the holding company for Scholar Rock, Inc. Scholar Rock, Inc. is a wholly owned subsidiary of Scholar Rock Holding Corporation. On December&#160;22, 2017, we completed a series of transactions pursuant to which Scholar Rock Merger&#160;Sub, LLC, a wholly owned subsidiary of Scholar Rock Holding Corporation, was merged with and into Scholar Rock, LLC, or the Reorganization. The purpose of the Reorganization was to reorganize our corporate structure so that we would continue as a corporation and so that our investors prior to the Reorganization would own our capital stock after the Reorganization rather than equity interests in a limited liability company. All of our convertible preferred stock converted into shares of common stock upon the completion of our initial public offering at the then effective conversion ratio. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential product candidates, producing drug substance and drug product material for use in preclinical studies and clinical trials, conducting preclinical studies of our product candidates and conducting clinical trials for our product candidates, apitegromab (formerly SRK-015) and SRK-181. We do not have any products approved for sale and have not generated any product revenue to date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our principal executive offices are located at 301 Binney Street, Cambridge, MA 02142, and our phone number is (857) 259-3860. Our website address is http://www.scholarrock.com. The information contained on our website or social media accounts, or that can be accessed through our website or social media accounts, is not a part of this prospectus and is not incorporated by reference into this prospectus. You should not rely on any such information in deciding whether to purchase our common stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:500pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include research and development costs, including the conduct of clinical trials and process development and manufacturing of our product candidates, services or technologies, expansion of our technology infrastructure and capabilities, working capital and capital expenditures. We may temporarily invest the net proceeds in a variety of capital preservation instruments, including investment grade, interest bearing instruments and U.S. government securities, until they are used for their stated purpose. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSWMO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">SECURITIES WE MAY OFFER</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains summary descriptions of the securities we may offer from time to time. These summary descriptions are not meant to be complete descriptions of each security. The particular terms of any security will be described in the applicable prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following description of our common stock and preferred stock, together with the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of the common stock and preferred stock that we may offer under this prospectus. The following description of our capital stock does not purport to be complete and is subject to, and qualified in its entirety by, our Amended and Restated Certificate of Incorporation, as amended to date, and our Amended and Restated Bylaws, which are exhibits to the registration statement of which this prospectus forms a part, and by applicable law. We refer in this section to our Amended and Restated Certificate of Incorporation, as amended to date, as our &#8220;certificate of incorporation,&#8221; and we refer to our Amended and Restated Bylaws as our &#8220;bylaws.&#8221; The terms of our common stock and preferred stock may also be affected by Delaware law. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Authorized Capital Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our authorized capital stock consists of 150,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share, all of which shares of preferred stock are undesignated. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2021, 35,209,099 shares of our common stock were outstanding and held by approximately 10 stockholders of record. In addition, as of December&#160;31, 2021, we had outstanding options to purchase 3,743,400 shares of our common stock, at a weighted-average exercise price of $25.55 per share, 1,544,062 of which were exercisable and 314,901 shares of unvested restricted stock&#160;units. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us will be, when issued and paid for, validly issued, fully paid and non-assessable. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Listing</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;SRRK.&#8221; On March&#160;1, 2022, the closing price for our common stock, as reported on The Nasdaq Global Select Market, was $16.92 per share. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Prefunded Warrants for Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2020, the Company sold pre-funded warrants to purchase 2,179,487 shares of common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Form.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The pre-funded warrants are issued as individual warrant agreements to each individual purchaser of a pre-funded warrant. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Term.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The pre-funded warrants do not expire. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exercisability.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The pre-funded warrants are exercisable at any time after their original issuance. The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">duly executed exercise notice and by payment in full of the exercise price in immediately available funds for the number of shares of our common stock purchased upon such exercise. As an alternative to payment of the exercise price in immediately available funds, the holder may elect to exercise the pre-funded warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of our common stock determined according to the formula set forth in the pre-funded warrants. No fractional shares of our common stock will be issued in connection with the exercise of a pre-funded warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the last closing trading price of our common stock on the exercise date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exercise limitations</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Under the pre-funded warrants, we may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant, which, upon giving effect to such exercise, would cause (i)&#160;the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii)&#160;the combined voting power of our securities beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such&#160;percentage ownership is determined in accordance with the terms of the pre-funded warrants. However, any holder may increase or decrease such&#160;percentage to any other&#160;percentage not in excess of 19.99% upon at least 61&#160;days&#8217; prior notice from the holder to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Exercise price</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The exercise price per whole share of our common stock purchasable upon the exercise of the pre-funded warrants is $0.0001 per share of our common stock. The exercise price of the prefunded warrants and the number of shares of our common stock issuable upon exercise of the pre-funded warrants are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. The exercise price will not be adjusted below the par value of our common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Transferability.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to applicable laws, the pre-funded warrants may be offered for sale, sold, transferred or assigned without our consent. The pre-funded warrants will be held in definitive form by the warrant agent. The ownership of the pre-funded warrants and any transfers of the pre-funded warrants will be registered in a warrant register maintained by the warrant agent. We will initially act as warrant agent. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Undesignated Preferred Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors or any authorized committee thereof has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. No shares of preferred stock are outstanding, and we have no present plans to issue any shares of preferred stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The purpose of authorizing our board of directors to issue preferred stock in one or more series and determine the number of shares in the series and its rights and preferences is to eliminate delays associated with a shareholder vote on specific issuances. Examples of rights and preferences that the board of directors may fix are: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">dividend rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">dividend rates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">conversion rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">voting rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">terms of redemption; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">liquidation preferences. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The existence of authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer, stockholder or stockholder group. The rights of holders of our common stock described above will be subject to, and may be adversely affected by, the rights of any preferred stock that we may designate and issue in the future. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Additional Series of Preferred Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will incorporate by reference as an exhibit to the registration statement, which includes this prospectus, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering. This description and the applicable prospectus supplement will include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the title and stated value; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number of shares authorized; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the liquidation preference per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the purchase price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the dividend rate, period and payment date, and method of calculation for dividends; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the procedures for any auction and remarketing, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the provisions for a sinking fund, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any listing of the preferred stock on any securities exchange or market; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">voting rights, if any, of the preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">preemptive rights, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions on transfer, sale or other assignment, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether interests in the preferred stock will be represented by depositary shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a discussion of any material United States federal income tax considerations applicable to the preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">When we issue shares of preferred stock under this prospectus, the shares will fully be paid and nonassessable and will not have, or be subject to, any preemptive or similar rights. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Registration Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Gilead Sciences, Inc., or Gilead,, is entitled to rights with respect to the registration of certain shares under the Securities Act pursuant to a registration rights agreement, or Registration Rights Agreement, and include demand registration rights, short-form and shelf registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations, subject to certain restrictions, will be borne by us and all selling expenses, including underwriting discounts and selling commissions, will be borne by Gilead. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Demand Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the Registration Rights Agreement with Gilead, beginning on December&#160;19, 2020, we are required, upon the written request of the stockholder to register securities with an aggregate value of at least $10.0&#160;million based on then-current value of the securities, to use reasonable best efforts to effect the registration of such shares on Form S-1, subject to certain exceptions. Under the terms of the Registration Rights Agreement, we are required to effect up to two registrations pursuant to this provision, and the short-form and shelf registration rights provisions of the Registration Rights Agreement, except that the number of shelf takedowns that are not underwritten offerings are not limited. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">An aggregate of up to 980,392 shares of common stock are entitled to the demand registration rights under the Registration Rights Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Short-Form and Shelf Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the Registration Rights Agreement, beginning on December&#160;19, 2020, if we are eligible to file a registration statement on Form S-3, upon the written request of the stockholder to register securities with an aggregate value of at least $3.0&#160;million based on then-current value of the securities, we will use reasonable best efforts to cause registration of the securities on Form S-3. In addition, under the terms of the Registration Rights Agreement, upon the written request of the stockholder, we will be required to file a shelf registration statement on Form S-3 to register the securities pursuant to Securities Act Rule&#160;415 and use our reasonable best efforts to cause such shelf registration statement to become effective, subject to certain exceptions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The right to have such shares registered on Form S-3 is further subject to other specified conditions and limitations in each case. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">An aggregate of up to 980,392 shares of common stock are entitled to the Form S-3 registration rights under the Registration Rights Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Piggyback Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we propose to register any of our securities, either for our own account or for the account of other security holders, under the Registration Rights Agreement, we will use reasonable best efforts to include the stockholder&#8217;s shares in the registration. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Registration Rights Agreement, subject to certain exceptions, the underwriters may limit the number of shares included in the underwritten offering to the number of shares which the underwriters determine in their sole discretion will not jeopardize the success of the offering, including, specifically, where the underwriter has determined that in their opinion there is a risk that the price of the securities will be reduced or the number of securities intended to be included on our behalf will be reduced. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">An aggregate of up to 980,392 shares of common stock are entitled to these piggyback registration rights under the Registration Rights Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Registration Rights Agreement contains customary cross- indemnification provisions, under which we are obligated to indemnify the stockholder in the event of material misstatements or omissions in the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">registration statement attributable to us, and the stockholder is obligated to indemnify us for material misstatements or omissions attributable to it. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Expiration of Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The registration rights granted under the Registration Rights Agreement will terminate, with respect to 50% of the Registrable Securities held by the stockholder, on December&#160;19, 2023 and with respect to 50% of the Registrable Securities held by the stockholder, on December&#160;19, 2024. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-Takeover Effects of Our Certificate of Incorporation and Our Bylaws</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our certificate of incorporation and bylaws contain certain provisions that are intended to enhance the likelihood of continuity and stability in the composition of the board of directors and which may have the effect of delaying, deferring or preventing a future takeover or change in control of the company unless such takeover or change in control is approved by the board of directors. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These provisions include: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Classified Board.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our certificate of incorporation provides that our board of directors is divided into three classes of directors, with the classes as nearly equal in number as possible. As a result, approximately one-third of our board of directors will be elected each year. The classification of directors has the effect of making it more difficult for stockholders to change the composition of our board. Our certificate of incorporation provides that, subject to any rights of holders of preferred stock to elect additional directors under specified circumstances, the number of directors will be fixed exclusively pursuant to a resolution adopted by our board of directors. Our board of directors has eight members. Our certificate of incorporation provides that the affirmative vote of at least two-thirds of the outstanding shares of capital stock entitled to vote, and the affirmative vote of at least two-thirds of the outstanding shares of each class entitled to vote as a class, is required to amend or repeal the foregoing provision. This requirement of a supermajority vote to amend or repeal that provision of our bylaws could enable a minority of our stockholders to prevent a declassification of our Board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Action by Written Consent; Special Meetings of Stockholders.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our certificate of incorporation provides that stockholder action can be taken only at an annual or special meeting of stockholders and cannot be taken by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders. Our certificate of incorporation provides that the affirmative vote of at least two-thirds of the outstanding shares of capital stock entitled to vote, and the affirmative vote of at least two-thirds of the outstanding shares of each class entitled to vote as a class, is required to amend or repeal the foregoing provision. Our certificate of incorporation and bylaws provide that, except as otherwise required by law, special meetings of the stockholders can be called only by or at the direction of the board of directors pursuant to a resolution adopted by a majority of the total number of directors, and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. Stockholders are not permitted to call a special meeting or to require the board of directors to call a special meeting. Our bylaws provide that the affirmative vote of at least two thirds of the outstanding shares entitled to vote, and of each class entitled to vote, respectively, is required to amend the or repeal the provision in our bylaws that&#160;provides that special meetings of the stockholders can be called only by or at the direction of the board of directors pursuant to a resolution adopted by a majority of the total number of directors, unless the Board first recommends such amendment or repeal to stockholders. This requirement of a supermajority vote to amend or repeal that provision of our bylaws could enable a minority of our stockholders to prevent a change to such provision and has the effect of making it more difficult for stockholders to call a special meeting of stockholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Removal of Directors.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our certificate of incorporation provides that our directors may be removed only for cause and then only by the affirmative vote of the holders of two-thirds or more of the shares then entitled to vote at an election of directors, at a meeting of the stockholders called for that purpose. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. This requirement of a supermajority vote to remove directors could enable a minority of our stockholders to prevent a change in the composition of our board, and the treatment of vacancies also has the effect of making it more difficult for stockholders to change the composition of our board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Advance Notice Procedures.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90&#160;days nor more than 120&#160;days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content of all stockholders&#8217; notices. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our secretary timely written notice, in proper form, of the stockholder&#8217;s intention to bring that&#160;business before the meeting. Although the bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, the bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Super Majority Approval Requirements and Amendment to Certificate of Incorporation and Bylaws.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder&#160;action, board composition, limitation of liability and the amendment of our bylaws and certificate of incorporation must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws, and may also be amended by the affirmative vote of at least two-thirds of the outstanding shares entitled to vote on the amendment, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Authorized but Unissued Shares.</font><font style="letter-spacing:0.2pt;"> Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital and corporate acquisitions. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of convertible preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of convertible preferred stock. The issuance of shares of convertible preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Choice of Forum.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:36pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(1) any derivative action or proceeding brought on our behalf; (2)&#160;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&#160;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4)&#160;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5)&#160;any action asserting a claim governed by the internal affairs doctrine. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, our bylaws contain a provision by virtue of which, unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts will be the exclusive forum for any complaint asserting a cause of action arising under the Securities Act. In addition, our bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have chosen the United States District Court for the District of Massachusetts as the exclusive forum for such causes of action because our principal executive offices are located in Cambridge, Massachusetts. Some companies that have adopted similar federal district court forum selection provisions are currently subject to a suit in the Court of Chancery of the State of Delaware brought by stockholders who assert that the federal district court forum selection provision is not enforceable. While the Delaware Supreme Court ruled in March&#160;2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our federal forum selection provision, and we may incur additional costs of litigation should such enforceability be challenged. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;203 of the Delaware General Corporation Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law, or Section&#160;203. In general, Section&#160;203 prohibits a publicly-held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or did own within three&#160;years prior to the determination of interested stockholder status, 15% or more of the corporation&#8217;s voting stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: before the stockholder became interested, the board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#8217; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDODS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF DEBT SECURITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The paragraphs below describe the general terms and provisions of the debt securities we may issue. When we offer to sell a particular series of debt securities, we will describe the specific terms of the securities in a supplement to this prospectus, including any additional covenants or changes to existing covenants relating to such series. The prospectus supplement also will indicate whether the general terms and provisions described in this prospectus apply to a particular series of debt securities. You should read the actual indenture if you do not fully understand a term or the way we use it in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may offer senior or subordinated debt securities. Each series of debt securities may have different terms. The senior debt securities will be issued under one or more senior indentures, dated as of a date prior to such issuance, between us and the trustee identified in the applicable prospectus supplement, as amended or supplemented from time to time. We will refer to any such indenture throughout this prospectus as the &#8220;senior indenture.&#8221; Any subordinated debt securities will be issued under one or more separate indentures, dated as of a date prior to such issuance, between us and the trustee identified in the applicable prospectus supplement, as amended or supplemented from time to time. We will refer to any such indenture throughout this prospectus as the &#8220;subordinated indenture&#8221; and to the trustee under the senior or subordinated indenture as the &#8220;trustee.&#8221; The senior indenture and the subordinated indenture are sometimes collectively referred to in this prospectus as the &#8220;indentures.&#8221; The indentures will be subject to and governed by the Trust Indenture Act of 1939, as amended. We included copies of the forms of the indentures as exhibits to our registration statement and they are incorporated into this prospectus by reference. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we issue debt securities at a discount from their principal amount, then, for purposes of calculating the aggregate initial offering price of the offered securities issued under this prospectus, we will include only the initial offering price of the debt securities and not the principal amount of the debt securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have summarized below the material provisions of the indentures and the debt securities, or indicated which material provisions will be described in the related prospectus supplement. The prospectus supplement relating to any particular securities offered will describe the specific terms of the securities, which may be in addition to or different from the general terms summarized in this prospectus. Because the summary in this prospectus and in any prospectus supplement does not contain all of the information that you may find useful, you should read the documents relating to the securities that are described in this prospectus or in any applicable prospectus supplement. Please read &#8220;Where You Can Find More Information&#8221; to find out how you can obtain a copy of those documents. Except as otherwise indicated, the terms of the indentures are identical. As used under this caption, the term &#8220;debt securities&#8221; includes the debt securities being offered by this prospectus and all other debt securities issued by us under the indentures. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The indentures: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">do not limit the amount of debt securities that we may issue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">allow us to issue debt securities in one or more series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">do not require us to issue all of the debt securities of a series at the same time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">allow us to reopen a series to issue additional debt securities without the consent of the holders of the debt securities of such series; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that the debt securities will be unsecured, except as may be set forth in the applicable prospectus supplement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless we give you different information in the applicable prospectus supplement, the senior debt securities will be unsubordinated obligations and will rank equally with all of our other senior unsecured and unsubordinated indebtedness. Payments on the subordinated debt securities will be subordinated to the prior payment in full of all of our senior indebtedness, as described under &#8220;Description of Debt Securities&#8201;&#8212;&#8201;Subordination&#8221; and in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each indenture provides that we may, but need not, designate more than one trustee under an indenture. Any trustee under an indenture may resign or be removed and a successor trustee may be appointed to act </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">with respect to the series of debt securities administered by the resigning or removed trustee. If two or more persons are acting as trustee with respect to different series of debt securities, each trustee shall be a&#160;trustee of a trust under the applicable indenture separate and apart from the trust administered by any other trustee. Except as otherwise indicated in this prospectus, any action described in this prospectus to be taken by each trustee may be taken by each trustee with respect to, and only with respect to, the one or more series of debt securities for which it is trustee under the applicable indenture. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The prospectus supplement for each offering will provide the following terms, where applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the title of the debt securities and whether they are senior or subordinated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the aggregate principal amount of the debt securities being offered, the aggregate principal amount of the debt securities outstanding as of the most recent practicable date and any limit on their aggregate principal amount, including the aggregate principal amount of debt securities authorized; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the price at which the debt securities will be issued, expressed as a&#160;percentage of the principal and, if other than the principal amount thereof, the portion of the principal amount thereof payable&#160;upon declaration of acceleration of the maturity thereof or, if applicable, the portion of the principal amount of such debt securities that is convertible into common stock or other securities of ours or the&#160;method by which any such portion shall be determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if convertible, the terms on which such debt securities are convertible, including the initial conversion price or rate and the conversion period and any applicable limitations on the ownership or transferability of common stock or other securities of ours received on conversion; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the date or dates, or the method for determining the date or dates, on which the principal of the debt securities will be payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the fixed or variable interest rate or rates of the debt securities, or the method by which the interest rate or rates is determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the date or dates, or the method for determining the date or dates, from which interest will accrue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the dates on which interest will be payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the record dates for interest payment dates, or the method by which such dates will be determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the persons to whom interest will be payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the basis upon which interest will be calculated if other than that of a 360-day year of twelve 30- day&#160;months; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any make-whole amount, which is the amount in addition to principal and interest that is required to be paid to the holder of a debt security as a result of any optional redemption or accelerated payment of such debt security, or the method for determining the make-whole amount; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the place or places where the principal of, and any premium or make-whole amount, and interest on, the debt securities will be payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">where the debt securities may be surrendered for registration of transfer or conversion or exchange; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">where notices or demands to or upon us in respect of the debt securities and the applicable indenture may be served; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the times, prices and other terms and conditions upon which we may redeem the debt securities; any obligation we have to redeem, repay or purchase the debt securities pursuant to any sinking fund or analogous provision or at the option of holders of the debt securities, and the times and prices at which we must redeem, repay or purchase the debt securities as a result of such obligation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the currency or currencies in which the debt securities are denominated and payable if other than United States dollars, which may be a foreign currency or&#160;units of two or more foreign currencies or a composite currency or currencies and the terms and conditions relating thereto, and the manner of determining the equivalent of such foreign currency in United States dollars; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether the principal of, and any premium or make-whole amount, or interest on, the debt securities of the series are to be payable, at our election or at the election of a holder, in a currency or currencies </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">other than that in which the debt securities are denominated or stated to be payable, and other related terms and conditions; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether the amount of payments of principal of, and any premium or make-whole amount, or interest on, the debt securities may be determined according to an index, formula or other method and how such amounts will be determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether the debt securities will be in registered form, bearer form, or both, and (i)&#160;if in registered form, the person to whom any interest shall be payable, if other than the person in whose name the security is registered at the close of business on the regular record date for such interest, or (ii)&#160;if in bearer form, the manner in which, or the person to whom, any interest on the security shall be payable if otherwise than upon presentation and surrender upon maturity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any restrictions applicable to the offer, sale or delivery of securities in bearer form and the terms upon which securities in bearer form of the series may be exchanged for securities in registered form of the series and vice versa, if permitted by applicable laws and regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether any debt securities of the series are to be issuable initially in temporary global form and whether any debt securities of the series are to be issuable in permanent global form with or without coupons and, if so, whether beneficial owners of interests in any such permanent global security may, or shall be required to, exchange their interests for other debt securities of the series, and the manner in which interest shall be paid; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the identity of the depositary for securities in registered form, if such series are to be issuable as a global security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the date as of which any debt securities in bearer form or in temporary global form shall be dated if other than the original issuance date of the first security of the series to be issued; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the applicability, if any, of the defeasance and covenant defeasance provisions described in this prospectus or in the applicable indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether and under what circumstances we will pay any additional amounts on the debt securities in respect of any tax, assessment or governmental charge and, if so, whether we will have the option to redeem the debt securities in lieu of making such a payment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether and under what circumstances the debt securities being offered are convertible into common stock or other securities of ours, as the case may be, including the conversion price or rate and the manner or calculation thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the circumstances, if any, specified in the applicable prospectus supplement, under which beneficial owners of interests in the global security may obtain definitive debt securities and the manner in which payments on a permanent global debt security will be made if any debt securities are issuable in temporary or permanent global form; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any provisions granting special rights to holders of securities upon the occurrence of such events as specified in the applicable prospectus supplement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if the debt securities of such series are to be issuable in definitive form only upon receipt of certain certificates or other documents or satisfaction of other conditions, then the form and/or terms of such certificates, documents or conditions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the name of the applicable trustee and the nature of any material relationship with us or any of our affiliates, and the&#160;percentage of debt securities of the class necessary to require the trustee to take action; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any deletions from, modifications of or additions to our events of default or covenants with regard to such debt securities and any change in the right of any trustee or any of the holders to declare the principal amount of any of such debt securities due and payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">applicable CUSIP numbers; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any other terms of such debt securities not inconsistent with the provisions of the applicable indenture. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue debt securities that provide for less than the entire principal amount thereof to be payable upon declaration of acceleration of the maturity of the debt securities. We refer to any such debt securities throughout this prospectus as &#8220;original issue discount securities.&#8221; The applicable prospectus supplement will describe the United States federal income tax consequences and other relevant considerations applicable to original issue discount securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also may issue indexed debt securities. Payments of principal of, and premium and interest on, indexed debt securities are determined with reference to the rate of exchange between the currency or currency unit in which the debt security is denominated and any other currency or currency unit specified by us, to the relationship between two or more currencies or currency&#160;units or by other similar methods or formulas specified in the prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except as described under &#8220;&#8212; Merger, Consolidation or Sale of Assets&#8221; or as may be set forth in any prospectus supplement, the debt securities will not contain any provisions that (i)&#160;would limit our ability to incur indebtedness or (ii)&#160;would afford holders of debt securities protection in the event of (a)&#160;a highly leveraged or similar transaction involving us, or (b)&#160;a change of control or reorganization, restructuring, merger or similar transaction involving us that may adversely affect the holders of the debt securities. In the future, we may enter into transactions, such as the sale of all or substantially all of our assets or a merger or consolidation, that may have an adverse effect on our ability to service our indebtedness, including the debt securities, by, among other things, substantially reducing or eliminating our assets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our governing instruments do not define the term &#8220;substantially all&#8221; as it relates to the sale of assets. Additionally, Delaware cases interpreting the term &#8220;substantially all&#8221; rely upon the facts and circumstances of each particular case. Consequently, to determine whether a sale of &#8220;substantially all&#8221; of our assets has occurred, a holder of debt securities must review the financial and other information that we have disclosed to the public. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will provide you with more information in the applicable prospectus supplement regarding any deletions, modifications, or additions to the events of default or covenants that are described below, including any addition of a covenant or other provision providing event risk or similar protection. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Payment</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless we give you different information in the applicable prospectus supplement, the principal of, and any premium or make-whole amount, and interest on, any series of the debt securities will be payable at the corporate trust office of the trustee. We will provide you with the address of the trustee in the applicable prospectus supplement. We may also pay interest by mailing a check to the address of the person entitled to it as it appears in the applicable register for the debt securities or by wire transfer of funds to that person at an account maintained within the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All monies that we pay to a paying agent or a trustee for the payment of the principal of, and any premium or make-whole amount, or interest on, any debt security will be repaid to us if unclaimed at the end of two&#160;years after the obligation underlying payment becomes due and payable. After funds have been returned to us, the holder of the debt security may look only to us for payment, without payment of interest for the period which we hold the funds. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Denomination, Interest, Registration and Transfer</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise described in the applicable prospectus supplement, the debt securities of any series will be issuable in denominations of $1,000 and integral multiples of $1,000. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the limitations imposed upon debt securities that are evidenced by a computerized entry in the records of a depository company rather than by physical delivery of a note, a holder of debt securities of any series may: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">exchange them for any authorized denomination of other debt securities of the same series and of a like aggregate principal amount and kind upon surrender of such debt securities at the corporate trust office of the applicable trustee or at the office of any transfer agent that we designate for such purpose; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">surrender them for registration of transfer or exchange at the corporate trust office of the applicable trustee or at the office of any transfer agent that we designate for such purpose. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Every debt security surrendered for registration of transfer or exchange must be duly endorsed or accompanied by a written instrument of transfer satisfactory to the applicable trustee or transfer agent. Payment of a service charge will not be required for any registration of transfer or exchange of any debt securities, but we or the trustee may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. If in addition to the applicable trustee, the applicable prospectus supplement refers to any transfer agent initially designated by us for any series of debt securities, we may at any time rescind the designation of any such transfer agent or approve a change in the location through which any such transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for such series. We may at any time designate additional transfer agents for any series of debt securities. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we, nor any trustee, will be required to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">issue, register the transfer of or exchange debt securities of any series during a period beginning at the opening of business 15&#160;days before the day that the notice of redemption of any debt securities selected for redemption is mailed and ending at the close of business on the day of such mailing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">register the transfer of or exchange any debt security, or portion thereof, so selected for redemption, in whole or in part, except the unredeemed portion of any debt security being redeemed in part; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">issue, register the transfer of or exchange any debt security that has been surrendered for repayment at the option of the holder, except the portion, if any, of such debt security not to be so repaid. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Merger, Consolidation or Sale of Assets</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The indentures provide that we may, without the consent of the holders of any outstanding debt securities, (i)&#160;consolidate with, (ii)&#160;sell, lease or convey all or substantially all of our assets to, or (iii)&#160;merge with or into, any other entity provided that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">either we are the continuing entity, or the successor entity, if other than us, assumes the obligations (a) to pay the principal of, and any premium or make-whole amount, and interest on, all of the debt securities and (b)&#160;to duly perform and observe all of the covenants and conditions contained in each indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">after giving effect to the transaction, there is no event of default under the indentures and no event which, after notice or the lapse of time, or both, would become such an event of default, occurs and continues; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an officers&#8217; certificate and legal opinion covering such conditions are delivered to each applicable trustee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Covenants</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Existence.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except as described under &#8220;&#8212; Merger, Consolidation or Sale of Assets,&#8221; the indentures require us to do or cause to be done all things necessary to preserve and keep in full force and effect our existence, rights and franchises. However, the indentures do not require us to preserve any right or franchise if we determine that any right or franchise is no longer desirable in the conduct of our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Payment of taxes and other claims.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The indentures require us to pay, discharge or cause to be paid or discharged, before they become delinquent (i)&#160;all taxes, assessments and governmental charges levied or imposed on us, and (ii)&#160;all lawful claims for labor, materials and supplies which, if unpaid, might by law become a lien upon our property. However, we will not be required to pay, discharge or cause to be paid or discharged any such tax, assessment, charge or claim whose amount, applicability or validity is being contested in good faith by appropriate proceedings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Provision of financial information.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The indentures require us to (i)&#160;within 15&#160;days of each of the respective dates by which we are required to file our annual reports, quarterly reports and other documents </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">with the SEC, file with the trustee copies of the annual report, quarterly report and other documents that we file with the SEC under Section&#160;13 or 15(d) of the Exchange Act, (ii)&#160;file with the trustee and the SEC any additional information, documents and reports regarding compliance by us with the conditions and covenants of the indentures, as required, (iii)&#160;within 30&#160;days after the filing with the trustee, mail to all holders of debt securities, as their names and addresses appear in the applicable register for such debt securities, without cost to such holders, summaries of any documents and reports required to be filed by us pursuant to (i)&#160;and (ii)&#160;above, and (iv)&#160;supply, promptly upon written request and payment of the reasonable cost of duplication and delivery, copies of such documents to any prospective holder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Additional covenants.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The applicable prospectus supplement will set forth any of our additional covenants relating to any series of debt securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Events of Default, Notice and Waiver</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the applicable prospectus supplement states otherwise, when we refer to &#8220;events of default&#8221; as defined in the indentures with respect to any series of debt securities, we mean: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">default in the payment of any installment of interest on any debt security of such series continuing for 30&#160;days; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">default in the payment of principal of, or any premium or make-whole amount on, any debt security of such series for five business days at its stated maturity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">default in making any sinking fund payment as required for any debt security of such series for five business days; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">default in the performance or breach of any covenant or warranty in the debt securities or in the indenture by us continuing for 60&#160;days after written notice as provided in the applicable indenture, but not of a covenant added to the indenture solely for the benefit of a series of debt securities issued thereunder other than such series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a default under any bond, debenture, note, mortgage, indenture or instrument: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">having an aggregate principal amount of at least $30,000,000; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">under which there may be issued, secured or evidenced any existing or later created indebtedness for money borrowed by us, if we are directly responsible or liable as obligor or guarantor, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">if the default results in the indebtedness becoming or being declared due and payable prior to the date it otherwise would have, without such indebtedness having been discharged, or such acceleration having been rescinded or annulled, within 30&#160;days after notice to the issuing company specifying such default. Such notice shall be given to us by the trustee, or to us and the trustee by the holders of at least 10% in principal&#160;amount of the outstanding debt securities of that series. The written notice shall specify such default and require us to cause such indebtedness to be discharged or cause such acceleration to be rescinded or annulled and shall state that such notice is a &#8220;Notice of Default&#8221; under such indenture; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">bankruptcy, insolvency or reorganization, or court appointment of a receiver, liquidator or trustee of us; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any other event of default provided with respect to a particular series of debt securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If an event of default occurs and is continuing with respect to debt securities of any series outstanding, then the applicable trustee or the holders of 25% or more in principal amount of the debt securities of that series will have the right to declare the principal amount of all the debt securities of that series to be due and payable. If the debt securities of that series are original issue discount securities or indexed securities, then the applicable trustee or the holders of 25% or more in principal amount of the debt securities of that series will have the right to declare the portion of the principal amount as may be specified in the terms thereof to be due and payable. However, at any time after such a declaration of acceleration has been made, but before a judgment or decree for payment of the money due has been obtained by the applicable trustee, the&#160;holders </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">of at least a majority in principal amount of outstanding debt securities of such series or of all debt securities then outstanding under the applicable indenture may rescind and annul such declaration and its consequences if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we have deposited with the applicable trustee all required payments of the principal, any premium or make-whole amount, interest and, to the extent permitted by law, interest on overdue installment of interest, plus applicable fees, expenses, disbursements and advances of the applicable trustee; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">all events of default, other than the non-payment of accelerated principal, or a specified portion thereof, and any premium or make-whole amount, have been cured or waived. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The indentures also provide that the holders of at least a majority in principal amount of the outstanding debt securities of any series or of all debt securities then outstanding under the applicable indenture may, on behalf of all holders, waive any past default with respect to such series and its consequences, except a default: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">in the payment of the principal, any premium or make-whole amount, or interest; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">in respect of a covenant or provision contained in the applicable indenture that cannot be modified or amended without the consent of the holders of the outstanding debt security that is affected by the default; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">in respect of a covenant or provision for the benefit or protection of the trustee, without its express written consent. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The indentures require each trustee to give notice to the holders of debt securities within 90&#160;days of a default unless such default has been cured or waived. However, the trustee may withhold notice if specified persons of such trustee consider such withholding to be in the interest of the holders of debt securities. The trustee may not withhold notice of a default in the payment of principal, any premium or interest on any debt security of such series or in the payment of any sinking fund installment in respect of any debt security of such series. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The indentures provide that holders of debt securities of any series may not institute any proceedings, judicial or otherwise, with respect to such indenture or for any remedy under the indenture, unless the trustee fails to act for a period of 60&#160;days after the trustee has received a written request to institute proceedings in respect of an event of default from the holders of 25% or more in principal amount of the outstanding debt securities of such series, as well as an offer of indemnity reasonably satisfactory to the trustee. However, this provision will not prevent any holder of debt securities from instituting suit for the enforcement of payment of the principal of, and any premium or make-whole amount, and interest on, such debt securities at the respective due dates thereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The indentures provide that, subject to provisions in each indenture relating to its duties in the case of a default, a trustee has no obligation to exercise any of its rights or powers at the request or direction of any holders of any series of debt securities then outstanding under the indenture, unless the holders have&#160;offered to the trustee reasonable security or indemnity. The holders of at least a majority in principal amount of the outstanding debt securities of any series or of all debt securities then outstanding under an indenture shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the applicable trustee, or of exercising any trust or power conferred upon such trustee. However, a trustee may refuse to follow any direction which: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">is in conflict with any law or the applicable indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">may involve the trustee in personal liability; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">may be unduly prejudicial to the holders of debt securities of the series not joining the proceeding. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Within 120&#160;days after the close of each fiscal year, we will be required to deliver to each trustee a certificate, signed by one of our several specified officers, stating whether or not that officer has knowledge of any default under the applicable indenture. If the officer has knowledge of any default, the notice must specify the nature and status of the default. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Modification of the Indentures</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The indentures provide that modifications and amendments may be made only with the consent of the affected holders of a majority in principal amount of all outstanding debt securities issued under that indenture. However, no such modification or amendment may, without the consent of the holders of the debt securities affected by the modification or amendment: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">change the stated maturity of the principal of, or any premium or make-whole amount on, or any installment of principal of or interest on, any such debt security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reduce the principal amount of, the rate or amount of interest on, or any premium or make-whole amount payable on redemption of, any such debt security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reduce the amount of principal of an original issue discount security that would be due and payable upon declaration of acceleration of the maturity thereof or would be provable in bankruptcy, or adversely affect any right of repayment of the holder of any such debt security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">change the place of payment or the coin or currency for payment of principal of, or any premium or make-whole amount, or interest on, any such debt security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">impair the right to institute suit for the enforcement of any payment on or with respect to any such debt security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reduce the&#160;percentage in principal amount of any outstanding debt securities necessary to modify or amend the applicable indenture with respect to such debt securities, to waive compliance with particular provisions thereof or defaults and consequences thereunder or to reduce the quorum or voting requirements set forth in the applicable indenture; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">modify any of the foregoing provisions or any of the provisions relating to the waiver of particular past defaults or covenants, except to increase the required&#160;percentage to effect such action or to provide that some of the other provisions may not be modified or waived without the consent of the holder of such debt security. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of a majority in aggregate principal amount of the outstanding debt securities of each series may, on behalf of all holders of debt securities of that series, waive, insofar as that series is concerned, our compliance with material restrictive covenants of the applicable indenture. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and our respective trustee may make modifications and amendments of an indenture without the consent of any holder of debt securities for any of the following purposes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to evidence the succession of another person to us as obligor under such indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to add to our covenants for the benefit of the holders of all or any series of debt securities or to surrender any right or power conferred upon us in such indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to add events of default for the benefit of the holders of all or any series of debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to add or change any provisions of an indenture (i) to change or eliminate restrictions on the payment of principal of, or premium or make-whole amount, or interest on, debt securities in bearer form, or (ii)&#160;to permit or facilitate the issuance of debt securities in uncertificated form, provided that such action shall not adversely affect the interests of the holders of the debt securities of any series in any material respect; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to change or eliminate any provisions of an indenture, provided that any such change or elimination shall become effective only when there are no debt securities outstanding of any series created prior thereto which are entitled to the benefit of such provision; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to secure the debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to establish the form or terms of debt securities of any series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to provide for the acceptance of appointment by a successor trustee or facilitate the administration of the trusts under an indenture by more than one trustee; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to cure any ambiguity, defect or inconsistency in an indenture, provided that such action shall not adversely affect the interests of holders of debt securities of any series issued under such indenture; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to supplement any of the provisions of an indenture to the extent necessary to permit or facilitate defeasance and discharge of any series of such debt securities, provided that such action shall not adversely affect the interests of the holders of the outstanding debt securities of any series. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The indentures provide that in determining whether the holders of the requisite principal amount of outstanding debt securities of a series have given any request, demand, authorization, direction, notice, consent or waiver under the indentures or whether a quorum is present at a meeting of holders of debt securities: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the principal amount of an original issue discount security that shall be deemed to be outstanding shall be the amount of the principal thereof that would be due and payable as of the date of such determination upon declaration of acceleration of the maturity thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the principal amount of any debt security denominated in a foreign currency that shall be deemed outstanding shall be the United States dollar equivalent, determined on the issue date for such debt security, of the principal amount or, in the case of an original issue discount security, the United States dollar equivalent on the issue date of such debt security of the amount determined as provided in the preceding bullet point; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the principal amount of an indexed security that shall be deemed outstanding shall be the principal face amount of such indexed security at original issuance, unless otherwise provided for such indexed security under such indenture; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">debt securities owned by us or any other obligor upon the debt securities or by any affiliate of ours or of such other obligor shall be disregarded. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The indentures contain provisions for convening meetings of the holders of debt securities of a series. A meeting will be permitted to be called at any time by the applicable trustee, and also, upon request, by us or the holders of at least 25% in principal amount of the outstanding debt securities of such series, in any such case upon notice given as provided in such indenture. Except for any consent that must be given by the holder of each debt security affected by the modifications and amendments of an indenture described above, any resolution presented at a meeting or adjourned meeting duly reconvened at which a quorum is present may be adopted by the affirmative vote of the holders of a majority of the aggregate principal amount of the outstanding debt securities of that series represented at such meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the preceding paragraph, except as referred to above, any resolution relating to a request, demand, authorization, direction, notice, consent, waiver or other action that may be made, given or taken by the holders of a specified&#160;percentage, which is less than a majority of the aggregate principal amount of the outstanding debt securities of a series, may be adopted at a meeting or adjourned meeting duly reconvened at which a quorum is present by the affirmative vote of such specified&#160;percentage. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any resolution passed or decision taken at any properly held meeting of holders of debt securities of any series will be binding on all holders of such series. The quorum at any meeting called to adopt a resolution, and at any reconvened meeting, will be persons holding or representing a majority in principal amount of the outstanding debt securities of a series. However, if any action is to be taken relating to a consent or waiver which may be given by the holders of at least a specified&#160;percentage in principal amount of the outstanding debt securities of a series, the persons holding such&#160;percentage will constitute a quorum. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the foregoing provisions, the indentures provide that if any action is to be taken at a meeting with respect to any request, demand, authorization, direction, notice, consent, waiver or other action that such indenture expressly provides may be made, given or taken by the holders of a specified&#160;percentage in principal amount of all outstanding debt securities affected by such action, or of the holders of such series and one or more additional series: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">there shall be no minimum quorum requirement for such meeting; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the principal amount of the outstanding debt securities of such series that vote in favor of such request, demand, authorization, direction, notice, consent, waiver or other action shall be taken account in determining whether such request, demand, authorization, direction, notice, consent, waiver or other action has been made, given or taken under such indenture. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Subordination</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise provided in the applicable prospectus supplement, subordinated debt securities will be subject to the following subordination provisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon any distribution to our creditors in a liquidation, dissolution or reorganization, the payment of the principal of and interest on any subordinated debt securities will be subordinated to the extent provided in the applicable indenture in right of payment to the prior payment in full of all senior debt. However, our obligation to make payments of the principal of and interest on such subordinated debt securities otherwise will not be affected. No payment of principal or interest will be permitted to be made on subordinated debt securities at any time if a default on senior debt exists that permits the holders of such senior debt to accelerate its maturity and the default is the subject of judicial proceedings or we receive notice of the default. After all senior debt is paid in full and until the subordinated debt securities are paid in full, holders of subordinated debt securities will be subrogated to the rights of holders of senior debt to the extent that distributions otherwise payable to holders of subordinated debt securities have been applied to the payment of senior debt. The subordinated indenture will not restrict the amount of senior debt or other indebtedness of ours. As a result of these subordination provisions, in the event of a distribution of assets upon insolvency, holders of subordinated debt securities may recover less, ratably, than our general creditors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The term &#8220;senior debt&#8221; will be defined in the applicable indenture as the principal of and interest on, or substantially similar payments to be made by us in respect of, other outstanding indebtedness, whether outstanding at the date of execution of the applicable indenture or subsequently incurred, created or assumed. The prospectus supplement may include a description of additional terms implementing the subordination feature. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No restrictions will be included in any indenture relating to subordinated debt securities upon the creation of additional senior debt. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If this prospectus is being delivered in connection with the offering of a series of subordinated debt securities, the accompanying prospectus supplement or the information incorporated in this prospectus by reference will set forth the approximate amount of senior debt outstanding as of the end of our most recent fiscal quarter. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Discharge, Defeasance and Covenant Defeasance</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated in the applicable prospectus supplement, the indentures allow us to discharge our obligations to holders of any series of debt securities issued under any indenture when: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">either (i)&#160;all securities of such series have already been delivered to the applicable trustee for cancellation; or (ii)&#160;all securities of such series have not already been delivered to the applicable trustee for cancellation but (a)&#160;have become due and payable, (b)&#160;will become due and payable within one year, or (c)&#160;if redeemable at our option, are to be redeemed within one year, and we have irrevocably deposited with the applicable trustee, in trust, funds in such currency or currencies, currency unit or&#160;units or composite currency or currencies in which such debt securities are payable, an amount sufficient to pay the entire indebtedness on such debt securities in respect of principal and any premium or make-whole amount, and interest to the date of such deposit if such debt securities have become due and payable or, if they have not, to the stated maturity or redemption date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we have paid or caused to be paid all other sums payable; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an officers&#8217; certificate and an opinion of counsel stating the conditions to discharging the debt securities have been satisfied has been delivered to the trustee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated in the applicable prospectus supplement, the indentures provide that, upon our irrevocable deposit with the applicable trustee, in trust, of an amount, in such currency or currencies, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">currency unit or&#160;units or composite currency or currencies in which such debt securities are payable at stated maturity, or government obligations, or both, applicable to such debt securities, which through the scheduled payment of principal and interest in accordance with their terms will provide money in an amount sufficient to pay the principal of, and any premium or make-whole amount, and interest on, such debt securities, and any mandatory sinking fund or analogous payments thereon, on the scheduled due dates therefor, the issuing company may elect either: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to defease and be discharged from any and all obligations with respect to such debt securities; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to be released from its obligations with respect to such debt securities under the applicable indenture or, if provided in the applicable prospectus supplement, its obligations with respect to any other covenant, and any omission to comply with such obligations shall not constitute an event of default with respect to such debt securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the above, we may not elect to defease and be discharged from the obligation to pay any additional amounts upon the occurrence of particular events of tax, assessment or governmental charge with respect to payments on such debt securities and the obligations to register the transfer or exchange of such debt securities, to replace temporary or mutilated, destroyed, lost or stolen debt securities, to maintain an office or agency in respect of such debt securities, or to hold monies for payment in trust. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The indentures only permit us to establish the trust described in the paragraph above if, among other things, we have delivered to the applicable trustee an opinion of counsel to the effect that the holders of such debt securities will not recognize income, gain or loss for United States federal income tax purposes as a result of such defeasance or covenant defeasance and will be subject to United States federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such defeasance or covenant defeasance had not occurred. Such opinion of counsel, in the case of defeasance, will be required to refer to and be based upon a ruling received from or published by the Internal Revenue Service or a change in applicable United States federal income tax law occurring after the date of the indenture. In the event of such defeasance, the holders of such debt securities would be able to look only to such trust fund for payment of principal, any premium or make-whole amount, and interest. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">When we use the term &#8220;government obligations,&#8221; we mean securities that are: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">direct obligations of the United States or the government that issued the foreign currency in which the debt securities of a particular series are payable, for the payment of which its full faith and credit is pledged; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obligations of a person controlled or supervised by and acting as an agency or instrumentality of the United States or other government that issued the foreign currency in which the debt securities of such series are payable, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the United States or such other government, which are not callable or redeemable at the option of the issuer thereof and shall also include a depository receipt issued by a bank or trust company as custodian with respect to any such government obligation or a specific payment of interest on or principal of any such government obligation held by such custodian for the account of the holder of a depository receipt. However, except as required by law, such custodian is not authorized to make any deduction from the amount payable to the holder of such depository receipt from any amount received by the custodian in respect of the government obligation or the specific payment of interest on or principal of the government obligation evidenced by such depository receipt. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise provided in the applicable prospectus supplement, if after we have deposited funds and/or government obligations to effect defeasance or covenant defeasance with respect to debt securities of any series, (i)&#160;the holder of a debt security of such series is entitled to, and does, elect under the terms of the applicable indenture or the terms of such debt security to receive payment in a currency, currency unit or composite currency other than that in which such deposit has been made in respect of such debt security, or (ii) a conversion event occurs in respect of the currency, currency unit or composite currency in which such deposit has been made, the indebtedness represented by such debt security will be deemed to have been, and will be, fully discharged and satisfied through the payment of the principal of, and premium or make-whole amount, and interest on, such debt security as they become due out of the proceeds yielded by converting the amount so deposited in respect of such debt security into the currency, currency unit or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">composite currency in which such debt security becomes payable as a result of such election or such cessation of usage based on the applicable market exchange rate. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">When we use the term &#8220;conversion event,&#8221; we mean the cessation of use of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a currency, currency unit or composite currency both by the government of the country that issued such currency and for the settlement of transactions by a central bank or other public institutions of or within the international banking community; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the European Currency Unit both within the European Monetary System and for the settlement of transactions by public institutions of or within the European Communities; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any currency unit or composite currency other than the European Currency Unit for the purposes for which it was established. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise provided in the applicable prospectus supplement, all payments of principal of, and any premium or make-whole amount, and interest on, any debt security that is payable in a foreign currency that ceases to be used by its government of issuance shall be made in United States dollars. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that (i)&#160;we effect covenant defeasance with respect to any debt securities and (ii)&#160;those debt securities are declared due and payable because of the occurrence of any event of default, the amount in the currency, currency unit or composite currency in which such debt securities are payable, and government obligations on deposit with the applicable trustee, will be sufficient to pay amounts due on such debt securities at the time of their stated maturity but may not be sufficient to pay amounts due on such debt securities at the time of the acceleration resulting from such event of default. However, the issuing company would remain liable to make payments of any amounts due at the time of acceleration. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The applicable prospectus supplement may further describe the provisions, if any, permitting such defeasance or covenant defeasance, including any modifications to the provisions described above, with respect to the debt securities of or within a particular series. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Conversion Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The terms and conditions, if any, upon which the debt securities are convertible into common stock or other securities of ours will be set forth in the applicable prospectus supplement. The terms will include whether the debt securities are convertible into shares of common stock or other securities of ours, the conversion price, or manner of calculation thereof, the conversion period, provisions as to whether conversion will be at the issuing company&#8217;s option or the option of the holders, the events requiring an adjustment of the conversion price and provisions affecting conversion in the event of the redemption of the debt securities and any restrictions on conversion. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Global Securities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The debt securities of a series may be issued in whole or in part in the form of one or more global securities that will be deposited with, or on behalf of, a depository identified in the applicable prospectus supplement relating to such series. Global securities, if any, issued in the United States are expected to be deposited with The Depository Trust Company, or DTC, as depository. We may issue global securities in either registered or bearer form and in either temporary or permanent form. We will describe the specific terms of the depository arrangement with respect to a series of debt securities in the applicable prospectus supplement relating to such series. We expect that unless the applicable prospectus supplement provides otherwise, the following provisions will apply to depository arrangements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Once a global security is issued, the depository for such global security or its nominee will credit on its book-entry registration and transfer system the respective principal amounts of the individual debt securities represented by such global security to the accounts of participants that have accounts with such depository. Such accounts shall be designated by the underwriters, dealers or agents with respect to such debt securities or by us if we offer such debt securities directly. Ownership of beneficial interests in such global security will be limited to participants with the depository or persons that may hold interests through those participants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect that, under procedures established by DTC, ownership of beneficial interests in any global security for which DTC is the depository will be shown on, and the transfer of that ownership will be effected </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">only through, records maintained by DTC or its nominee, with respect to beneficial interests of participants with the depository, and records of participants, with respect to beneficial interests of persons who hold through participants with the depository. Neither we nor the trustee will have any responsibility or liability for any aspect of the records of DTC or for maintaining, supervising or reviewing any records of DTC or any of its participants relating to beneficial ownership interests in the debt securities. The laws of some states require that certain purchasers of securities take physical delivery of such securities in definitive form. Such limits and laws may impair the ability to own, pledge or transfer beneficial interest in a global security. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">So long as the depository for a global security or its nominee is the registered owner of such global security, such depository or such nominee, as the case may be, will be considered the sole owner or holder of the debt securities represented by the global security for all purposes under the applicable indenture.&#160;Except as described below or in the applicable prospectus supplement, owners of beneficial interest in a global security will not be entitled to have any of the individual debt securities represented by such global security registered in their names, will not receive or be entitled to receive physical delivery of any such debt securities in definitive form and will not be considered the owners or holders thereof under the applicable indenture. Beneficial owners of debt securities evidenced by a global security will not be considered the owners or holders thereof under the applicable indenture for any purpose, including with respect to the giving of any direction, instructions or approvals to the trustee under the indenture. Accordingly, each person owning a beneficial interest in a global security with respect to which DTC is the depository must rely on the procedures of DTC and, if such person is not a participant with the depository, on the procedures of the participant through which such person owns its interests, to exercise any rights of a holder under the applicable indenture. We understand that, under existing industry practice, if DTC requests any action of holders or if an owner of a beneficial interest in a global security desires to give or take any action which a holder is entitled to give or take under the applicable indenture, DTC would authorize the participants holding the relevant beneficial interest to give or take such action, and such participants would authorize beneficial owners through such participants to give or take such actions or would otherwise act upon the instructions of beneficial owners holding through them. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Payments of principal of, and any premium or make-whole amount, and interest on, individual debt securities represented by a global security registered in the name of a depository or its nominee will be made to or at the direction of the depository or its nominee, as the case may be, as the registered owner of the global security under the applicable indenture. Under the terms of the applicable indenture, we and the trustee may treat the persons in whose name debt securities, including a global security, are registered as the owners thereof for the purpose of receiving such payments. Consequently, neither we nor the trustee have or will have any responsibility or liability for the payment of such amounts to beneficial owners of debt securities including principal, any premium or make-whole amount, or interest. We believe, however, that it is currently the policy of DTC to immediately credit the accounts of relevant participants with such payments, in amounts proportionate to their respective holdings of beneficial interests in the relevant global security as shown on the records of DTC or its nominee. We also expect that payments by participants to owners of beneficial interests in such global security held through such participants will be governed by standing instructions and customary practices, as is the case with securities held for the account of customers in bearer form or registered in street name, and will be the responsibility of such participants. Redemption notices with respect to any debt securities represented by a global security will be sent to the depository or its nominee. If less than all of the debt securities of any series are to be redeemed, we expect the depository to determine the amount of the interest of each participant in such debt securities to be redeemed to be determined by lot. Neither we, the trustee, any paying agent nor the security registrar for such debt securities will have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial ownership interests in the global security for such debt securities or for maintaining any records with respect thereto. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the trustee will be liable for any delay by the holders of a global security or the depository in identifying the beneficial owners of debt securities, and we and the trustee may conclusively rely on, and will be protected in relying on, instructions from the holder of a global security or the depository for all purposes. The rules applicable to DTC and its participants are on file with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a depository for any debt securities is at any time unwilling, unable or ineligible to continue as depository and we do not appoint a successor depository within 90&#160;days, we will issue individual debt </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:408pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">securities in exchange for the global security representing such debt securities. In addition, we may at any time and at our sole discretion, subject to any limitations described in the applicable prospectus supplement relating to such debt securities, determine not to have any of such debt securities represented by one or more global securities and in such event will issue individual debt securities in exchange for the global security or securities representing such debt securities. Individual debt securities so issued will be issued in denominations of $1,000 and integral multiples of $1,000. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The debt securities of a series may also be issued in whole or in part in the form of one or more bearer global securities that will be deposited with a depository, or with a nominee for such depository, identified&#8199;&#8199;in the applicable prospectus supplement. Any such bearer global securities may be issued in temporary or permanent form. The specific terms and procedures, including the specific terms of the depositary arrangement, with respect to any portion of a series of debt securities to be represented by one or more bearer global securities will be described in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">No Recourse</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There is no recourse under any obligation, covenant or agreement in the applicable indenture or with respect to any security against any of our or our successor&#8217;s past, present or future shareholders, employees, officers or directors. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF WARRANTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the material terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms described below. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement, which includes this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement. We will enter into the warrant agreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will describe in the applicable prospectus supplement the terms of the series of warrants, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the offering price and aggregate number of warrants offered; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the currency for which the warrants may be purchased; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if applicable, the date on and after which the warrants and the related securities will be separately transferable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the terms of any rights to redeem or call the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the periods during which, and places at which, the warrants are exercisable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the manner of exercise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the dates on which the right to exercise the warrants will commence and expire; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the manner in which the warrant agreement and warrants may be modified; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">federal income tax consequences of holding or exercising the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the terms of the securities issuable upon exercise of the warrants; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOU">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF UNITS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue&#160;units comprised of shares of common stock, shares of preferred stock, debt securities and warrants in any combination. We may issue&#160;units in such amounts and in as many distinct series as we wish. This section outlines certain provisions of the&#160;units that we may issue. If we issue&#160;units, they will be issued under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit agent. The information described in this section may not be complete in all respects and is qualified entirely by reference to the unit agreement with respect to the&#160;units of any particular series. The specific terms of any series of&#160;units offered will be described in the applicable prospectus supplement. If so described in a particular supplement, the specific terms of any series of&#160;units may differ from the general description of terms presented below. We urge you to read any prospectus supplement related to any series of&#160;units we may offer, as well as the complete unit agreement and unit certificate that contain the terms of the&#160;units. If we issue&#160;units, forms of unit agreements and unit certificates relating to such&#160;units will be incorporated by reference as exhibits to the registration statement, which includes this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each unit that we may issue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The applicable prospectus supplement may describe: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the designation and terms of the&#160;units and of the securities comprising the&#160;units, including whether and under what circumstances those securities may be held or transferred separately; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any provisions of the governing unit agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the price or prices at which such&#160;units will be issued; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the applicable United States federal income tax considerations relating to the&#160;units; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any provisions for the issuance, payment, settlement, transfer or exchange of the&#160;units or of the securities comprising the&#160;units; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any other terms of the&#160;units and of the securities comprising the&#160;units. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The provisions described in this section, as well as those described under &#8220;Description of Capital Stock,&#8221; &#8220;Description of Debt Securities&#8221; and &#8220;Description of Warrants&#8221; will apply to the securities included in each unit, to the extent relevant and as may be updated in any prospectus supplements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Issuance in Series</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue&#160;units in such amounts and in as many distinct series as we wish. This section summarizes terms of the&#160;units that apply generally to all series. Most of the financial and other specific terms of your series will be described in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unit Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will issue the&#160;units under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit agent. We may add, replace or terminate unit agents from time to time. We will identify the unit agreement under which each series of&#160;units will be issued and the unit agent under that agreement in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following provisions will generally apply to all unit agreements unless otherwise stated in the applicable prospectus supplement: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Modification without Consent</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and the applicable unit agent may amend any unit or unit agreement without the consent of any holder: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to cure any ambiguity, including modifying any provisions of the governing unit agreement that differ from those described below; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to correct or supplement any defective or inconsistent provision; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">to make any other change that we believe is necessary or desirable and will not adversely affect the interests of the affected holders in any material respect. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not need any approval to make changes that affect only&#160;units to be issued after the changes take effect. We may also make changes that do not adversely affect a particular unit in any material respect, even if they adversely affect other&#160;units in a material respect. In those cases, we do not need to obtain the approval of the holder of the unaffected unit; we need only obtain any required approvals from the holders of the affected&#160;units. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Modification with Consent</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may not amend any particular unit or a unit agreement with respect to any particular unit unless we obtain the consent of the holder of that unit, if the amendment would: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">impair any right of the holder to exercise or enforce any right under a security included in the unit if the terms of that security require the consent of the holder to any changes that would impair the exercise or enforcement of that right; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reduce the&#160;percentage of outstanding&#160;units or any series or class the consent of whose holders is required to amend that series or class, or the applicable unit agreement with respect to that series or class, as described below. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any other change to a particular unit agreement and the&#160;units issued under that agreement would require the following approval: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">If the change affects only the&#160;units of a particular series issued under that agreement, the change must be approved by the holders of a majority of the outstanding&#160;units of that series; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">If the change affects the&#160;units of more than one series issued under that agreement, it must be approved by the holders of a majority of all outstanding&#160;units of all series affected by the change, with the&#160;units of all the affected series voting together as one class for this purpose. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These provisions regarding changes with majority approval also apply to changes affecting any securities issued under a unit agreement, as the governing document. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In each case, the required approval must be given by written consent. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unit Agreements Will Not Be Qualified under Trust Indenture Act</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No unit agreement will be qualified as an indenture, and no unit agent will be required to qualify as a trustee, under the Trust Indenture Act. Therefore, holders of&#160;units issued under unit agreements will not have the protections of the Trust Indenture Act with respect to their&#160;units. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Mergers and Similar Transactions Permitted; No Restrictive Covenants or Events of Default</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unit agreements will not restrict our ability to merge or consolidate with, or sell our assets to, another corporation or other entity or to engage in any other transactions. If at any time we merge or consolidate with, or sell our assets substantially as an entirety to, another corporation or other entity, the successor entity will succeed to and assume our obligations under the unit agreements. We will then be relieved of any further obligation under these agreements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unit agreements will not include any restrictions on our ability to put liens on our assets, nor will they restrict our ability to sell our assets. The unit agreements also will not provide for any events of default or remedies upon the occurrence of any events of default. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Governing Law</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The unit agreements and the&#160;units will be governed by Delaware law. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:130pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Form, Exchange and Transfer</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the accompanying prospectus supplement states otherwise, we will issue each unit in global&#8201;&#8212;&#8201;i.e., book-entry&#8201;&#8212;&#8201;form only. Units in book-entry form will be represented by a global security registered in the name of a depositary, which will be the holder of all the&#160;units represented by the global security. Those who own beneficial interests in a unit will do so through participants in the depositary&#8217;s system, and the rights of these indirect owners will be governed solely by the applicable procedures of the depositary and its participants. We will describe book-entry securities, and other terms regarding the issuance and registration of the&#160;units in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the accompanying prospectus supplement states otherwise, each unit and all securities comprising the unit will be issued in the same form. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we issue any&#160;units in registered, non-global form, the following will apply to them. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The&#160;units will be issued in the denominations stated in the applicable prospectus supplement. Holders may exchange their&#160;units for&#160;units of smaller denominations or combined into fewer&#160;units of larger denominations, as long as the total amount is not changed. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Holders may exchange or transfer their&#160;units at the office of the unit agent. Holders may also replace lost, stolen, destroyed or mutilated&#160;units at that office. We may appoint another entity to perform these functions or perform them ourselves. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Holders will not be required to pay a service charge to transfer or exchange their&#160;units, but they may be required to pay for any tax or other governmental charge associated with the transfer or exchange. The transfer or exchange, and any replacement, will be made only if our transfer agent is satisfied with the holder&#8217;s proof of legal ownership. The transfer agent may also require an indemnity before replacing any&#160;units. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">If we have the right to redeem, accelerate or settle any&#160;units before their maturity, and we exercise our right as to less than all those&#160;units or other securities, we may block the exchange or transfer of those&#160;units during the period beginning 15&#160;days before the day we mail the notice of exercise and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing. We may also refuse to register transfers of or exchange any unit selected for early settlement, except that we will continue to permit transfers and exchanges of the unsettled portion of any unit being partially settled. We may also block the transfer or exchange of any unit in this manner if the unit includes securities that are or may be selected for early settlement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Only the depositary will be entitled to transfer or exchange a unit in global form, since it will be the sole holder of the unit. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Payments and Notices</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In making payments and giving notices with respect to our&#160;units, we will follow the procedures as described in the applicable prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may sell securities: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">through underwriters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">through dealers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">through agents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">directly to purchasers; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">through a combination of any of these methods or any other method permitted by law. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may issue the securities as a dividend or distribution or in a subscription rights offering to our existing security holders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may directly solicit offers to purchase securities, or agents may be designated to solicit such offers. In the prospectus supplement relating to such offering, we will name any agent that could be viewed as an underwriter under the Securities Act and describe any commissions that we must pay to any such agent. Any such agent will be acting on a best efforts basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities through any of these methods or other methods described in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The distribution of the securities may be effected from time to time in one or more transactions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">at a fixed price, or prices, which may be changed from time to time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">at market prices prevailing at the time of sale; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">at prices related to such prevailing market prices; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">at negotiated prices. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each prospectus supplement will describe the method of distribution of the securities and any applicable restrictions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The prospectus supplement with respect to the securities of a particular series will describe the terms of the offering of the securities, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the name of the agent or any underwriters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the public offering or purchase price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any discounts and commissions to be allowed or paid to the agent or underwriters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">all other items constituting underwriting compensation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any discounts and commissions to be allowed or paid to dealers; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any exchanges on which the securities will be listed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If any underwriters or agents are used in the sale of the securities in respect of which this prospectus is delivered, we will enter into an underwriting agreement, sales agreement or other agreement with them at the time of sale to them, and we will set forth in the prospectus supplement relating to such offering the names of the underwriters or agents and the terms of the related agreement with them. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the offering of securities, we may grant to the underwriters an option to purchase additional securities with an additional underwriting commission, as may be set forth in the accompanying prospectus supplement. If we grant any such option, the terms of such option will be set forth in the prospectus supplement for such securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a dealer is used in the sale of the securities in respect of which the prospectus is delivered, we will sell such securities to the dealer, as principal. The dealer, who may be deemed to be an &#8220;underwriter&#8221; as that term </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">is defined in the Securities Act, may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we offer securities in a subscription rights offering to our existing security holders, we may enter into a standby underwriting agreement with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a standby underwriting arrangement, we may retain a dealer-manager to manage a subscription rights offering for us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Agents, underwriters, dealers and other persons may be entitled under agreements which they may enter into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in transactions with or perform services for us in the ordinary course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If so indicated in the applicable prospectus supplement, we will authorize underwriters or other persons acting as our agents to solicit offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus supplement. Each contract will be for an amount not less than, and the aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts, when authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will not be subject to any conditions except that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the purchase by an institution of the securities covered under that contract shall not at the time of delivery be prohibited under the laws of the jurisdiction to which that institution is subject; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if the securities are also being sold to underwriters acting as principals for their own account, the underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Offered securities may also be offered and sold, if so indicated in the prospectus supplement, in connection with a remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or more remarketing firms, acting as principals for their own accounts or as agents for us. Any remarketing firm will be identified and the terms of its agreement, if any, with us and its compensation will be described in the applicable prospectus supplement. Remarketing firms may be deemed to be underwriters in connection with their remarketing of offered securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain agents, underwriters and dealers, and their associates and affiliates, may be customers of, have borrowing relationships with, engage in other transactions with, or perform services, including investment banking services, for us or one or more of our respective affiliates in the ordinary course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering, creating a short position for their own accounts. In addition, to cover overallotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other securities in the open market. Finally, in any offering of the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels. Any such underwriters are not required to engage in these activities and may end any of these activities at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may engage in at the market offerings into an existing trading market in accordance with Rule&#160;415 (a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under Rule&#160;15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. The applicable prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the second business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than two scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The securities may be new issues of securities and may have no established trading market. The securities may or may not be listed on a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The specific terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The anticipated date of delivery of offered securities will be set forth in the applicable prospectus supplement relating to each offer. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain legal matters in connection with this offering will be passed upon for us by Goodwin Procter&#160;LLP, Boston, Massachusetts. Any underwriters will also be advised about the validity of the securities and other legal matters by their own counsel, which will be named in the prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young&#160;LLP&#8217;s report, given on their authority as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to the information requirements of the Exchange Act and, in accordance therewith, file annual, quarterly and special reports, proxy statements and other information with the SEC. These documents also may be accessed through the SEC&#8217;s electronic data gathering, analysis and retrieval system, or EDGAR, via electronic means, including the SEC&#8217;s home page on the Internet (</font><font style="font-style:italic;letter-spacing:0.2pt;">www.sec.gov</font><font style="letter-spacing:0.2pt;">). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have the authority to designate and issue more than one class or series of stock having various preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends, qualifications, and terms and conditions of redemption. See &#8220;Description of Capital Stock.&#8221; We will furnish a full statement of the relative rights and preferences of each class or series of our stock which has been so </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIBR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:38pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">designated and any restrictions on the ownership or transfer of our stock to any shareholder upon request and without charge. Written requests for such copies should be directed to Investor Relations, Scholar Rock Holding Corporation, 301 Binney Street, Cambridge, MA 02142. Our website is located at </font><font style="font-style:italic;letter-spacing:0.2pt;">http://www.scholarrock.com.</font><font style="letter-spacing:0.2pt;"> Information contained on our website is not incorporated by reference into this prospectus and, therefore, is not part of this prospectus or any accompanying prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede the information already incorporated by reference. We are incorporating by reference the documents listed below, which we have already filed with the SEC, and any future filings we make with the SEC under Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act, including all filings made after the date of the filing of this registration statement and prior to the effectiveness of this registration statement, except as to any portion of any future report or document that is not deemed filed under such provisions, until we sell all of the securities: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000155837021002641/srrk-20201231x10k.htm">our Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the SEC on March&#160;9, 2021;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our Quarterly Reports on Form 10-Q for the periods ended March&#160;31, 2021, filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000155837021007006/srrk-20210331x10q.htm">May&#160;13, 2021</a>, June&#160;30, 2021, filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000155837021011162/srrk-20210630x10q.htm">August&#160;10, 2021</a>, and September&#160;30, 2021, filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000155837021015180/srrk-20210930x10q.htm">November&#160;9, 2021</a>; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our Current Reports on Form 8-K, filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000308/a52392795.htm">March&#160;9, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000363/a52398331.htm">March&#160;18, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000429/a52406941.htm">April&#160;6, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000657/a52428778.htm">May&#160;13, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000719/a52436081.htm">May&#160;26, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000110465921075400/tm2118189d2_8k.htm">June&#160;2, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000791/a52445497.htm">June&#160;15, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000978/a52470483.htm">August&#160;3, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321001034/a52474958.htm">August&#160;10, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321001375/a52525640.htm">November&#160;9, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000110465921140588/tm2133126d1_8k.htm">November&#160;17, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321001456/a52542691.htm">November&#160;30, 2021</a> and <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752322000039/a52559698.htm">January&#160;10, 2022</a> (to the extent the information in such report is filed and not furnished); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1727196/000104746920002534/a2241420zdef14a.htm">our Definitive Proxy Statement on Schedule&#160;14A (other than information furnished rather than filed), filed with the SEC on April&#160;23, 2020; and</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;letter-spacing:0.2pt;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;letter-spacing:0.2pt;">
          <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1727196/000110465918034869/a18-8552_78a12b.htm">the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on May&#160;21, 2018, including any amendments or reports filed for the purposes of updating this description.</a><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, a copy of the documents incorporated by reference into this prospectus but not delivered with the prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus, at no cost by writing us at the following address: Investor Relations, Scholar Rock Holding Corporation, 301 Binney Street, Cambridge, MA 02142. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of a registration statement we filed with the SEC. We have incorporated exhibits into this registration statement. You should read the exhibits carefully for provisions that may be important to you. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. We have not authorized anyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus or in the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus or those documents.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.8pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.8pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;margin-top:86.3pt; text-align:center; width:456pt;">
          <img src="lg_scholarrocknew-4clr.jpg" alt="[MISSING IMAGE: lg_scholarrocknew-4clr.jpg]" height="60" width="317" >
        </div>
        <div style="margin-top:40.6pt; text-align:center; width:456pt; line-height:26pt;font-weight:bold;font-size:24pt;">
          <font style="letter-spacing:-0.48pt;">Scholar Rock</font><font style="font-weight:normal;letter-spacing:0.48pt;"> </font>
        </div>
        <div style="margin-top:22.23pt; text-align:center; width:456pt; line-height:18pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">$300,000,000</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:32.43pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common Stock</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Preferred Stock</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Debt Securities</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Warrants </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Units</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:51.717pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 51.7166666666667pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:27.8pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>
        <div style="margin-top:20.943pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 20.9433333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:51.8pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">March&#160;7, 2022</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:42.44pt; width:456pt; line-height:11.5pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We have not authorized any dealer, salesperson or other person to give any information or represent anything not contained in this prospectus. You must not rely on any unauthorized information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus does not offer to sell any securities in any jurisdiction where it is unlawful. Neither the delivery of this prospectus, nor any sale made hereunder, shall create any implication that the information in this prospectus is correct after the date hereof. </font>
        </div>
        <div style="margin-top:38.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 38.3000000000001pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.8pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.79999999999995pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Scholar Rock Holding Corporation</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lg_scholarrocknew-4clr.jpg" alt="[MISSING IMAGE: lg_scholarrocknew-4clr.jpg]" height="60" width="317" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to $150,000,000</font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:19.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We previously entered into a certain Open Market Sale Agreement</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">SM</font><font style="letter-spacing:0.2pt;">, or sales agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus. We originally filed a prospectus supplement, dated March&#160;9, 2021, or the Prior Prospectus Supplement, for the offer and sale of up to $150,000,000 of shares of our common stock, from time to time through Jefferies, acting as our agent, pursuant to the sales agreement under the shelf registration statement on Form S-3 (Registration Statement No. 333-254057). As of the date of this prospectus, we have issued and sold $13,500,000 of our common stock pursuant to the sales agreement and the Prior Prospectus Supplement filed on March&#160;9, 2021. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $150,000,000 from time to time through Jefferies, acting as agent. The common stock remaining available to be sold under the Prior Prospectus as of the date of this prospectus will no longer be offered and sold under the Prior Prospectus, but will instead be offered and sold under this prospectus. Accordingly, this prospectus covers the offer and sale of $150,000,000 to be sold under the sales agreement as of the date of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;SRRK.&#8221; On March&#160;1, 2022, the closing price of our common stock, as reported on The Nasdaq Global Select Market, was $16.92 per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sales of our common stock, if any, under this prospectus may be made in sales deemed to be &#8220;at the market offerings&#8221; as defined in Rule&#160;415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Jefferies is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Jefferies and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The compensation to Jefferies for sales of common stock sold pursuant to the sales agreement will be equal to 3.0% of the gross proceeds of any shares of common stock sold under the sales agreement. In connection with the sale of the common stock on our behalf, Jefferies will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Jefferies with respect to certain liabilities, including liabilities under the Securities Act. See the section titled &#8220;Plan of Distribution&#8221; on page S-19 of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties referenced under the heading &#8220;</font><font style="font-style:italic;letter-spacing:-0.2pt;">Risk Factors</font><font style="letter-spacing:-0.2pt;">&#8221; on page <a href="#sRIFA">S-13</a> of this prospectus and in the documents that are incorporated by reference into this prospectus.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:18pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">Jefferies</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The date of this prospectus supplement is March&#160;7, 2022</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:313.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:173.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:419.84pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">S-Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:419.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sATP"><font style="letter-spacing:0.2pt;">About this Prospectus </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sATP">S-1</a></font> <a href="#sATP"></a></td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sPRSU"><font style="letter-spacing:0.2pt;">Prospectus Summary </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sPRSU">S-2</a></font> <a href="#sPRSU"></a></td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sRIFA"><font style="letter-spacing:0.2pt;">Risk Factors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sRIFA">S-13</a></font> <a href="#sRIFA"></a></td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sCSRF"><font style="letter-spacing:0.2pt;">Cautionary Statement Regarding Forward-Looking Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sCSRF">S-15</a></font> <a href="#sCSRF"></a></td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sUOP"><font style="letter-spacing:0.2pt;">Use of Proceeds </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sUOP">S-17</a></font> <a href="#sUOP"></a></td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sDIL"><font style="letter-spacing:0.2pt;">Dilution </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sDIL">S-18</a></font> <a href="#sDIL"></a></td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sPOD"><font style="letter-spacing:0.2pt;">Plan of Distribution </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sPOD">S-20</a></font> <a href="#sPOD"></a></td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sLEMA"><font style="letter-spacing:0.2pt;">Legal Matters </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sLEMA">S-22</a></font> <a href="#sLEMA"></a></td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sEXP"><font style="letter-spacing:0.2pt;">Experts </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sEXP">S-22</a></font> <a href="#sEXP"></a></td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sWYCF"><font style="letter-spacing:0.2pt;">Where You Can Find More Information </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sWYCF">S-22</a></font> <a href="#sWYCF"></a></td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:419.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sIOCI"><font style="letter-spacing:0.2pt;">Incorporation of Certain Information by Reference </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sIOCI">S-22</a></font>
            </td>
            <td style="padding:0pt;padding-left:2.655pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are responsible for the information contained and incorporated by reference in this prospectus, in any accompanying prospectus, and in any related free writing prospectus we prepare or authorize. We have not authorized anyone to give you any other information, and we take no responsibility for any other information that others may give you. If you are in a jurisdiction where offers to sell, or solicitations of offers to purchase, the securities offered by this documentation are unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this document does not extend to you. The information contained in this document speaks only as of the date of this document, unless the information specifically indicates that another date applies. Our business, financial condition, results of operations and prospects may have changed since those dates.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="sATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:76pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus relates to the offering of our common stock. Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus together with the information incorporated by reference as described under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in this prospectus, and any free writing prospectus or prospectus supplement that we have authorized for use in connection with this offering. These documents contain important information that you should consider when making your investment decision. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus describes the terms of this offering of common stock and also adds to and updates information contained in the documents incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference into this prospectus that was filed with the Securities and Exchange Commission, or the SEC, before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#8201;&#8212;&#8201;for example, a document incorporated by reference into this prospectus&#8201;&#8212;&#8201;the statement in the document having the later date modifies or supersedes the earlier statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have not authorized anyone to provide you with information in addition to or different from that contained in this prospectus, any applicable prospectus supplement and any related free writing prospectus. We take no responsibility for, and can provide no assurances as to the reliability of, any information not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, the accompanying prospectus or any related free writing prospectus, or any sale of a security. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus and the accompanying prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find More Information&#8221;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the context otherwise indicates, references in this prospectus to &#8220;Scholar Rock&#8221;, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221; and &#8220;the Company&#8221; refer, collectively, to Scholar Rock Holding Corporation and its subsidiaries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We own various U.S. federal trademark applications and unregistered trademarks, including &#8220;Scholar Rock&#8221; and our corporate logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this&#8199;&#8199;prospectus are referred to without the symbols &#174; and &#8482;, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="sPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The following summary of our business highlights some of the information contained elsewhere in, or incorporated by reference into, this prospectus supplement. Because this is only a summary, however, it does not contain all of the information that may be important to you. You should carefully read this prospectus supplement and the accompanying prospectus, including the documents incorporated by reference, which are described under &#8220;Incorporation of certain information by reference&#8221; in this prospectus supplement. You should also carefully consider the matters discussed in the section of this prospectus supplement entitled &#8220;Risk factors&#8221; and under similar sections of the accompanying prospectus and other periodic reports incorporated herein and therein by reference.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Company overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. By targeting the signaling proteins at the cellular level and acting in the disease microenvironment, we believe we may avoid the historical dose-limiting safety challenges associated with inhibiting growth factors for therapeutic effect. We believe our focus on biologically validated growth factors may facilitate a more efficient development path. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our first product candidate, apitegromab (formerly SRK-015), is a highly selective, fully human, monoclonal antibody, with a unique mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-directed therapy for the treatment of SMA. We are conducting SAPPHIRE, a pivotal Phase&#160;3 trial to evaluate the efficacy and safety of apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA (which is estimated to represent the majority of the current prevalent SMA patient population in the U.S. and Europe). Apitegromab was evaluated in our TOPAZ Phase&#160;2 proof-of-concept clinical trial for the treatment of patients with Type 2 and Type 3 SMA. Positive 12-month top-line results were announced in April&#160;2021 showing apitegromab&#8217;s transformative potential (see &#8220;TOPAZ Twelve-Month Analysis&#8221; below). The FDA granted fast track designation, rare pediatric disease designation and orphan drug designation to apitegromab for the treatment of SMA in May&#160;2021, August&#160;2020 and March&#160;2018, respectively. The European Medicines Agency (&#8220;EMA&#8221;) granted PRIority MEdicines (&#8220;PRIME&#8221;) designation in March&#160;2021 and the European Commission (&#8220;EC&#8221;) granted orphan medicinal product designation in December&#160;2018 to apitegromab for the treatment of SMA. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our second product candidate, SRK-181, is being developed for the treatment of cancers that are resistant to checkpoint inhibitor therapies (&#8220;CPI therapies&#8221;), such as anti-PD-1 or anti-PD-L1 antibody therapies. SRK-181 is a highly selective inhibitor of the activation of latent TGF&beta;1 that is being investigated in our DRAGON Phase&#160;1 proof-of-concept clinical trial in patients with locally advanced or metastatic solid tumors that exhibit primary resistance to anti-PD-(L)1 antibodies. This two-part clinical trial consists of a dose escalation portion (Part&#160;A) and a dose expansion portion evaluating SRK-181 in combination with an approved anti-PD-(L)1 antibody therapy (Part&#160;B). Part&#160;B encompasses five cohorts, including urothelial carcinoma, cutaneous melanoma, non-small cell lung cancer, clear cell renal cell carcinoma and other solid tumors and commenced in 2021. Initial clinical data from Part&#160;A were presented in November&#160;2021 at the Society for Immunotherapy of Cancer (&#8220;SITC&#8221;) 36th Annual Meeting. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our approach and proprietary platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Beyond these programs, we continue to discover and develop highly specific monoclonal antibodies to selectively modulate growth factor signaling. Growth factors are naturally occurring proteins that typically act as signaling molecules between cells and play a fundamental role in regulating a variety of normal cellular processes, including cell growth and differentiation. Current therapeutic approaches to treating diseases in which growth factors play a fundamental role involve directly targeting the active form of the growth factor </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">or its receptor systemically throughout the body. These approaches have suffered from a variety of shortcomings, including lack of pathway selectivity, lack of target selectivity, and non-localized target inhibition. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our innovative approach is rooted in our structural biology insights into the mechanism by which certain growth factors are activated in close proximity to the cell surface. We integrate these insights with sophisticated protein expression, assay development and monoclonal antibody discovery capabilities. We believe our proprietary platform can address the challenges of treating diseases in which growth factors play a fundamental role by: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">targeting the natural activation mechanism to prevent activation of the growth factor rather than attempting to inhibit the growth factor after activation; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">achieving heightened specificity for the targeted growth factor while minimizing interactions with structurally similar and related growth factors, thereby potentially reducing the risk of unintended systemic adverse events; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">targeting the disease microenvironment, where we believe we can interfere with the disease process while minimizing the effects on the normal physiological processes mediated by the same growth factors. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our structural insights and unique antibody discovery capabilities can be applied to other protein classes beyond growth factors, with an aim of generating differentiated candidates targeting cell surface receptors such as immune cell receptors or G-protein coupled receptors, where selectivity remains challenging. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our programs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Apitegromab in spinal muscular atrophy</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are developing apitegromab, a novel, highly selective inhibitor of the activation of the growth factor myostatin, as a potential first muscle-directed therapy for the treatment of SMA. Myostatin, a member of the TGF&beta; superfamily of growth factors, is expressed primarily in skeletal muscle cells and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species. We believe that inhibition of the activation of myostatin may promote a clinically meaningful increase in motor function. As a result, we have focused our initial development efforts for apitegromab on the treatment of SMA. SMA is a rare, and often fatal, genetic disorder arising from a deficiency of a protein known as &#8220;survival of motor neuron,&#8221; or SMN. This disease typically manifests in young children and is characterized by atrophy of the voluntary muscles of the limbs and trunk and dramatically reduced normal neuromuscular function. An estimated 30,000 to 35,000 patients suffer from SMA in the U.S. and Europe alone, and many more patients are affected worldwide. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In preclinical studies, we have shown that apitegromab selectively avoids interaction with other closely related growth factors that play distinct physiological roles. We observed multi-fold increases in serum latent myostatin levels in mouse models of both early and late SMN restoration and that apitegromab promoted increased strength (as measured by torque generation) in SMN-deficient mice. In a Phase&#160;1 clinical trial designed to evaluate the safety, tolerability, and pharmacokinetic (&#8220;PK&#8221;)/pharmacodynamic (&#8220;PD&#8221;) profile of apitegromab in adult healthy volunteers, there were no dose-limiting toxicities and robust and sustained target engagement following administration of apitegromab was observed. Apitegromab was evaluated in our TOPAZ Phase&#160;2 proof-of-concept clinical trial for the treatment of patients with Type 2 and Type 3 SMA and positive 12-month top-line results were announced in April&#160;2021 showing apitegromab&#8217;s transformative potential. See &#8220; TOPAZ Twelve-Month Analysis&#8221; below. We are currently conducting SAPPHIRE, a pivotal Phase&#160;3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA receiving background SMN upregulator treatment. We believe that apitegromab has the potential to be the first muscle-directed therapy, which is aimed at improving motor function in patients with SMA and could be used both as a monotherapy or in conjunction with SMN upregulator therapies (i.e., therapies that upregulate the expression of SMN, such as SMN splicing modulators or gene therapy). </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Apitegromab in other myostatin-related disorders</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We see potential for apitegromab broadly across SMA (i.e., Type 1 SMA and ambulatory SMA) and our intention is to further investigate this potential. We also believe that the role of apitegromab as a muscle-directed therapy has broad potential beyond SMA, spanning a number of muscle disorders in which fast-twitch fibers may play an important role in motor function. In some settings, we believe that disease-stabilizing therapy may be necessary to address the underlying defect, which can then be complemented by the potential motor function-building benefit of apitegromab. In settings in which the defect may be less severe and/or the disease may have a slower rate of progression, apitegromab may have the potential to serve as a monotherapy. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">There is also increasing recognition of the important role of skeletal muscle in modulating metabolic physiology, highlighting a potential therapeutic opportunity for myostatin blockade. For example, data emerging from our preclinical experiments support the hypothesis that blockade of the myostatin pathway has the potential to reduce the mass of visceral fat, a significant driver of cardiometabolic pathophysiology. Excessive fat mass and metabolic abnormalities have been observed in many muscle atrophy states, such as SMA and spinal cord injury. More broadly, reducing visceral fat mass, or improving body compositions (e.g., enhanced muscle-to-fat ratios), may be a potential therapeutic strategy to address a wide range of disorders, such as non-alcoholic steatohepatitis (&#8220;NASH&#8221;), diabetes, and obesity. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Based on this evidence, we believe a wide range of potential therapeutic applications may be envisioned for apitegromab. We are considering the investigation of apitegromab in multiple indications beyond SMA and have efforts underway to evaluate these opportunities (including preclinical and translational research, clinical development and regulatory path assessments, and commercial assessments). </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">SRK-181 in cancer immunotherapy</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our second antibody product candidate, SRK-181, a highly selective inhibitor of the activation of latent TGF&beta;1, is in clinical development for the treatment of locally advanced or metastatic solid tumors that are resistant to anti-PD-(L)1 therapies. We estimate at least 750,000 cancer patients in the US are eligible for treatment with checkpoint inhibitor therapies every year, of which the majority do not respond to treatment. Increased signaling by TGF&beta;1 is a key driver of a number of disease-relevant processes, including immune system evasion by cancer cells, bone marrow fibrosis associated with hematological disorders, and tissue and organ fibrosis. Historically, selectively targeting TGF&beta;1 signaling has been challenging due to the inability of either small molecule inhibitors or antibodies to avoid off-target inhibition of other, closely related growth factors, TGF&beta;2 and TGF&beta;3. Treatment of animals with these non-selective TGF&beta; inhibitors has been associated with a range of toxicities, most notably cardiac toxicity. Furthermore, since each of these growth factors signals through the same TGF&beta; receptor, ALK5, inhibitors of the TGF&beta; receptor kinase suffer from similar dose-limiting toxicities. In preclinical studies of our antibodies, we have observed selective inhibition of TGF&beta;1 activation </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> and immunomodulatory and antifibrotic activity in multiple disease models </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;">. A 28-day pilot nonclinical toxicology study in rats of our leading antibody did not observe any drug-related toxicity up to the highest dose (100 mg/kg weekly) tested in the study. In the same study, we tested non-selective TGF&beta; inhibitors and observed the published toxicities, including cardiac toxicity as well as death. We have also completed four-week GLP toxicology studies in rats and non-human primates and no SRK-181 related adverse effects were observed up to the highest evaluated dose of 200 mg/kg per week and 300 mg/kg per week, respectively. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In many human cancers, TGF&beta; signaling is associated with lack of response to PD-(L)1 blockade, particularly in patients with tumors harboring an immune excluded phenotype (i.e., CD8+ T cells present in nearby stroma but excluded from the tumor parenchyma). We have observed multiple mouse models that recapitulate the immune-excluded phenotype and are resistant to PD-1 blockade become responsive to the combination of SRK-181-mIgG1, the murine analog of SRK-181, and an anti-PD-1 antibody. These models, including the MBT-2 bladder cancer model, the Cloudman S91 melanoma model and the EMT6 breast cancer model, were poorly responsive or unresponsive to single agent treatment with either anti-PD-1 or SRK-181-mIgG1, with little or no effect on tumor growth. However, in representative experiments, the combination of SRK-181-mIgG1 and anti-PD-1 resulted in tumor regressions of 72%, 57% and 70% in these three mouse models, respectively. Furthermore, this combination treatment led to statistically significant survival benefit in all three models. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our DRAGON Phase&#160;1 clinical trial of SRK-181 is intended to initially evaluate our therapeutic hypothesis that SRK-181 in combination with anti-PD-(L)1 therapy may overcome primary resistance to anti-PD-(L)1 therapy and lead to anti-tumor responses. This clinical trial in patients with locally advanced or metatstatic solid tumors is ongoing and investigates the safety, PK and efficacy of SRK-181. The DRAGON trial consists of two parts: Part&#160;A (dose escalation of SRK-181 as a single-agent or in combination with an approved anti-PD-(L)1 therapy) and Part&#160;B (dose expansion evaluating SRK-181 in combination with an approved anti-PD-(L)1 antibody therapy). Part&#160;B encompasses five cohorts, including urothelial carcinoma, cutaneous melanoma, non-small cell lung cancer, clear cell renal cell carcinoma and other solid tumors and commenced in 2021. Initial clinical data from Part&#160;A, primarily focused on safety and PK, was presented in November&#160;2021 at the Society for Immunotherapy of Cancer (&#8220;SITC&#8221;) 36th Annual Meeting. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">SRK-181 in other oncology settings</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We believe SRK-181 has potential for use in additional oncology settings, such as in immunotherapy- naive patients, in combination with therapies beyond checkpoint inhibitors and in myelofibrosis. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">TGF&beta; in fibrotic diseases</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In December&#160;2018, we entered into a three-year collaboration with Gilead to discover and develop therapeutics that target TGF&beta;-driven signaling, a central regulator of fibrosis. Under the collaboration, Gilead had exclusive options to license worldwide rights to antibodies from certain TGF&beta; programs being developed by us. We received $80.0&#160;million in proceeds upon signing the agreement and an additional $25.0&#160;million for a preclinical milestone achieved in December&#160;2019 for the successful demonstration of efficacy in preclinical in vivo proof-of-concept studies. The collaboration period concluded on December&#160;19, 2021 and on January&#160;6, 2022, Gilead agreed that its option exercise period for all programs terminated which returned rights to us to a suite of antibodies with novel pharmacological profiles that were discovered over the course of the collaboration with Gilead. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Of particular note, we have discovered antibodies that selectively inhibit the activation of latent TGF&beta;1 in the context of fibrotic extracellular matrix and that avoid perturbing TGF&beta;1 presented by cells of immune system. Such antibodies demonstrated significant antifibrotic activity in a variety of preclinical rodent models and safety at all doses tested in a non-GLP mouse safety study. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Discovery and Preclinical Programs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Utilizing our proprietary platform, we have multiple early stage and preclinical programs directed against targets that are known to be important in serious diseases. We are discovering and generating highly selective and differentiated monoclonal antibodies against difficult targets by 1) applying our structural insights and antibody discovery expertise, 2) prioritizing human biology, and 3) embedding translational thinking early in the research and development process. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Additional therapeutic areas and targets that we could potentially apply our scientific platform and expertise to include: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Advancing active discovery programs for context-dependent inhibitors of TGF&beta;1. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Advancing programs which selectively inhibit other TGF&beta; superfamily pathways such as BMPs via targeting of BMP co-receptors as controllers of iron regulation. This approach could provide the potential for tissue specific modulation of BMP signaling and iron regulation. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Exploring opportunities in modulating metabolic physiology including understanding the important role of skeletal muscle in modulating metabolism. This is highlighted by potential therapeutic opportunity for myostatin blockade. For example, evidence is emerging that blockade of the myostatin pathway can reduce the mass of visceral fat, a significant driver of cardiometabolic pathophysiology. We have efforts underway to evaluate these opportunities, including preclinical and translational research, development path assessments, and commercial evaluations. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Exploring mechanisms to selectively modulate growth and survival mechanisms among multiple immune cell types which are important in human disease including plasma cells, macrophages, T cells and NK cells. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Exploring the tumor microenvironment and its critical role in tumor initiation and progression. A major avenue of communication between tumor cells and their microenvironment is through secretion of stimulatory growth factors and via cell surface receptors for these growth factors. Through the tumor microenvironment, tumor cells can efficiently recruit stromal cells, immune cells and vascular cells which, in-turn, release further tumor growth-promoting signals to remodel tissue structures and promote pro-tumor environments. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We continue to enhance our internal biologics discovery capabilities including the use of humanized transgenic rodents as well as single-domain antibody libraries. These new capabilities allow us to more efficiently discover antibodies and furthers our commitment to building a differentiated portfolio of product candidates. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Using our innovative approach and proprietary platform, we are creating a differentiated pipeline of novel product candidates that selectively inhibit the activation of latent growth factors believed to be important drivers in a variety of diseases, including neuromuscular disorders, cancer and fibrosis. Our proprietary platform includes (i)&#160;our know-how enabling expression and purification of latent protein growth factor complexes in quantity and quality sufficient to enable antibody discovery; (ii)&#160;strategies to identify rare antibodies that selectively bind targeted latent protein growth factor complexes using our own proprietary antibody libraries; and (iii)&#160;assays developed by us in which to test the highly selective antibodies&#8217; ability to modulate the activation of specific latent growth factors. We have worldwide rights to our proprietary platform and all of our product candidates, with the exception of certain early stage antibodies that specifically inhibit the activation of TGF&beta;1 in the context of regulatory T cells, which we licensed to Janssen Biotech, Inc., or Janssen. </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The following summarizes our pipeline of programs as of the date of this prospectus: </font>
          </div>
          <div style="position:relative;margin-top:9.9pt; text-align:center; width:456pt;">
            <img src="tm228243d1-fc_summaris4clr.jpg" alt="[MISSING IMAGE: tm228243d1-fc_summaris4clr.jpg]" height="256" width="499" >
          </div>
          <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">COVID-19 pandemic</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In March&#160;2020, the World Health Organization declared the outbreak of a novel coronavirus, or COVID-19, as a pandemic, or, the COVID-19 pandemic, which continues to spread throughout the U.S. and worldwide. We could be materially and adversely affected by the risks, or the public perception of the risks, related to an epidemic, pandemic, outbreak, or other public health crisis, such as the COVID-19 pandemic. The ultimate extent of the impact of any epidemic, pandemic, outbreak, or other public health crisis on our business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of such epidemic, pandemic, outbreak, or other public health crisis and actions taken to contain or prevent the further spread, including the development and deployment of any vaccine program. Accordingly, we cannot predict the extent to which our business, including our clinical trials, financial </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">condition and results of operations will be affected. As a result of the COVID-19 pandemic, we have experienced disruptions that have impacted our business, preclinical studies and clinical trials, including disruptions or restrictions on our ability to access and monitor certain clinical trial sites, restrictions on clinical trial participants&#8217; ability to access our clinical trial sites and delays in enrollment. Some clinical trial participants have missed or experienced delays in receiving doses of study drug and completing their clinical trial assessments. For example, four patients (one in Cohort 2 and three in Cohort 3) of the TOPAZ clinical trial each missed three doses of apitegromab over the course of the 12-month treatment period due to COVID-19-related site access restrictions. This has affected our clinical trials and could result in further impacts, including delays in or adverse impacts to data readouts from our clinical trials and delays in our ability to identify and enroll patients in current or future clinical trials and decision by enrolled patients to discontinue from our clinical trials due to COVID-19 related concerns. While our laboratory operations have resumed to near-normal capacity, we may continue to experience challenges in procuring materials and supplies, as well as research services from our vendors in a consistently timely manner due to COVID-19 related supply chain issues. Some of our third-party manufacturers have diverted resources or manufacturing capacity to accommodate the development or manufacture of COVID-19 vaccines. Although this has not yet had an impact on our ability to produce sufficient quantities of apitegromab or SRK-181 for our clinical trials, we continue to work closely with our third-party manufacturers to mitigate potential impacts to our clinical supply chain. In addition, delays in the development of COVID-19 vaccines or the deployment of vaccines which are approved or otherwise authorized for emergency use, a recurrence or &#8220;subsequent waves&#8221; of COVID-19 cases, or the discovery of vaccine-resistant COVID-19 variants could cause other widespread or more severe impacts. We continue to monitor developments as we adjust to the disruptions and uncertainties relating to the COVID-19 pandemic. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Recent developments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">SAPPHIRE Phase&#160;3 Pivotal Trial Design</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">SAPPHIRE is a randomized, double-blind, placebo-controlled, Phase&#160;3 clinical trial. Approximately 156 patients aged 2-12&#160;years old with non-ambulatory Type 2 or Type 3 SMA are anticipated to be enrolled in the main efficacy population. Patients will be randomized 1:1:1 to receive for 12&#160;months either apitegromab 10 mg/kg, apitegromab 20 mg/kg, or placebo by intravenous (IV)&#160;infusion every 4 weeks in addition to background SMN treatment. Patients receiving the background SMN treatment of nusinersen as well as patients receiving background SMN treatment of risdiplam will both be eligible for enrollment. </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Additional key elements of the study design include the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">At baseline, all patients will be required to be in the chronic maintenance phase of SMN treatment, corresponding to either at least 6&#160;months of prior treatment in the case of risdiplam or at least 10&#160;months of prior treatment in the case of nusinersen. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Randomization of patients will be stratified by both the background SMN treatment (nusinersen vs. risdiplam) as well as the age at which SMN treatment had been initiated (&le; 5&#160;years vs. &gt; 5&#160;years). </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The primary efficacy endpoint will evaluate the mean change from baseline in the HFMSE total score after 12&#160;months of treatment. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Additional endpoints will evaluate safety, proportion of patients with &ge;3-point HFMSE increase, Revised Upper Limb Module (&#8220;RULM&#8221;), World Health Organization (&#8220;WHO&#8221;) motor developmental milestones, pharmacokinetics, pharmacodynamics, anti-drug antibody, and other outcome measures. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition, this clinical trial provides the opportunity for an interim analysis when at least 50% of patients in the main efficacy population (age 2-12&#160;years) have completed 12&#160;months of treatment. Separately from the main efficacy population, an exploratory population of 48 patients aged 13-21&#160;years old with non-ambulatory Type 2 or Type 3 SMA will be evaluated. These patients will be randomized 2:1 to receive either apitegromab 20 mg/kg or placebo added to background SMN treatment with nusinersen or risdiplam. In this subpopulation of older individuals with SMA, the safety and tolerability of apitegromab will be characterized, and efficacy will also be evaluated in an exploratory, nonpowered manner. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">TOPAZ Phase&#160;2 Proof-of-Concept Trial</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We completed enrollment of 58 patients in our TOPAZ Phase&#160;2 proof-of-concept trial of apitegromab in SMA in January&#160;2020. One patient discontinued from the 12-month treatment period for reasons that were determined to be unrelated to apitegromab treatment. All remaining 57 patients completed the 12-month treatment period and opted into the extension period. As of February&#160;2022, 55 of the patients remain enrolled. </font>
          </div>
          <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The clinical trial consisted of three distinct cohorts of patients with Type 2 or Type 3 SMA and evaluated the safety and efficacy of apitegromab over a 12-month treatment period. All patients in the clinical trial received apitegromab dosed every four weeks (Q4W) either as a monotherapy or in conjunction with an approved SMN upregulator therapy. </font>
          </div>
          <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In our view, this approach of having evaluated multiple distinct cohorts offers a greater number of opportunities to discern the effects of apitegromab on clinically meaningful motor function measures across multiple patient subpopulations. It is estimated that patients with Type 2 or Type 3 SMA represent over 85% of the overall patient population. We view each of the cohorts evaluated in the TOPAZ trial as representing a significant proportion of patients suffering from SMA. </font>
          </div>
          <div style="text-indent:20pt; margin-top:7.51pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The primary efficacy objectives evaluated in the TOPAZ trial, HFMSE and Revised Hammersmith Scale (&#8220;RHS&#8221;), are clinically meaningful outcome measures validated for SMA. These endpoints assess motor tasks involving short-term bursts of strength and thus involve fast-twitch fiber function. As the hypothesized effect of myostatin blockade under investigation is to drive increases in fast-twitch fiber function, we believe these endpoints are of direct relevance in assessing the clinical effect of apitegromab. </font>
          </div>
          <div style="text-indent:20pt; margin-top:7.51pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our overall approach to the efficacy analysis is informed by SMA disease biology, the anticipated mechanism of action of apitegromab, the effects of SMN upregulators, and available clinical data on SMA. The primary effect of SMN upregulator therapy appears to be to address the SMN deficiency and to modify the disease course; thus, the key in preventing significant motor functional deterioration is intervening at a very young age. For most patients with SMA, however, this window for early intervention is no longer available. As a result, these individuals have already suffered considerable atrophy and motor function impairment. Natural history data indicate that most patients with Type 2 or 3 SMA, other than very young individuals, generally have a stable functional baseline over a 12-month period as evidenced by their HFMSE scores. A one-point improvement on the Hammersmith scale may be considered meaningful on an individual level and a spontaneous improvement of 3 or more points from one&#8217;s baseline would be a notable divergence from the otherwise expected course of disease for most patients. </font>
          </div>
          <div style="margin-left:20pt; margin-top:7.52pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">TOPAZ Twelve-Month Analysis </font>
          </div>
          <div style="text-indent:20pt; margin-top:7.51pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">On April&#160;6, 2021, we announced positive top-line data for the 12-month treatment period of our TOPAZ Phase&#160;2 proof-of-concept trial, which enrolled 58 patients with Type 2 and Type 3 SMA across 16 study sites in the United States and Europe. The clinical trial evaluated the safety and efficacy of intravenous apitegromab dosed every four weeks (Q4W) over a 12-month treatment period. Four patients (one in Cohort 2 and three in Cohort 3) each missed three consecutive doses of apitegromab over the course of the 12-month treatment period due to COVID-19-related site access restrictions and were excluded from the prespecified intent-to-treat primary analysis. </font>
          </div>
          <div style="text-indent:20pt; margin-top:7.51pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Cohort 1: &nbsp;&nbsp;&nbsp;This open-label, single-arm cohort enrolled 23 patients with ambulatory Type 3 SMA. Patients were treated with 20 mg/kg of apitegromab either as a monotherapy or in conjunction with an approved SMN upregulator therapy (nusinersen). The primary objectives of Cohort 1 were to assess safety and the mean change from baseline in RHS following 12&#160;months of treatment. </font>
          </div>
          <div style="position:relative;margin-top:7.52pt; text-align:center; width:456pt;">
            <img src="tm228243d1-tbl_cohort14clr.jpg" alt="[MISSING IMAGE: tm228243d1-tbl_cohort14clr.jpg]" height="149" width="468" >
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Cohort 2: &nbsp;&nbsp;&nbsp;This open-label, single-arm cohort enrolled 15 patients with Type 2 or non-ambulatory Type 3 SMA and who were already receiving treatment with an approved SMN upregulator (nusinersen) initiated at age five&#160;years or older. One patient missed three consecutive doses of apitegromab due to COVID-19-related site access restrictions and was excluded from the prespecified intent-to-treat primary analysis. The primary objectives of the cohort were to assess safety and the mean change from baseline in HFMSE following 12&#160;months of treatment. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">One patient in Cohort 2 was identified as having received concomitant treatment with an acetylcholinesterase inhibitor before and during the study, which was not permitted by the trial protocol. This patient experienced a 7-point decline in HFMSE score at the 12-month timepoint. In the per protocol analysis conducted in accordance with the prespecified approach, which excludes this patient as well as the patient who missed three consecutive doses due to COVID-19-related site access restrictions, the mean change from baseline in HFMSE score for Cohort 2 was a 1.2-point improvement. </font>
          </div>
          <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
            <img src="tm228243d1-tbl_cohort24clr.jpg" alt="[MISSING IMAGE: tm228243d1-tbl_cohort24clr.jpg]" height="137" width="461" >
          </div>
          <div style="text-indent:20pt; margin-top:12.6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Cohort 3: &nbsp;&nbsp;&nbsp;This randomized, double-blind, parallel arm portion of the clinical trial enrolled patients with Type 2 SMA who had initiated treatment with an approved SMN upregulator (nusinersen) before five&#160;years of age. Twenty patients were randomized in a 1:1 ratio to receive the low dose (apitegromab 2 mg /kg Q4W) or high dose (apitegromab 20 mg/kg Q4W); both treatment arms were in conjunction with an approved SMN upregulator therapy (nusinersen). Three patients (two in high-dose arm and one in low-dose arm) each missed three consecutive doses of apitegromab due to COVID-19-related site access restrictions and were excluded from the prespecified intent-to-treat primary analysis. The primary objectives of the cohort were to assess safety and the mean change from baseline in HFMSE following 12&#160;months of treatment. </font>
          </div>
          <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
            <img src="tm228243d1-tbl_cohort34clr.jpg" alt="[MISSING IMAGE: tm228243d1-tbl_cohort34clr.jpg]" height="147" width="459" >
          </div>
          <div style="text-indent:20pt; margin-top:12.6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Dose response was observed; the 20 mg/kg dose achieved numerically greater mean improvements from baseline in HFMSE scores than the 2 mg/kg dose across all assessed timepoints in the 12-month treatment period. The clinically observed dose response was consistent with the pharmacodynamic (target engagement) results. Both the 20 mg/kg and 2 mg/kg doses yielded high levels of target engagement (&gt;100-fold increase from baseline), but the 20 mg/kg dose led to a relatively higher absolute level of target engagement. </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Overall safety and tolerability profile: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Incidence and severity of adverse events were consistent with the underlying patient population and background therapy. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Five most frequently reported treatment-emergent adverse events: Headache (24%), pyrexia (22%), upper respiratory tract infection (22%), cough (22%), and nasopharyngitis (21%). </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Five patients experienced a serious treatment-emergent adverse event, all assessed by the respective trial investigator as unrelated to apitegromab: </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">One patient treated with 2 mg/kg dose (Cohort 3) hospitalized due to adenoidal hypertrophy and tonsillar hypertrophy to perform scheduled adenotonsillectomy (Grade 2). Event resolved without sequelae. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Two patients treated with 20 mg/kg dose (both Cohort 1) with gait inability considered a significant disability (both Grade 3). Events remain ongoing. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">One patient treated with 20 mg/kg dose (Cohort 1) hospitalized with post lumbar puncture syndrome (Grade 2). Event resolved without sequelae. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">One patient treated with 20 mg/kg dose (Cohort 1) hospitalized due to viral upper respiratory tract infection (Grade 2). Event resolved without sequelae. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">One patient (Cohort 1) presented with a non-serious Grade 3 post lumbar puncture syndrome; assessed by trial investigator as unrelated to apitegromab. Event resolved without sequelae. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">One patient (Cohort 1) discontinued from the clinical trial due to Grade 2 muscle fatigue that started prior to initiation of dosing with study drug; assessed by the clinical trial investigator as unrelated to apitegromab. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">From June to October&#160;2021, we announced supportive data from additional exploratory analyses from the TOPAZ Phase&#160;2 clinical trial at various medical congresses, including the Cure SMA virtual conference, the World Muscle Society virtual congress, the Child Neurology Society annual meeting, and the World Congress of Neurology. We believe these exploratory analyses further demonstrate the potential of apitegromab in patients with SMA: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Time to achieving various thresholds of improvement in HFMSE scores further supported the dose response in clinical efficacy. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Increases in RULM were also observed in both non-ambulatory cohorts. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Greater increases in HFMSE (non-ambulatory) and RHS (ambulatory) scores were seen in patients who were not limited by scoliosis or joint contractures. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Company information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We were incorporated in 2017 under the laws of the State of Delaware as the holding company for Scholar Rock, Inc. Scholar Rock, Inc. is a wholly owned subsidiary of Scholar Rock Holding Corporation. On December&#160;22, 2017, we completed a series of transactions pursuant to which Scholar Rock Merger Sub, LLC, a wholly owned subsidiary of Scholar Rock Holding Corporation, was merged with and into Scholar Rock, LLC, or the Reorganization. The purpose of the Reorganization was to reorganize our corporate structure so that we would continue as a corporation and so that our investors prior to the Reorganization would own our capital stock after the Reorganization rather than equity interests in a limited liability company. All of our convertible preferred stock converted into shares of common stock upon the completion of our initial public offering at the then effective conversion ratio. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential product candidates, producing drug substance and drug product material for use in preclinical studies and clinical trials, conducting preclinical studies of our product candidates and conducting clinical trials for our product candidates, apitegromab and SRK-181. We do not have any products approved for sale and have not generated any product revenue to date. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our principal executive offices are located at 301 Binney Street, Cambridge, MA 02142, and our phone number is (857) 259-3860. Our website address is http://www.scholarrock.com. The information contained on our website or social media accounts, or that can be accessed through our website or social media accounts, is not a part of this prospectus and is not incorporated by reference into this prospectus. You should not rely on any such information in deciding whether to purchase our common stock. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of being an emerging growth company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">As a company with less than $1.07&#160;billion in revenue during our most recently completed fiscal year, we qualify as an &#8220;emerging growth company&#8221; and &#8220;smaller reporting company&#8221; as defined in Section&#160;2(a) of </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">the Securities Act of 1933, as amended, or the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable, in general, to public companies that are not emerging growth companies. These provisions include: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">reduced disclosure about our executive compensation arrangements; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">exemption from the non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">reduced disclosure of financial information in this prospectus supplement, the accompanying prospectus and the information incorporated herein and therein, such as being permitted to include only two&#160;years of audited financial information and two&#160;years of selected financial information in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We may take advantage of these exemptions until we are no longer an emerging growth company. We would cease to be an emerging growth company on the last day of 2023, or sooner if we have more than $1.07&#160;billion in annual revenues as of the end of a fiscal year, have more than $700&#160;million in market value of our capital stock held by non-affiliates as of any June&#160;30 before that time or if we issue more than $1.0&#160;billion of non-convertible debt over a three-year-period. We may choose to take advantage of some, but not all, of the available exemptions. We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act, and have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The JOBS Act permits an emerging growth company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:8pt; margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">THE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:192pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Common stock offered by us </font>
            </div>
          </div>
          <div style="margin-left:216pt; margin-top:-12pt; width:240pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Shares of our common stock having an aggregate offering price of up to $150,000,000. </font>
          </div>
          <div style="width:192pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Common stock to be outstanding immediately after this offering </font>
            </div>
          </div>
          <div style="margin-left:216pt; margin-top:-12pt; width:240pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Up to 8,865,248 shares (as more fully described in the notes following this table), assuming sales of 8,865,248 shares of our common stock in this offering at an offering price of $16.92 per share, which was the last reported sale price of our common stock on The Nasdaq Global Select Market on March&#160;1, 2022. The actual number of shares issued will vary depending on the sales price under this offering. </font>
          </div>
          <div style="width:192pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Plan of Distribution </font>
            </div>
          </div>
          <div style="margin-left:216pt; margin-top:-12pt; width:240pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;At the market offering&#8221; that may be made from time to time through our sales agent, Jefferies LLC, or Jefferies. See &#8220;Plan of Distribution&#8221; on page <a href="#sPOD">S-20</a> of this prospectus. </font>
          </div>
          <div style="width:192pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of Proceeds </font>
            </div>
          </div>
          <div style="margin-left:216pt; margin-top:-12pt; width:240pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We currently intend to use the net proceeds from this offering for general corporate purposes. General corporate purposes may include research and development costs, including the conduct of clinical trials and process development and manufacturing of our product candidates, services or technologies, expansion of our technology infrastructure and capabilities, working capital, and capital expenditures. See &#8220;Use of Proceeds&#8221; on page <a href="#sUOP">S-17</a> of this prospectus. </font>
          </div>
          <div style="width:192pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Risk Factors </font>
            </div>
          </div>
          <div style="margin-left:216pt; margin-top:-12pt; width:240pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Investing in our common stock involves significant risks. See &#8220;Risk Factors&#8221; on page <a href="#sRIFA">S-13</a> of this prospectus and under similar headings in other documents incorporated by reference into this prospectus. </font>
          </div>
          <div style="width:192pt;">
            <div style="white-space:nowrap; margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">The Nasdaq Global Select Market </font>
              <br >
              <font style="letter-spacing:0.2pt;">Symbol </font>
            </div>
          </div>
          <div style="margin-left:216pt; margin-top:-12pt; width:240pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;SRRK&#8221; </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The number of shares of our common stock that will be outstanding immediately after this offering as shown above is based on 35,209,099 shares outstanding as of December&#160;31, 2021. The number of shares outstanding as of December&#160;31, 2021 as used throughout this prospectus, unless otherwise indicated, excludes: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">2,179,487 pre-funded warrants to purchase shares of common stock with an exercise price of $0.0001 per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">351,784 shares of common stock issuable upon the exercise of stock options outstanding as of December&#160;31, 2021 under our 2017 Stock Option and Incentive Plan at a weighted-average exercise price of $6.08 per share </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">3,391,616 shares of common stock issuable upon the exercise of stock options outstanding as of December&#160;31, 2021 under our 2018 Stock Option and Incentive Plan at a weighted-average exercise price of $27.57 per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">314,901 shares of common stock issuable upon the vesting and settlement of restricted stock&#160;units issued under our 2018 Stock Option and Incentive Plan; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">2,394,091 shares of common stock reserved for the future issuance under our 2018 Stock Option and Incentive Plan as of December&#160;31, 2021; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">1,137,373 shares of our common stock available for future issuance under our 2018 Employee Stock Purchase Plan as of December&#160;31, 2021.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="sRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described below and in the documents incorporated by reference in this prospectus, as well as other information we include or incorporate by reference into this prospectus, before making an investment decision. Our business, financial condition and results of operations could be materially adversely affected by the materialization of any of these risks. The trading price of our securities could decline due to the materialization of any of these risks, and you may lose all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks described in the documents incorporated herein by reference, including our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, which is on file with the SEC and is incorporated herein by reference, and other reports and documents that are incorporated by reference into this prospectus and other documents we file with the SEC that are deemed incorporated by reference into this prospectus supplement.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks related to this offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You will experience immediate and substantial dilution.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The offering price per share in this offering will be substantially higher than the net tangible book value per share of our common stock outstanding prior to this offering. Based on an estimated public offering price of $16.92 per share, and a net tangible book value of $172.1&#160;million, or $4.89 per share of common stock, as of December&#160;31, 2021, if you purchase securities in this offering, you will suffer immediate and substantial dilution of $9.72 per share in the net tangible book value of the securities you purchase representing the difference between our as adjusted net tangible book value per share after giving effect to this offering and the public offering price per share of common stock. The exercise of outstanding stock options and warrants will result in further dilution of your investment. See the section titled &#8220;Dilution&#8221; below for a more detailed illustration of the dilution you would incur if you participate in this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have broad discretion in the use of our existing cash, cash equivalents and marketable securities and the net proceeds from this offering and may not use them effectively.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our management will have broad discretion in the application of our existing cash, cash equivalents and marketable securities and the net proceeds from this offering, including for any of the purposes described in the section titled &#8220;Use of proceeds,&#8221; and you will not have the opportunity as part of your investment decision to assess whether such proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of our existing cash and cash equivalents and the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our existing cash and cash equivalents and the net proceeds from this offering in ways that ultimately increase the value of your investment. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You may experience future dilution as a result of future equity offerings.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to those of existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sales of a substantial number of shares of our common stock in the public market after this offering could cause our stock price to fall.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. In addition, the sale of substantial amounts of our common stock could adversely impact the price of our common stock. As of December&#160;31, 2021, 35,209,099 shares of our common stock were outstanding. The sale, or the availability for sale, of a large number of shares of our common stock in the public market could cause the price of our common stock to decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The common stock offered hereby will be sold in &#8220;at the market&#8221; offerings, and investors who buy shares at different times will likely pay different prices.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investors who purchase shares in this offering at different times will likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold, and there is no minimum or maximum sales price. Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices they paid. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The actual number of shares we will issue under the sales agreement, at any one time or in total, is uncertain.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver placement notices to Jefferies LLC, or Jefferies, at any time throughout the term of the sales agreement. The number of shares that are sold by Jefferies after delivering a placement notice will fluctuate based on the market price of the common stock during the sales period and limits we set with Jefferies. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since our common stock began trading on The Nasdaq Global Select Market on May&#160;29, 2018, our stock has traded at prices as low as $6.95 per share and as high as $70.00 per share through March&#160;1, 2022. This volatility may affect the price at which you could sell the shares of our common stock, and the sale of substantial amounts of our common stock could adversely affect the price of our common stock. Our stock price is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and other factors, including those described in the sections captioned &#8220;Risk factors&#8221; in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a result, you may not be able to sell your shares of common stock at or above the price at which you purchase them. In addition, the stock market in general, and The Nasdaq Global Select Market and the stock of biotechnology and emerging pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="sCSRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement and the accompanying prospectus, including the documents that we incorporate by reference herein and therein, contain forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions, or the negative of these terms, or similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus supplement and the accompanying prospectus, and in particular those factors referenced in the section &#8220;Risk factors.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement and the accompanying prospectus contain forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. These statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success, cost and timing of preclinical studies and clinical trials for apitegromab, including, but not limited to, progress and completion of clinical trials for apitegromab, and the results, and the timing of results, from these trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success, cost and timing of clinical trials for SRK-181, including the results, progress and completion of our DRAGON Phase&#160;1 clinical trial for SRK-181, any preclinical studies and any future clinical trials for SRK-181, and the results, and the timing of results, from these trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success, cost and timing of our other product development activities, preclinical studies and clinical trials, and the results, and timing of results, from these studies and trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our success in identifying and executing a development program for additional indications for apitegromab, SRK-181 and in identifying product candidates from our other programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the clinical utility of our product candidates and their potential advantages over other therapeutic options; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to obtain, generally or on terms acceptable to us, funding for our operations, including funding necessary to complete further development and, upon successful development, if approved, commercialization of apitegromab, SRK-181 or any of our future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">risks associated with the COVID-19 pandemic, which may adversely impact our workforce, global supply chain, business, preclinical studies, clinical trials and financial results; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential for our identified research priorities to advance our proprietary platform, development programs or product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing, scope or likelihood of our ability to obtain and maintain regulatory approval from the </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">U.S. Food and Drug Administration, or FDA, the European Commission and other regulatory authorities for apitegromab, SRK-181 and any future product candidates, and any related restrictions, limitations or warnings in the label of any approved product candidate; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to continue to grow our organization, including our personnel, systems and relationships with third parties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to retain our executives and highly skilled technical and managerial personnel, which could be affected due to any transition in management, or if we fail to recruit additional highly skilled personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:138pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and the duration of such protection; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability and the potential to successfully manufacture our product candidates for clinical trials and for commercial use, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to establish or maintain collaborations or strategic relationships, including our collaboration with Gilead Sciences Inc., or Gilead; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations relating to the potential of our proprietary platform technology; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to obtain additional funding when necessary; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets, either alone or in combination with others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations related to the use of our cash reserves; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact of new laws and regulations or amendments to existing laws and regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">developments and projections relating to our competitors and our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expected use of proceeds from this offering; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our estimates and expectations regarding cash and expense levels, future revenues, capital requirements and needs for additional financing, including our expected use of proceeds from our public offerings, and liquidity sources; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations regarding the period during which we qualify as an emerging growth company, or EGC, under the Jumpstart Our Business Startups Act. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have included important factors in the cautionary statements included in this prospectus supplement and the accompanying prospectus and the documents we incorporate by reference herein and therein, particularly in the &#8220;Risk factors&#8221; sections of these documents, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. No forward-looking statement is a guarantee of future performance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should read this prospectus supplement the accompanying prospectus and the documents that we incorporate by reference herein and therein completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements in this prospectus supplement and the accompanying prospectus and the documents we incorporate by reference herein and therein represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward- looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="sUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:456pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $150,000,000 from time to time. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently intend to use the net proceeds from this offering for general corporate purposes. General corporate purposes may include research and development costs, including the conduct of clinical trials and process development and manufacturing of our product candidates, services or technologies, expansion of our technology infrastructure and capabilities, working capital, and capital expenditures. We may temporarily invest the net proceeds in a variety of capital preservation instruments, including investment grade, interest bearing instruments and U.S. government securities, until they are used for their stated purpose. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="sDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DILUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Purchasers of common stock offered by this prospectus will suffer immediate and substantial dilution in the net tangible book value per share of common stock. Our net tangible book value as of December&#160;31, 2021 was approximately $172.1&#160;million, or approximately $4.89 per share of common stock. Net tangible book value per share represents the amount of total tangible assets (total assets less intangible assets) less total liabilities, divided by the number of shares of our common stock outstanding as of December&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dilution in net tangible book value per share represents the difference between the amount per share paid by purchasers in this offering and the net tangible book value (deficit) per share of our common stock immediately after this offering. After giving effect to the assumed sale of shares of our common stock in the aggregate amount of approximately $150,000,000 at an assumed offering price of $16.92 per share, the last reported sale price of our common stock on March&#160;1, 2022, and after deduction of commissions and offering expenses payable by us, our as adjusted net tangible book value as of December&#160;31, 2021 would have been approximately $317.2&#160;million, or $7.20 per share of common stock. This represents an immediate increase in net tangible book value of $2.31 per share of common stock to our existing stockholders and an immediate dilution in net tangible book value of $9.72 per share of common stock to investors participating in this offering at an assumed offering price of $16.92 per share. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table illustrates this per share dilution: </font>
        </div>
        <table style="width:456pt;height:83pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:381.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Assumed offering price per share </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">16.92 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:381.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net tangible book value per share as of December&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">4.89 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:381.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Increase in per share attributable to new investors attributable to this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">2.31 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:381.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">As adjusted net tangible book value per share as of December&#160;31, 2021, after giving effect </font>
                <br >
                <font style="letter-spacing:0.2pt;">to this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">7.20 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 4pt 0pt; width:381.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dilution per share to new investors participating in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt;border-bottom:3px double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">9.72</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.3pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The table above assumes for illustrative purposes that an aggregate of 8,865,248 shares of our common stock are sold at a price of $16.92 per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on March&#160;1, 2022, for aggregate gross proceeds of approximately $150,000,000. The shares sold in this offering, if any, will be sold from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $16.92 per share shown in the table above, assuming all of our common stock in the aggregate amount of approximately $150,000,000 is sold at that price, would result in an increase to our adjusted net tangible book value per share after the offering to $7.28 and an increase in the dilution in net tangible book value per share to new investors in this offering to $10.64, after deducting commissions and estimated offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $16.92 per share shown in the table above, assuming all of our common stock in the aggregate amount of approximately $150,000,000 is sold at that price, would result in a decrease to our adjusted net tangible book value per share after the offering to $7.11and a decrease in the dilution in net tangible book value per share to new investors in this offering to $8.81, after deducting commissions and estimated offering expenses payable by us. This information is supplied for illustrative purposes only, and will adjust based on the actual offering prices, the actual number of shares that we offer and sell in this offering and other terms of each sale of shares in this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The information above and in the foregoing table is based upon 35,209,099 shares of our common stock outstanding as of December&#160;31, 2021. The information above and in the foregoing table excludes as of December&#160;31, 2021: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">2,179,487 pre-funded warrants to purchase shares of common stock with an exercise price of $0.0001 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">351,784 shares of common stock issuable upon the exercise of stock options outstanding as of December&#160;31, 2021 under our 2017 Stock Option and Incentive Plan at a weighted-average exercise price of $6.08 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:422pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">3,391,616 shares of common stock issuable upon the exercise of stock options outstanding as of December&#160;31, 2021 under our 2018 Stock Option and Incentive Plan at a weighted-average exercise price of $27.57 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">314,901 shares of common stock issuable upon the vesting and settlement of restricted stock&#160;units issued under our 2018 Stock Option and Incentive Plan; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">2,394,091 shares of common stock reserved for the future issuance under our 2018 Stock Option and Incentive Plan as of December&#160;31, 2021; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">1,137,373 shares of our common stock available for future issuance under our 2018 Employee Stock Purchase Plan as of December&#160;31, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may choose to raise additional capital in the future through the sale of equity or convertible debt securities due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that any of our outstanding options are exercised, new options are issued under our equity incentive plans or we issue additional shares of common stock or other equity or convertible debt securities in the future, there will be further dilution to investors participating in this offering. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="sPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We previously entered into a certain Open Market Sale Agreement</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">SM</font><font style="letter-spacing:0.2pt;">, or sales agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus. We originally filed a prospectus supplement, dated March&#160;9, 2021, or the Prior Prospectus Supplement, for the offer and sale of up to $150,000,000 of shares of our common stock, from time to time through Jefferies, acting as our agent, pursuant to the sales agreement under the shelf registration statement on Form S-3 (Registration Statement No. 333-254057). As of the date of this prospectus, we have issued and sold $13,500,000 of our common stock pursuant to the sales agreement and the Prior Prospectus Supplement filed on March&#160;9, 2021. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $150,000,000 from time to time through Jefferies, acting as agent. The common stock remaining available to be sold under the Prior Prospectus as of the date of this prospectus will no longer be offered and sold under the Prior Prospectus, but will instead be offered and sold under this prospectus. Accordingly, this prospectus covers the offer and sale of $150,000,000 to be sold under the sales agreement as of the date of this prospectus. Sales of our shares of common stock, if any, under this prospectus will be made by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each time we wish to issue and sell shares of common stock under the sales agreement, we will notify Jefferies of the number of shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be made. Once we have so instructed Jefferies, unless Jefferies declines to accept the terms of such notice, Jefferies has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of Jefferies under the sales agreement to sell our shares of common stock are subject to a number of conditions that we must meet. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The settlement of sales of shares between us and Jefferies is generally anticipated to occur on the second trading day following the date on which the sale was made. Sales of our shares of common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by such other means as we and Jefferies may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will pay Jefferies a commission equal to 3.0% of the aggregate gross proceeds we receive from each sale of our shares of common stock. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. In addition, we have agreed to reimburse Jefferies for the fees and disbursements of its counsel, payable upon execution of the sales agreement, in an amount not to exceed </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">$50,000, in addition to certain ongoing disbursements of its legal counsel unless we and Jefferies otherwise agree. We estimate that the total expenses for the offering, excluding any commissions or expense reimbursement payable to Jefferies under the terms of the sales agreement, will be approximately $0.6&#160;million. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale of such shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Jefferies will provide written confirmation to us before the open on The Nasdaq Global Select Market on the day following each day on which shares of common stock are sold under the sales agreement. Each confirmation will include the number of shares sold on that day, the aggregate gross proceeds of such sales and the proceeds to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the sale of the shares of common stock on our behalf, Jefferies will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have agreed to indemnify Jefferies against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to contribute to payments Jefferies may be required to make in respect of such liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The offering of our shares of common stock pursuant to the sales agreement will terminate as permitted therein. We and Jefferies may each terminate the sales agreement at any time upon ten days&#8217; prior notice. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:480pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This summary of the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions. A copy of the sales agreement is filed as an exhibit to the registration statement of which this prospectus supplement forms a part. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Jefferies and its affiliates may in the future provide various investment banking, commercial banking, financial advisory and other financial services for us and our affiliates, for which services they may in the future receive customary fees. In the course of its business, Jefferies may actively trade our securities for its own account or for the accounts of customers, and, accordingly, Jefferies may at any time hold long or short positions in such securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Jefferies, and Jefferies may distribute the prospectus supplement and the accompanying prospectus electronically. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="sLEMA">&#8203;</a><a name="sEXP">&#8203;</a><a name="sWYCF">&#8203;</a><a name="sIOCI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain legal matters, including the legality of the securities offered, will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Jefferies LLC is being represented in this offering by Cooley LLP, New York, New York. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of a registration statement that we have filed with the SEC. Certain information in the registration statement has been omitted from this prospectus in accordance with the rules of the SEC. We are subject to the information requirements of the Exchange Act and, in accordance therewith, file annual, quarterly and special reports, proxy statements and other information with the SEC. These documents also may be accessed through the SEC&#8217;s electronic data gathering, analysis and retrieval system, or EDGAR, via electronic means, including the SEC&#8217;s home page on the Internet (www.sec.gov). You may also inspect the registration statement and this prospectus on this website. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have the authority to designate and issue more than one class or series of stock having various preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends, qualifications, and terms and conditions of redemption. We will furnish a full statement of the relative rights and preferences of each class or series of our stock which has been so designated and any restrictions on the ownership or transfer of our stock to any shareholder upon request and without charge. Written requests for such copies should be directed Investor Relations, Scholar Rock Holding Corporation, 301 Binney Street, Cambridge, MA 02142. Our website is located at http://www.scholarrock.com. Information contained on our website is not incorporated by reference into this prospectus, and, except for the documents incorporated by reference as noted below, you should not consider any information on, or that can be accessed from, our website as part of this prospectus or any accompanying prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus, and information that we file after the date hereof with the SEC will automatically update and supersede the information already incorporated by reference. We are incorporating by reference the documents listed below, which we have already filed with the SEC, and any future filings we make with the SEC under Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any future report or document that is not deemed filed under such provisions, after the date of this prospectus and prior to the termination of this offering: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000155837021002641/srrk-20201231x10k.htm">our Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the SEC on March&#160;9, 2021;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our Quarterly Reports on Form 10-Q for the periods ended March&#160;31, 2021, filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000155837021007006/srrk-20210331x10q.htm">May&#160;13, 2021</a>, June&#160;30, 2021, filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000155837021011162/srrk-20210630x10q.htm">August&#160;10, 2021</a>, and September&#160;30, 2021, filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000155837021015180/srrk-20210930x10q.htm">November&#160;9, 2021</a>; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our Current Reports on Form 8-K, filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000308/a52392795.htm">March&#160;9, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000363/a52398331.htm">March&#160;18, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000429/a52406941.htm">April&#160;6, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000657/a52428778.htm">May&#160;13, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000719/a52436081.htm">May&#160;26, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000110465921075400/tm2118189d2_8k.htm">June&#160;2, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000791/a52445497.htm">June&#160;15, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321000978/a52470483.htm">August&#160;3, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321001034/a52474958.htm">August&#160;10, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321001375/a52525640.htm">November&#160;9, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000110465921140588/tm2133126d1_8k.htm">November&#160;17, 2021</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752321001456/a52542691.htm">November&#160;30, 2021</a> and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1727196/000115752322000039/a52559698.htm">January&#160;10, 2022</a> (to the extent the information in such report is filed and not furnished; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1727196/000104746920002534/a2241420zdef14a.htm">our Definitive Proxy Statement on Schedule&#160;14A (other than information furnished rather than filed), filed with the SEC on April&#160;23, 2020; and</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:264pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;letter-spacing:0.2pt;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;letter-spacing:0.2pt;">
          <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1727196/000110465918034869/a18-8552_78a12b.htm">the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on May&#160;21, 2018, including any amendments or reports filed for the purposes of updating this description.</a><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to Rule&#160;412 under the Securities Act, any statement contained in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, a copy of the documents incorporated by reference into this prospectus but not delivered with the prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus, at no cost by writing us at the following address: Investor Relations, Scholar Rock Holding Corporation, 301 Binney Street, Cambridge, MA 02142. Our website is located at </font><font style="font-style:italic;letter-spacing:0.2pt;">http://www.scholarrock.com</font><font style="letter-spacing:0.2pt;">. The reference to our website is intended to be an inactive textual reference and, except for the documents incorporated by reference as noted above, the information on, or accessible through, our website is not intended to be part of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on the information incorporated by reference or provided in this prospectus and the accompanying prospectus. We have not authorized anyone else to provide you with different information. You should not assume that the information in this prospectus or in the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus or those documents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We advise that there have been no material changes in our affairs that have occurred since the end of the latest fiscal period for which audited financial statements were included in the latest Form 10-K and that have not been described in a Form 10-Q or Form 8-K filed under the Exchange Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of a registration statement we filed with the SEC. We have incorporated exhibits into this registration statement. You should read the exhibits carefully for provisions that may be important to you.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;margin-top:98.5pt; text-align:center; width:456pt;">
          <img src="lg_scholarrocknew-4clr.jpg" alt="[MISSING IMAGE: lg_scholarrocknew-4clr.jpg]" height="60" width="317" >
        </div>
        <div style="margin-top:65pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to $150,000,000</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:119.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 119.166666666667pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:28pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>
        <div style="margin-top:22.833pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 22.8333333333333pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:88pt; text-align:center; width:456pt; line-height:18pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">Jefferies</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:59.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 59.1666666666666pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:40pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">March&#160;7, 2021 </font>
        </div>
        <div style="margin-top:38.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 38.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Part&#160;II&#8201;&#8212;&#8201;INFORMATION NOT REQUIRED IN PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;14.&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The expenses payable by Scholar Rock Holding Corporation (the &#8220;Registrant&#8221; or the &#8220;Company&#8221;) in connection with the issuance and distribution of the securities being registered (other than underwriting discounts and commissions, if any) are set forth below. Each item listed is estimated, except for the Securities and Exchange Commission (the &#8220;SEC&#8221;) registration fee. </font>
        </div>
        <table style="width:416pt;height:115.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:365.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Securities and Exchange Commission registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">27,810<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:365.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">FINRA filing fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">225,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:365.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:365.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accounting fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:365.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Printing fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:365.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Transfer agent and trustee fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:365.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Miscellaneous </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:365.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Estimated expenses not presently known </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:3.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The registrant previously paid a fee of $16,365 related to $150,000,000 of the registrant&#8217;s common stock pursuant to the Prior Prospectus. Of such shares of common stock, $136,500,000 remain unsold, and the registration fee in the amount of $14,892 related thereto is applied to the registrant&#8217;s total registration fee hereunder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;15.&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145 of the Delaware General Corporation Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys&#8217; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section&#160;145 permits corporations to pay expenses (including attorneys&#8217; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&#160;145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section&#160;145. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have adopted provisions in our certificate of incorporation and bylaws that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any breach of the director&#8217;s duty </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">of loyalty to us or our stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any transaction from which the director derived an improper personal benefit. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:7.5pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, our bylaws provide that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we will advance reasonable expenses, including attorneys&#8217; fees, to our directors and, in the discretion of our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have entered, and intend to continue to enter, into separate indemnification agreements with our directors, officers and certain of our key employees, in addition to the indemnification provided for in our amended and restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, require us to indemnify our directors, officers and key employees for certain expenses, including attorneys&#8217; fees, judgments, penalties, fines and settlement amounts actually incurred by these individuals in any action or proceeding arising out of their service to us or any of our subsidiaries or any other company or enterprise to which these individuals provide services at our request. Subject to certain limitations, our indemnification agreements also require us to advance expenses incurred by our directors, officers and key employees for the defense of any action for which indemnification is required or permitted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also maintain general liability insurance which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#8217;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;16.&nbsp;&nbsp;&nbsp;Exhibits</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A list of exhibits filed with this registration statement on Form S-3 is set forth on the Exhibit&#160;Index and is incorporated herein by reference. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXHIBIT INDEX</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:182.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:38.91pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit&#160;No. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:405.09pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;1.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:405.09pt;">
              <font style="letter-spacing:0.2pt;">Form of Underwriting Agreement </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;1.2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000110465921033893/tm219041d2_ex1-2.htm">Open Market Sale Agreement</a><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000110465921033893/tm219041d2_ex1-2.htm">SM</a></font><a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000110465921033893/tm219041d2_ex1-2.htm">, by and between Scholar Rock Holding Corporation and Jefferies LLC, dated March&#160;9, 2021 (incorporated by reference to Exhibit&#160;1.2 to the Registrant&#8217;s Form S-3ASR filed on March&#160;9, 2021)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;3.1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000104746918003566/a2235535zex-3_2.htm">Amended and Restated Certificate of Incorporation of Scholar Rock Holding Corporation (incorporated by reference to Exhibit&#160;3.2 to the Registrant&#8217;s Form S-1/A filed on May&#160;8, 2018)</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;3.2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000104746918003733/a2235690zex-3_11.htm">Amendment to Amended and Restated Certificate of Incorporation of Scholar Rock Holding Corporation (incorporated by reference to Exhibit&#160;3.1.1 to the Registrant&#8217;s Form S-1/A filed on May&#160;14, 2018)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;3.3 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000104746918003566/a2235535zex-3_4.htm">Amended and Restated Bylaws of Scholar Rock Holding Corporation (incorporated by reference to Exhibit&#160;3.4 to the Registrant&#8217;s Form S-1/A filed on May&#160;8, 2018)</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;4.1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000104746918003733/a2235690zex-4_2.htm">Specimen Stock Certificate evidencing shares of common stock (incorporated by reference to Exhibit&#160;4.2 to the Registrant&#8217;s Form S-1/A filed on May&#160;14, 2018)</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:395.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:justify;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:38.91pt;">
              <div style="white-space:nowrap; text-align:justify;">
                <font style="letter-spacing:-0.16pt;">Exhibit&#160;No. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:405.09pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;4.2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000104746918003300/a2235501zex-4_3.htm">Amended and Restated Warrant to Purchase Stock, by and between Scholar Rock Holding Corporation and Silicon Valley Bank, dated December&#160;22, 2017 (incorporated by reference to Exhibit&#160;4.3 to the Registrant&#8217;s Form S-1 filed on April&#160;27, 2018)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;4.3 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000110465918074533/a18-42019_1ex10d4.htm">Registration Rights Agreement, by and among Scholar Rock Holding Corporation, Gilead Sciences, Inc. and certain of the Registrant&#8217;s stockholders named therein (incorporated by reference to Exhibit&#160;10.4 to the Current Report on Form 8-K/A filed on December&#160;24, 2018)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;4.4 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000110465921033893/tm219041d2_ex4-5.htm">Form of indenture for senior debt securities and the related form of senior debt security (incorporated by reference to Exhibit&#160;4.5 to the Registrant&#8217;s Form S-3ASR filed on March&#160;9, 2021)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;4.5 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000110465921033893/tm219041d2_ex4-6.htm">Form of indenture for subordinated debt securities and the related form of subordinated debt security (incorporated by reference to Exhibit&#160;4.6 to the Registrant&#8217;s Form S-3ASR filed on March&#160;9, 2021)</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;4.6* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <font style="letter-spacing:0.2pt;">Form of Certificate of Designations </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;4.8* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <font style="letter-spacing:0.2pt;">Form of Warrant Agreements </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;4.9* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <font style="letter-spacing:0.2pt;">Form of Unit Certificate</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;4.10* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <font style="letter-spacing:0.2pt;">Form of Preferred Stock Certificate </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;5.1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm228243d2_ex5-1.htm">Opinion of Goodwin Procter LLP </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;5.2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000110465921033893/tm219041d2_ex5-2.htm">Opinion of Goodwin Procter LLP relating to the sales agreement prospectus (incorporated by reference to Exhibit&#160;5.2 to the Registrant&#8217;s Form S-3ASR filed on March&#160;9, 2021)</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;23.1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm228243d2_ex23-1.htm">Consent of Ernst &amp; Young LLP </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;23.2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm228243d2_ex5-1.htm">Consent of Goodwin Procter LLP (included in Exhibit&#160;5.1 hereto) </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;23.3 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1727196/000110465921033893/tm219041d2_ex5-2.htm">Consent of Goodwin Procter LLP (included in Exhibit&#160;5.2 hereto)</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;24.1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:405.09pt;">
              <div style="letter-spacing:0.2pt;">
                <a href="#tSIG">Power of Attorney (included on the signature pages to this registration statement) </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;25.1** </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Form T-1 Statement of Eligibility of Trustee for Senior Indenture under the Trust Indenture Act of 1939 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">&#8199;25.2** </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:405.09pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Form T-1 Statement of Eligibility of Trustee for Subordinated Indenture under the Trust Indenture Act of 1939 </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:38.91pt;">
              <font style="letter-spacing:0.2pt;">107 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:405.09pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm228243d2_ex-filingfees.htm">Filing Fee table</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.1pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">To be filed if necessary by amendment or as an exhibit to a document to be incorporated or deemed to be incorporated by reference in this registration statement, including a Current Report on Form 8-K. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">**</font>
          <br >
        </div>
        <div style=" margin-top:4.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">To be filed by amendment pursuant to Section&#160;305(b)(2) of the Trust Indenture Act of 1939.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;17.&nbsp;&nbsp;&nbsp;Undertakings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.69pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:8.69pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:60pt; width:396pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">represent no more than a 20&#160;percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </font>
        </div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that paragraphs (l)(i), (l)(ii) and (l)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is part of the registration statement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> offering thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">Each prospectus filed by the registrant pursuant to Rule&#160;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">Each prospectus required to be filed pursuant to Rule&#160;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&#160;430B relating to an offering made pursuant to Rule&#160;415(a)(l)(i), (vii), or (x)&#160;for the purpose of providing the information required by Section&#160;10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> offering thereof; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided, however</font><font style="letter-spacing:0.2pt;">, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:260pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:40pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iii)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> offering thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">To file an application for the purpose of determining the eligibility of the trustee to act under subsection (a)&#160;of Section&#160;310 of the Trust Indenture Act of 1939 in accordance with the rules and regulations prescribed by the Securities and Exchange Commission under Section&#160;305(b)(2) of the Trust Indenture Act of 1939.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSIG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:11.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the city of Cambridge, Massachusetts, on this 7th day of March, 2022. </font>
        </div>
        <table style="width:456pt;height:63pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:11.5pt 0pt 1.5pt 0pt; width:0pt;" colspan="4">
              <font style="letter-spacing:-0.2pt;">SCHOLAR ROCK HOLDING CORPORATION</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:12pt;">
              <font style="letter-spacing:0.2pt;">By: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:210pt;white-space:normal;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Nagesh K. Mahanthappa</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 210pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Nagesh K. Mahanthappa </font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Interim President and Chief Executive Officer</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby severally constitutes and appoints each of Stuart A. Kingsley and Edward H. Myles, and each of them singly, as such person&#8217;s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in such person&#8217;s name, place and stead, in any and all capacities, to sign any or all amendments (including, without limitation, post-effective amendments) to this registration statement (or any registration statement for the same offering that is to be effective upon filing pursuant to Rule&#160;462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities indicated on the date indicated: </font>
        </div>
        <table style="width:456pt;height:254.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:204pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:41.25pt; white-space:normal;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:144pt;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Nagesh K. Mahanthappa</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Nagesh K. Mahanthappa </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:204pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Interim President, Chief Executive Officer and Director (Principal Executive Officer) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:84pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">March&#160;7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:41pt; white-space:normal;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:144pt;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Edward H. Myles </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Edward H. Myles</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:204pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Chief Financial Officer (Principal Financial and Accounting Officer) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:84pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">March&#160;7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:41pt; white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ David Hallal </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">David Hallal</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:204pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:84pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">March&#160;7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:41pt; white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Kristina Burow </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Kristina Burow</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:204pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:84pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">March&#160;7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:41pt; white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Jeffrey S. Flier </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Jeffrey S. Flier, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:204pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Director</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:84pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">March&#160;7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:12pt;white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Michael Gilman </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Michael Gilman, Ph.D.</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:204pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:84pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">March&#160;7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:479.5pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:131.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:204pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:41.25pt; white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Amir Nashat </font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Amir Nashat, Sc.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:204pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:84pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">March&#160;7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:41pt; white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Akshay Vaishnaw</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Akshay Vaishnaw M.D., Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:204pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:84pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">March&#160;7, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:12pt;white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:144pt;white-space:normal;vertical-align:top;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">/s/ Joshua Reed</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Joshua Reed </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:204pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:84pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">March&#160;7, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm228243d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 71%">
    <IMG SRC="tm228243d1_ex5-1img001.jpg" ALT=""><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 29%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Goodwin Procter&nbsp;<FONT STYLE="font-variant: small-caps">llp</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 Northern Avenue<BR>
    Boston, MA 02210</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">goodwinlaw.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 617 570 1000</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5in">March 7, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock Holding Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">301 Binney Street, 3<SUP>rd</SUP>&nbsp;Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cambridge, MA 02142</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Being Registered under Registration Statement on Form S-3</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel to
you in connection with your filing of a Post-Effective Amendment No. 1 (the &ldquo;Amendment&rdquo;) to the Registration Statement on
Form S-3 (File No. 333-254057) (as amended or supplemented, the &ldquo;Registration Statement&rdquo;) pursuant to the Securities Act of
1933, as amended (the &ldquo;Securities Act&rdquo;), relating to the offering by Scholar Rock Holding Corporation, a Delaware corporation
(the &ldquo;Company&rdquo;), of up to $300,000,000 of any combination of (i)&nbsp;common stock, par value $0.001 per share (the &ldquo;Common
Stock&rdquo;), of the Company, (ii)&nbsp;preferred stock, par value $0.001 per share, of the Company (the &ldquo;Preferred Stock&rdquo;),
(iii)&nbsp;debt securities of the Company (&ldquo;Debt Securities&rdquo;), (iv)&nbsp;warrants to purchase Common Stock, Preferred Stock,
Debt Securities or Units (as defined below ) (&ldquo;Warrants&rdquo;) and (v)&nbsp; units comprised of Common Stock, Preferred Stock,
Debt Securities, Warrants and other securities in any combination (&ldquo;Units&rdquo;). The Common Stock, Preferred Stock, Debt Securities,
Warrants and Units are sometimes referred to collectively herein as the &ldquo;Securities.&rdquo; Pursuant to the Amendment, up to $300,000,000
of Securities may be issued in an unspecified number (with respect to Common Stock, Preferred Stock, Warrants and Units) or up to $300,000,000
in an unspecified principal amount (with respect to Debt Securities). The Registration Statement provides that the Securities may be offered
separately or together, in separate series, in amounts, at prices and on terms to be set forth in one or more prospectus supplements (each
a &ldquo;Prospectus Supplement&rdquo;) to the prospectus contained in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have reviewed such documents
and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent
verification, on certificates of public officials and, as to matters of fact material to the opinions set forth below, on certificates
of officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The opinions set forth below
are limited to the Delaware General Corporation Law and the law of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the opinions
set forth below, without limiting any other exceptions or qualifications set forth herein, we have assumed that (i) each of the Debt Securities,
Warrants and Units, and the indentures, warrant agreements, unit agreements and other agreements governing Securities offered pursuant
to the Registration Statement will be governed by the internal law of New York and (ii) after the issuance of any Securities offered pursuant
to the Registration Statement, the total number of issued shares of Common Stock or Preferred Stock, as applicable, together with the
total number of shares of such stock issuable upon the exercise, exchange, conversion or settlement, as the case may be, of any exercisable,
exchangeable or convertible security (including without limitation any Unit), as the case may be, then outstanding, will not exceed the
total number of authorized shares of Common Stock or Preferred Stock, as applicable, available for issuance under the Company&rsquo;s
certificate of incorporation as then in effect (the &ldquo;Charter&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the opinions
set forth below, we refer to the following as the &ldquo;Future Authorization and Issuance&rdquo; of Securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">with respect to any of the Securities, (a)&nbsp;the authorization by the Company of the amount, terms and issuance of such Securities (the &ldquo;Authorization&rdquo;) and (b)&nbsp;the issuance of such Securities in accordance with the Authorization therefor upon the receipt by the Company of the consideration (which, in the case of shares of Common Stock or Preferred Stock, is not less than the par value of such shares) to be paid therefor in accordance with the Authorization;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">with respect to Preferred Stock, (a)&nbsp;the establishment of the terms of such Preferred Stock by the Company in conformity with the Charter and applicable law and (b)&nbsp;the execution, acknowledgement and filing with the Delaware Secretary of State, and the effectiveness of, a certificate of designations to the Charter setting forth the terms of such Preferred Stock in accordance with the Charter and applicable law;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">with respect to Debt Securities, (a)&nbsp;the authorization, execution and delivery of the indenture or a supplemental indenture relating to such Securities by the Company and the trustee thereunder and/or (b)&nbsp;the establishment of the terms of such Securities by the Company in conformity with the applicable indenture or supplemental indenture and applicable law, and (c)&nbsp;the execution, authentication and issuance of such Securities in accordance with the applicable indenture or supplemental indenture and applicable law; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">with respect to Warrants or Units, (a)&nbsp;the authorization, execution and delivery by the Company and the other parties thereto of any agreement under which such Securities are to be issued, and (b)&nbsp;the establishment of the terms of such Securities and the issuance of such Securities in conformity with those terms, the terms of any applicable agreement and applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon the foregoing,
and subject to the additional qualifications set forth below, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the Future Authorization and Issuance of shares of Common Stock, such shares of Common Stock will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the Future Authorization and Issuance of shares of Preferred Stock, such shares of Preferred Stock will be validly issued, fully paid
and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the Future Authorization and Issuance of Debt Securities, such Debt Securities will be valid and binding obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the Future Authorization and Issuance of Warrants, such Warrants will be valid and binding obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the Future Authorization and Issuance of Units, such Units will be valid and binding obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The opinions expressed above
are subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general application affecting
the rights and remedies of creditors and to general principles of equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion letter and the
opinions it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74&nbsp;<I>Business Lawyer</I>&nbsp;815
(Summer 2019).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the inclusion
of this opinion as Exhibit 5.1 to the Registration Statement and to the references to our firm under the caption &ldquo;Legal Matters&rdquo;
in the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required
under Section 7 of the Securities Act or the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Goodwin Procter LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">GOODWIN PROCTER&nbsp;LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tm228243d2_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the reference to our firm under the caption &#8220;Experts&#8221;
in the Post-Effective Amendment No. 1 to the Registration Statement (Form S-3 No. 333-254057) and related Prospectus of Scholar Rock Holding
Corporation for the registration of common stock, preferred stock, debt securities, warrants and units of Scholar Rock Holding Corporation
and to the incorporation by reference therein of our report dated March 9, 2021, with respect to the consolidated financial statements
of Scholar Rock Holding Corporation included in its Annual Report (Form 10-K) for the year ended December 31, 2020, filed with the Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Ernst &amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boston, Massachusetts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 7, 2022</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>tm228243d2_ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt 0; font-size: 10pt"><B>Exhibit 107</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Calculation of Filing
Fee Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><U>Form S-3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">SCHOLAR ROCK HOLDING CORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Exact Name of Registrant
as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><U>Table 1: Newly Registered
and Carry Forward Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 7pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 7pt">
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; vertical-align: bottom; text-align: center">Security <BR> Type</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; vertical-align: bottom; text-align: center">Security <BR> Class <BR> Title</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 7pt; vertical-align: bottom; text-align: center">Fee <BR> Calculation <BR> or Carry <BR> Forward <BR> Rule</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 7pt; vertical-align: bottom; text-align: center">Amount <BR> Registered (1)</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 7pt; vertical-align: bottom; text-align: center">Proposed <BR> Maximum <BR> Offering <BR> Price Per <BR> Unit (2)</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 7pt; vertical-align: bottom; text-align: center">Maximum <BR> Aggregate <BR> Offering <BR> Price</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 7pt; vertical-align: bottom; text-align: center">Fee <BR> Rate</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 7pt; vertical-align: bottom; text-align: center">Amount of <BR> Registration <BR> Fee</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 7pt; vertical-align: bottom; text-align: center">Carry <BR> Forward <BR> Form <BR> Type</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; vertical-align: bottom; text-align: center">Carry <BR> Forward <BR> File <BR> Number</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 7pt; vertical-align: bottom; text-align: center">Carry <BR> Forward <BR> Initial <BR> effective <BR> date</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 7pt; vertical-align: bottom">Filing&nbsp;Fee <BR> Previously <BR> Paid&nbsp;In <BR> Connection <BR> with&nbsp;Unsold <BR> Securities&nbsp;to<BR> be&nbsp;Carried <BR> Forward</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: rgb(204,238,255)">
    <TD COLSPAN="40" STYLE="font-size: 7pt; vertical-align: middle; text-align: center">Newly Registered Securities</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: White">
    <TD STYLE="text-align: left; font-size: 7pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="padding-left: 2pt; font-size: 7pt; vertical-align: middle; text-align: left">Primary Offering of Securities:</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: left">Fees to Be Paid </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: center">Equity </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; vertical-align: middle; text-align: center">Common Stock, par value $0.001 per share (3)&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: middle; text-align: center">457(r)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: White">
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: left">Fees to Be Paid </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: center">Equity </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; vertical-align: middle; text-align: center">Preferred Stock, par value $0.001 per share (4)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: middle; text-align: center">457(r)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: left">Fees to Be Paid </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: center">Debt </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; vertical-align: middle; text-align: center">Debt Securities (5)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: middle; text-align: center">457(r)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: White">
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: left">Fees to Be Paid </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: center">Equity </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: middle; text-align: center">Warrants (6)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: middle; text-align: center">457(r)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: left">Fees to Be Paid </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: center">Equity </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; vertical-align: middle; text-align: center">Units (7)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: middle; text-align: center">457(r)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: White">
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: left">Fees to Be Paid</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: center">Unallocated (Universal) Shelf </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; vertical-align: middle; text-align: center">(1)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: middle; text-align: center">457(o)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">150,000,000&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">150,000,000</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">0.0000927</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">13,905</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font-size: 7pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="padding-left: 2pt; text-align: left; font-size: 7pt; vertical-align: middle">Primary Offering of Common Stock:</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: White">
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: left">Fees to Be Paid </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: center">Equity </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 7pt; vertical-align: middle; text-align: center">Common Stock, par value $0.001 per share</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: middle; text-align: center">457(o)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">150,000,000&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">N/A</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">150,000,000</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">0.0000927</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">13,905</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: left">Fees to Be Paid </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="padding-left: 2pt; text-align: left; font-size: 7pt; vertical-align: middle">Total Registration Fee:</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">300,000,000&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">N/A</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">300,000,000</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">27,810</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: White">
    <TD COLSPAN="40" STYLE="font-size: 7pt; vertical-align: middle; text-align: center">Carry Forward Securities &nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: left; width: 8%">Carry Forward Securities </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: top; text-align: center; width: 2%">Equity &nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: middle; text-align: center; width: 6%">Common Stock, par value $0.001 per share </TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: middle; text-align: center; width: 6%">457(b)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom; width: 8%">$136,500,000 (8)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom; width: 4%">N/A</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom; width: 1%">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right; width: 8%">136,500,000</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right; width: 7%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right; width: 6%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right; width: 3%">424</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom; width: 3%">(b)(5)</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right; width: 4%">333-254057</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right; width: 4%">March 9, 2021&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom; width: 1%">$</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom; width: 4%">14,892</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: White">
    <TD STYLE="text-align: left; font-size: 7pt; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: right; font-size: 7pt; vertical-align: middle">Total Offering&nbsp;Amounts &nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">300,000,000</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">27,810</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font-size: 7pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 7pt; vertical-align: middle; text-align: right">Total Fees Previously&nbsp;Paid&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: White">
    <TD STYLE="text-align: left; font-size: 7pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 7pt; vertical-align: middle; text-align: right">Total Fee Offsets&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">14,892</TD>
    <TD STYLE="text-align: left; font-size: 7pt; vertical-align: top">(9)&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font-size: 7pt; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: right; font-size: 7pt; vertical-align: middle">Net&nbsp;Fee&nbsp;Due&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">$</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">12,918</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 7pt; vertical-align: middle">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; font-size: 7pt; text-align: right">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>







<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The amount to be registered consists of up to $300,000,000 of an indeterminate amount of common stock, preferred stock, debt securities, warrants and/or units. There is also being registered hereunder such currently indeterminate number of (i) shares of common stock or other securities of the registrant as may be issued upon conversion of, or in exchange for, convertible or exchangeable debt securities and/or preferred stock registered hereby, or (ii) shares of preferred stock, common stock, debt securities or units as may be issued upon exercise of warrants registered hereby, as the case may be, including under any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The proposed maximum offering price per security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Including such indeterminate amount of common stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Including such indeterminate amount of preferred stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Including such indeterminate principal amount of debt securities as may be issued from time to time at indeterminate prices or upon exercise of warrants registered hereby, as the case may be.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Warrants may be sold separately or together with any of the securities registered hereby and may be exercisable for shares of common stock or preferred stock registered hereby. Because the warrants will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">(7)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Each unit will be issued under a unit agreement and will represent an interest in two or more securities registered pursuant to this registration statement, which may or may not be separable from one another. Because the units will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">(8)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The registrant previously paid a fee of $16,365 related to $150,000,000 of the registrant&rsquo;s shares of common stock that may be issued and sold under a certain sales agreement with Jefferies LLC pursuant to a prospectus supplement filed by the Registrant on March 9, 2021. Of such shares of common stock, $136,500,000 remain unsold, and the registration fee in the amount of $14,892 related thereto is applied to the registrant&rsquo;s total registration fee. Accordingly, the registrant is paying the registration fee due less the $14,892 that was previously paid, or $12,918.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">(9)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pursuant to 415(a)(6) under the Securities Act, the securities registered pursuant to this Registration Statement include unsold securities previously registered by the Registrant on the Registrant&rsquo;s Automatic Shelf Registration Statement on Form S-3 (File No. 333-254057), originally filed on March 9, 2021 (the &ldquo;Prior Registration Statement&rdquo;) and the prospectus supplement filed at the same time (the &ldquo;Prospectus Supplement&rdquo;). The Prior Registration Statement and Prospectus Supplement registered the offer and sale of up to $150,000,000 in shares of the Registrant&rsquo;s common stock, $136,500,000 of which remains unsold as the date of filing of this Amendment No. 1 to this Registration Statement. The Registrant has determined to include in this Registration Statement unsold securities under the Prior Registration Statement and Prospectus Supplement having an aggregate offering price of $136,500,000 (the &ldquo;Unsold Shelf Securities&rdquo;). Pursuant to Rule 457(b) under the Securities Act, the filing fee of $14,892 relating to the Unsold Shelf Securities under the Prior Registration Statement, which was paid under the Prior Registration Statement, will continue to be applied to the Unsold Shelf Securities registered pursuant to this Registration Statement.</FONT></TD></TR>
  </TABLE>











<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><U>Table 2: Fee Offset
Claims and Sources</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 7pt; vertical-align: bottom">
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: left; font-size: 7pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: center">Registrant <BR>or&nbsp;Filer <BR>Name</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: center">Form <BR>or <BR>Filing <BR>Type</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: center">File <BR>Number</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: center">Initial <BR>Filing <BR>Date</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: center">Filing <BR>Date</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: center">Fee&nbsp;Offset <BR>Claimed</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: center">Security <BR>Type <BR>Associated <BR>with&nbsp;Fee <BR>Offset <BR>Claimed</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: center">Security <BR>Title <BR>Associated <BR>with&nbsp;Fee <BR>Offset <BR>Claimed</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: center">Unsold <BR>Securities <BR>Associated <BR>with&nbsp;Fee <BR>Offset <BR>Claimed</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: center">Unsold <BR>Aggregate <BR>Offering <BR>Amount <BR>Associated <BR>with&nbsp;Fee <BR>Offset <BR>Claimed</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: center">Fee&nbsp;Paid <BR>with&nbsp;Fee <BR>Offset <BR>Source</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="45" STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">Rule 457(b) and 0-11(a)(2)</TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Fee Offset Claims </TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: top; width: 27%; text-align: left">Fee Offset Sources </TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 6%; text-align: center">Scholar Rock<BR>
 Holding Corporation&nbsp;&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%; text-align: center">424</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%; text-align: center">(b)(5)</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%; text-align: center">333-254057  </TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%; text-align: center">March 9, 2021 &nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 3%; font-size: 7pt; text-align: center">March 9, 2021</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">$</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%; text-align: center">14,892</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%; text-align: center">Equity &nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%; text-align: center">Common&nbsp;Stock, par value $0.001&nbsp;per</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%; text-align: center">N/A &nbsp; &nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">$</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%; text-align: center">136,500,000</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">$</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%; text-align: center">16,365</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
    <TD COLSPAN="45" STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">Rule 457(p)</TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Fee Offset </TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font-size: 7pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Claims&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 7pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 7pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD>
    <TD STYLE="vertical-align: bottom; font: 7pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 13pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt"></P>




<P STYLE="font-size: 10pt; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>lg_scholarrocknew-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_scholarrocknew-4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 6@'< P$1  (1 0,1 ?_$ -<  0 " 00# 0
M       )"@@! @8+ P0'!0$!   ' 0$               $#! 4&!P@""1
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M!]%)^[^H>O\ /]NG,!N0HT/8O7D$'LV._4[_ ,=M>V?B"\O_  >T?:JV#O\
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M-0<H\09B7BG'??6PRYEV'&<E]<%]$"6F6TN(L1+2,4%7=LVM-7<65MDK,S1
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M:E<67D>,V$Z51KMZ:1*+22_6_CH;DPL.'VPIR%WK=++BCV@]FRNO[S:(^I,
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M\E ?> 5IO#>H=Y=8IMC#'SY8S2LK0G02.(<=>PAK1_L[4"SP\=O';YB+WES
M.6_)/ROXZHL%KLFKKK*>"<$H69+%GC25.+EXU*M6<5@(AO'<)"T29BOIW4^>
MH,JYDLA'R0?CX]GL628;%=8F^_/96X#K8THS44UUK2HVT4W62;G$[_O'U)H[
M0^I.Y3"?/JK<_9_#5FMR1./$+8-V*V<E=^0_!=?=\&C91\GOCV-]]X7+:/\
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M)GA?REP*%R;PIGU9G6)6!]@2H:942966#72366]18QXEK3V3*R IF2TVOIN
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M6JI*:IBHAU]? A,)98CQF4>B$;'J?J*B223]1U_+*ZZ=SO\ Q$\5U=;6T-I
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M%6Y^W[-6 "@HMMKCV8?_ (4R7_W%;?\ L+^IT)I*T]X5)?Z64W_#=\"NK_\
M%WQWY!\J.<</X+XMLJ.ISK+49,_2V&16<ZHJVDT./W=Y9!V;6PK&<VM=7!>"
M0AI7=Z'H=;0_,1MQ/FR,'A] N%\?BK_.=5S66.>8YC34>_N'#M4P8_3S?(*I
M"5?[0.&U!7:LA6?YP1U(*O7!P"1UVZ#KJRQ9JP;&UKHV\P';^Q;%'I5UW_4N
MODX$D@T]A^U1V^;WQT^2'@M(Q"7S<S07%7GB);-3D^(V5Q=TJ;2&@+DTL^PM
M:FG<9LDL*#B6@%E;840>FVKUC+NRO*F-K0X'AK]RP+K?I+J/IN*.XS$CY(G4
MUUH!4<=JU_:K./P/^)OAS&X0Q[R8XZ?F\A<W6GXBAS.XS)BM3:<7Y$VW_P!;
M8OCU/ <=8K(DR/);E,S7%.2Y<*2TLK2E?MIQ+J*XNF7CH*_Y?AWC^G^E="^D
M_3G3?\F@R]F _(EAYG$"K'"H(''4:5[. 687S@8M8Y)\:?/C4%N6M= ,%R20
MQ!:]UQROI>0,<DS77D)V(AQ8Z2\Z?1#:"3T&J#"2BWOPXZU'AKHK]ZJ6[Y^A
M+SE!YV,<:=H'PW45?Z8GD&C:@>4O&+ST*/D2K3CG-:^.N0A,^SJ55V2TEFJ+
M'40X]%IIK$8.J3N$*G('VG5TZEBEYFO</EHM=^@=Y$VVN<:^@FYFNUWU#JZ=
MRMGI6-R"4C[1UZD$=#MK$MM.*Z,KV[K\^WF-08$B6^M#4=AIYY]UQ8;;;::8
M=<<6XXK9#: A)^HD)'VD:]QL+Y6M&_-^Q2YGL9;22N-&M82>&@77D>.3_P#M
MK^8S"KK#8KTV%D'E_9YA7NA'XA"Z''\QL<FF68++KI5$%36+?"D;A#1[U;#6
MS+I[8L2YK]_+(^I<<85L&3]1FW%F[F>+H&G#1VNHKV*=K]3-B5M9>/G &81F
M4*JL:Y3LJVS6H.J++^28V^S6**D(4VA"W*Y:2I9&RBD#<G6.=+O:+CRSQ*VA
MZZ0%V%@N:$M:[6G#4?9JLD_T]6>T63?'U1XO5O@VW'?)?(F.9#'6IL+9G6UN
MWF5>^E"%K7^&DTV3QTA:PCN>;<2 >PDTW54/+DY#KR$BA[N4+(_1V[M[CI"*
M"U(+HBX.[B7%W#A0A3L)*QMN$^@WV/3?KOMT_;K&Q0_AU 6V13E^;\2W]PW'
MUI'[#]O\R->J+Q45W0]QW&VPVW!WWW_AKR'?-2BC2O@NN_\ FZEOQ/E.\G9D
M9Q3$J%+X5DQGT[%;4EK@/B9QEQ'?](6TZV%#?IN.NMF8:-DN';$10.K4^TKB
MCUF\Z/K\36I)GJRGL8.RJYSX0?%EY"?(\CD7G;D/-+G$,;M8F1RZ/D+)HTNT
MN>1^1!$4Y5B+^*9)E8C'L%(1,G-J44!OVF I>^WBYRMOC)&PL:"T <::U*N7
M2WIYF>JVS7^3E>#RN #FEW-1H(U.NI)KI05[31<&\&_*WEOXG?,#(L1Y1I+F
M+B@O)>"\V8"XMR.'&8SJH<'-*(2@PW,<I%[2XKG:1/BAQ W4M!"^@M\M9&5A
M_>@B@T]NJI.CL_?^GO4,N.O6EL)<6N94@:Z<VV[2.( V!*[ [!,OH,\Q&BS'
M#[>!D.,Y+5P[NAN:V2B5 LJRQ91(AR(TEDK;=;4PXGJ-^H(]1K7D\)9)R.^4
M@KL>TN8KJT;=6[@]CQ4>WO[MO$+FNI2JDT1-$7A6VUV_6E/9L=P4@IVV^T;;
M;;:\R1QS-Y)6M<T]H!^* EAYFD@K"GROHO"K"<-LN3_*6'QAB.-17FXSV99*
MEJALI,XQY4R-45UK4F%?6-A-:CNK;B1W'77BCH@G;6%9?TQZ*S[W2W^.MGSN
MI5W(VIH*:FG<LHQG7_5. C#+&_N&0,K0!YH..@-?J4!M]YE_!YDMM(IZG/\
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M)ROTWGA&]<KG5^8<Y5=,MPK70Q,PQXQ5-J+P]G\4[B"K#M0AW8;/;@ :NO\
M/I-C$SF\ L*=Z78_SN9EU<"U_L\]13W5^M23>*'QK^(OAH567"7&R(&6R89@
MV&>9%9S<DS";%5M[D864YY46MC.  +;A,1D. #O"B-]6RXR-U.2":-/#@%EN
M)Z3PN'Y76D0,K1^,DEQX'4]NO!9XMM):&R?38#T2.@WV'0#TWU0CFW<:E9+H
M  !0!8I>5WACP%YE8(K ^=L/&1UD:2N?26D.<_49!C-HZCV56=%<15H>BOK:
M/:M#@=CN@#O;5L-5=K?RVVK#\O%63-=.XS/0^3?-UX.%0X'N([>*P+\:?A'\
M8/%WFK#N<L.R_EV^R/CYVYD8A5Y1EE5,HJYV]I+&AG+<C1,>KW7NZ%:N^CR-
MU[$[[#4^?(-N!L.=8SA?3ZTP]]^:%U<.@!_"YYY?A52D\E<1<><T8+>\=<IX
M?39GAF1PW*ZXQ^[CM284Z,ON&X6%I?9?1WE2'&W$K0K92"% '5.R:6)W-$X^
MQ9E>8^PRENZUR4;70G0$[T&@->VFQW4,.=_IUO!3*[R3<8M+Y:XQB2'U/?D>
M*YK&G5<;O<<<6S$7EM+D=FTRH.;=9:U]-^[<DFYQ9N9C>1[ ]U>(6 S>E^)%
MPZ:UGFBA<:\H>:5]H)VIQ63/BW\-WA'XK9/69WBN"VN<<@TLA,RGS3DF\=R>
M;2RVP W*J*Q"(..UTMM"4=LA$,R$]@V<'IJ5<9>>=G(&M9X"A5SQ?IY@<?<"
M]?S3S,U!>XNH0:U T%>^BR$Y;\%^).9/)'@[RDR>QRP<A\!L/LX;'KK.!&H)
M(=F3)A-S 76.OS%-*GN(3V.M;)/7<C?5")YF-Y*T'8K[?82ROLA'E"/WL0H/
M?59?Y)0Q\DH;C'Y:G$1;FMFU<E;*DI>3'GQG8CQ:4XEQ"7 TZ>TD'8ZD,<62
M"3B"KM<PMN+9UN?PN!'O6+GAIX8<7^$G'-SQEQ3-R>;07>:7.=3',JLX]K/%
MQ=PZN#*0Q(CPH26X:8]0UVH[20=R3JHN;DW+S(?Q&GU #[%:\)@[?!VPMK>O
ME\SCKVN))^*S!U2<5>UZ-I!9M*V?6R._V)\.1#>["E*_:DM*:<["L*2%=BSL
M2"-]>V/+'AXW!JI<L39XG0O_  .:0? J'_Q>^%#Q3\3.<,2Y^XVO.4IF8X6G
M(4U$;),GJK"G6,EQVWQJP_%PX]%#6Z4P;IY39]T=CFQ]!MJ[39J>X@_+.U"P
M#%>FN"Q&<&=MB_\ ,"O$TU%%,6WOV(W]>T;^GW?\7I_+5G\5L1U":C9%!1(Z
MCMV.X(WWUY=S4^7=>>/<HM_-/XD_%OS>S^EY0Y29S.DS&II!C\FUP6[@TSMY
M6-/%R"W<HFU5DB4[6!Q:&'!V*0TX4DD;;7>TRMQ;P>36H[%@/4_IS@NJ[@37
MW,R72KFFA^4U ^JG@LTO'#@RD\<.(,3X:QK)\ORS&\(A)J\=G9O8P;6^A4K"
M&VJ^F7/@P*]#\&K8;#4?O0IQ#0"2H@#:V2RF68EW%9AB<;!AK!F/M7.?"P4!
M<:FGBM>;O''AKR+PF9QWS5@%%GV'V3J9,BHN!(:]F8VOW&9]=/@R(=E56##A
M[DO17F7!Z;]O34^WN[J \T3B#7Z57C(X7$9B P96)DK3V\/#L]BACRO].#X1
M7MQ*L*'*>;,,@OK4M-+4YC26,2,DA(2AF3D>*W-AVM;';O?6KKU)U>?]0WE/
MQ&JU?=^C'35Q*91SLCX-#J#X+(KQQ^#SP.\=\@K\O9P:\Y1R^HD1IM7><I7I
MOHM=.B/LR&9L;':Z-38PY+2^RE86_#>*%=4=FJ2[S60G8&,<1K57[$>E_2N+
M<V<Q"61HTYR74/;3:OCVT4P,:*Q%8:CQD)::9 2VA&P2E(Z!( VZ >FK27N<
M:R:N*V"R-D;!'$*,"]A2>X;;D?R_D001J"]K$;R@\'_&KS$I(]%SSQE5Y>JL
M#PHK]+TJGR?'C(0E+HI<@J)$.RC,+* I3"E+CK4D*4V5==5UM?7%K3RW'E[%
MC^<Z;Q'4,/Y?(P,<*4YJ4=[PHD;;]-QX3RK!Z36<@<^4D5YPJ;KXF5XI+8BH
M"NX-HE6&&3+%Q("B 7G5JV]#JZ#J&](H25K:Y]"^E+DM<)96!A.@?IK334=W
M!9\>)WQ+^%OB#;1LNXZXZ<R#D.*T6F.0\^MI659)$2HH435HD>Q2T;@4@;.0
MHC#OWK.YU1766N[AI8YQ#3N%F/3W0'3?3S1^4A:Z5NSW:D'M%=BI*&&4LI*$
M*';UV "1L3U)V2 "2?4^IU:]:U<LX^0-Y&"@4/GD;\+7BOY-^1.5>2O(=YRG
M'SO+;#$K*SAT.35<&E;D87C>/XK4)AP':*4\TVY QN.I[^])6LJ/3?87:'+3
MPP&%M*'1:^RGIO@\QU S-W)>;D4.]!4"FRE^KX[<2*W&:4I26 EOZNWN':A(
M (0E*0>W8] .IU:GESG%[MSJL^CCCA;Y4?X&Z+S2&42&BTOM[21OW $=/3HH
M$;_=]VH EIJ-U[Y6N!:\5:5"1R[\#/A5RMRUD_+[K_)V#W^5Y <IF5V#9565
M%'"R%Z0)TRTJ(4^BL7*UZ=9C\4XEMP-A\E2$H]-7DYR=T(@.P"U;?>DO3EYD
M3E'/DCE+JT:X@;UV&E*\-E)#?>,>.Y1!X\CY!E&6W$WCSCG,.-XUS.EUAM,@
M@9OBM=B5W=9 ]'K&&G[UV)6I?]UE#"#(6I1000!;?.\5GTF/;-3FX CWBGPT
M7O<5^,?&G#V33,HPJOEUUC9U"JNY6[.?FHMGY%E$MY-G($M;RF93]C%+Q0P6
MHZ777%I;"EJ)E/=4\PXJ-EC8K-W[L4%/?]*+([;_ #[_ .7?7A7-?FW#!DUL
MR.DI27X[[0*B0G=;#@V)"5'8_;]H'4==1&A7E[>=A:.(753^6O$V;<&>2W-G
M&/(=8Y49)CO)>8-N!UJ0U'LX$O()TFIO*]R6W'7(K[J ^U(:6$[=KH'J-M5<
M-1&%@UPR:&5T9%:'<@E8[=5;=2H;GT0H[!/]2E!()2A/J2=@!U/349-0I0\Z
M3]W2E>S17#_T[7QY<@8%:W_FAR]C=MB"[K'9F&<-T=W&>K[6RI;AY/\ B/+I
M-;(C-2XM9,,-$>"I9'XA'N/)!;+9,HD-%#[5?L7826[2]_$:+/CY;,>?8S_B
MW*BEY,*9B4ZF+RDA,9MZ!;OS.P/=/[U3=@%$'KVC?T!U\^OU@X.Z?<VV3A:Y
MT0CIM4:./<OH)^D3,6D0N\3.YK9'2UU.M"UH^PJ) D'8#?8]/V]=ON&_J=<-
M,=<.B<0VKWD<.RNR[C#+9C) YP\N/3=3+?$YQ=;&PY$Y;E1%L5;]7&PVAD/-
MJ1^8..SXUK:.1E*V2[$C.5["5J!_K^D;D*V^@'Z2.C+ZP;==09")S&N$882*
M5J>8TJ.X+@#]5/6./ROY' 8^1DCHW2/> :T(HUM:>+J+ W]1+X5YQFSV!^6G
M'6-V.0HP[$QQYRK'J8[DN76XM M;2^QO)78L9M;KD*'8WDR/(<^HH2MLD!*2
M=?1/I?(LM[B2WEH(YA2OA0^S9?+3UHZ1ER=HS+V["YT ^?E&IX"M!7CV\%46
MBQ7[&9%KZ^/(G3ISZ(L.)#:7)?F2G"R&XT5#*7/Q,ATR$!*$%145;#KTUG/G
M6?\ V@]X7,#,9.^3R1%+6O8ZO'A3N^E17L5/AY\<L@\8O!SC/"\RKY-/F.3R
M;?DC*:J6")-79Y:(;C%;(;4E"V7X=1$BI<202E>X)W! U9G;AMW>DLV!I[B5
MW/Z;XA^%Z6BAE!;([YB#N.8-W%*[ >]2F @[[?8=C_('^W5H6>K71$VT2@6F
MP^X?R&HU*A0($I!W"0#]X W_ )ZAONHT"UT1-$6G:G??8;_?L-_Y^NG=P4*#
M?BFP'H!U]>FH4"BFP^X:BB;#[A_+1%KHB:(FB)L/NT1:$ ^H!_>-]% @'=:[
M :**>GITT1-$6A /0@$?<=*!$[4[;;#;[MAM_+2@1.T;;;#8>@V&VB;[K78>
MGV:(M-AZ;#;[M%"@0  ;  #[@ !J-2=U';9:Z@B:(FB)HB;#[M*#?BB:(FB)
MMOZ]=$6@ 'H /W :)MLA /J ?WC2J4"UT1-$HFB)HB:(M-AUZ#KZ]/7]^BA0
M+7116FP'V#1$V'KL/Y:(@ &^P W.YV'J?O/WGIHBUT1:%*5>H!_> ?\ /HH$
M [K71131$T1;%("DA))Z;;'ION/0]01N-*H-%B?Y#^"_B;Y6&&_SYP?@W(=I
M7(;:K\AM*AAC)X4=M1<3#BY+!3%NV87N'N+(?]ONV.W0:FME<T4&RII+6&5W
M,X?,OC/&GQ+?'EQ+DT7,,-\7^.49# <;?KY^05JLM%?)9<0ZS+A1,G<MH<>8
MRX@%#R6PX@^BAJ)F<X4-**6+"W!#J&H-5(<W"880E#*?;0VA*&VT!*&VT( "
M$(0A*4I2D)&PVV ]-M2'ZM(.Q!5<*:"@H%\&\BO'S#_(G I&$Y:Y+B=DINTI
M+FO$465);,,N,-S(2Y#+B=EL/N-NHZ!QM9&X.Q&O_43T_P 9Z@8;^6Y S-Y1
MH8RT._Z3'CZEF/0W6V4Z$S0RV+\MS^+9 XM(TW#7-.E-"#7?@2HX\(^)?'H%
M\)>>\GVEW1LOAV/4T-5'I94MEM9_N)\V<Y;)#:P '/9;2LI)V4@['7-^+_25
MC([LRW5W<FQYJAH=&'T['$Q4]S0M_P"2_57U)+8.MK>TLFS2#5Q;*:'M:/.^
M-1XJ6S!L,QG!,>KL5Q*L8IJ*DB-0:^OB-M,QV&4!75*&T))<6HE2E$DK4HD]
M2==;8'"V.!Q4>'Q[2VWB:!4TYCXD  ^Y<MY+)767OY,C>O+[B0U-=M>P<!W+
MDLJMB36GF)327V9"2AYIU#;C;B%;=Z%(6A22E8'U ]"-7UKW,IRZ$*W/BCE!
M;( YCMP=0L>J7PY\5\<SH\F4'CYP_2Y\0=LMJ^.\2A7B%%EJ.EQJQCU#<EEU
M#+"4I6A25 #;?4W\S/2G,5:F=/X:.?\ ,,MXO,_NCX461:(K3:.Q'<E.P  (
M  &_H -M^OKZG[=202#7<J[\K>7D&C5YTI"=]M^IWZ_N _LU!>ZUIW!;M%!-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-0
M.Q1>-?V?T_\ *_LU[;[5X=N@]3_7Z?\ )_AJD;_&/X]_9[.Y31^$;+5'JK^O
M[/Z_3[?Z=5*.X;>Q;]%Y31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31
3$T1-$31$T1-$31$T1-$31%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm228243d1-fc_summaris4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm228243d1-fc_summaris4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!@ +N P$1  (1 0,1 ?_$ 0D  0 !!0$! 0$
M       ! @4&!P@$"0,* 0$! 0$  P$! 0           0(#! 4(!@<)$
M!@$" @,'#08*$!$+  L! @,$!08' !$2""$Q$T%1%!465@EA<9$BTU24U%65
MU9;6@;'!T3(7H4)2DB-3)#08&?!R@L)SDT2$Q"4U184F-E>RTC-#PW2T=:6U
MQ4:&QF=W6.'Q8N)D978G-T=(HJ1F@X<X8[.FMB@1  $# @,$!0<(!0D$" <
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M!>\UOG&1^.Z:BM:([.I\E8,.IFL _P"^,E\<TU%#".SK#K!6HA-TB!$7)-T
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MN 2;O3IBW%QL0PEW =347+8KC&[$STD'2),[[\MM_2LR8\R-1>8VY>,F$A[
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MWFFKK$>8$B+<HD3=FZ0_D'%;5EN8>D5\V=UY\KZ)C>7Z,BY2VR;M+A:N6TO
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MD:]7IW-.)G62K7:+(@U? _EXZLQ\)(K,X]NHV4>K%1:BNF"AER&WX%/'F^D
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M+KGEEQ=;<4UF4K=AQM@3&S50T8JW1P=,6Z4;3SMNP0:.9:PIVFFU 6[PR2(
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MD-Q\8,@W "CN]0V$H<6Q=A/MM[8=-)-*H9C$Z=ML,%)7L5N(^,69NZ("\0.
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M=YV]V^HT/$%3Q9DES,,K);;F1-)*N7*<FZ^R)1U:VY*N>37.@OP-FRJA4!4
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MX,MZXGSG&WWEQHO,/9&*=1B;1B^+R9,,3O#2*4"R=P2<T\0*Z%%!1Z5HB8P
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M .=]^?\ K1Y%W+F'*M-P9BG(^9LB2K>#HF+*39K_ &Z6<G*1-E7ZI#NYJ45
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MTDW(UD'$MLSO3N:/#TWB*@6.&J=\O*%D(C%4ZP6)PP:0$=94GA&LA"&G%Y-
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MQ3]LO=J@?2\>DW#_ /-;,WK>$57[_DQI]W\G_9Q0?&OQ3]MO=J!Z7?TG _\
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M+)8[:Y";%M0LG[]O8$&#A!15;@%7VAL&414X='RK-GD[UJX!ZIM@ECJ+U?\
M5P?B]>"^:V/*];$LV<HG(ICR_P#+UFN!Y?.?"U9-BY"@4;+,=GJ/JL.MD"0N
M$SF]]::M#T:I'A3/BM%7+!_)*3KP4.'@3+Q&W^J^VWI7B1I<ART#"0C<=P"[
M5)=V Z0^ZB^M\!Z*C(;?D S=RQ/K3BB*S!?>9VV\QU<MD=&S,O1YI9#/,5F[
M'M1R85Q"0,_*P;Q.!;1DRB5%<J"1A%#M@3* S6Q9]R\[ZE(<M*R2/$UF0/\
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M<^>8Q_GB$^/ZGUWE?;[BI_ 'Q;]D/[=OZ2?P2,^>8Q_GB#^D=7Z[ROM]Q3^
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M]7+#]%Z,C@8J?**._:ICZN6'Z+U6*:AQ["L;LEEC 8E 2RX;."!TUVP]X_\
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MUC=H'#D 8OBH>>N0)UVR!&32J"SX=/4MG9]]+O+8RM/-(.+>4V[YVPWR90[
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M67$ID&KY/K#>\5HF.&;V*R&G2U#2!XT\B/&V=+)'()!3$1  'Q?M"QS/-3G
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M$6GY+@?GV0^SVK1/6X=_F5)E;.<-C1,"(?[^R/X*]J45>0R[_,A%;,0! D3
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MQYJ3/PJ'^D-704UC9O.I\O''FI,_"H?Z0TT'CV)K&S>=1Y>./-29^%0P??D
MTT%-83R\<]05.9$1V#]]0^W3ZH/QVU-*:\@5?"SLJ8H&"K2@ (;]+F-_ Z'4
M !WA:<Y*KQY*^:TI\)COC6KI&81SDGCR5\UI3X3'?&M-(S".<D\>2OFM*?"8
M[XUII&81SDGCR5\UI3X3'?&M-(S".<D\>2OFM*?"8[XUII&81SDGCR5\UI3X
M3'?&M-(S".<D\>2OFM*?"8[XUII&81SDGCR5\UI3X3'?&M-(S".<D\>2OFM*
M?"8[XUII&81SDGCR5\UI3X3'?&M-(S".<EXWEHD628*JU26,3B NY',9N B
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M:]HH*:)5%# &_P"E =;MPE.>B ]8X+P/>//\K[LY27/\[/1RT*F3$\, #W+
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M\YXVQA/0UGQ=.V6V6NJKQ$M1;!!2+F#,QEXF'.@LW.FR61,!/"$P$^^M@-(
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MOW:IR#E.8Q%/H3;:>D(]@JR;C)',W,1(I#IBE2JZ6+>NQ<M3,HZ9DZ1+"@8
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M[?I4> 6GSG;?<@&P?V9II5HGB^T>="'S"V^,FTTH^6W>GB^T!_SH;CZ\"V_
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MNPLL:X;N-_K$=@JWWE6TMKI6O W+:KVBK60G;F@%HQ=P95^@9-0BI$RBF *
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MB[R?D*,P3B?!O+3A>VV*HV?%JU@_/9EE?+N/'-+2B+DP?PD;%4\*\DY,X?J
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M-67=CN7EHG$/5))6+:R+EJ@C/MB*JJ-^T(5,P% 0*&\$G+[MMO,NUJP;?*^
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M/?\ WI_Y?5TTR36$&V5TNXC(*%$1#VP1\@ CL ![;]Q^V'K]G00D<-R>) <
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M^CD_T"FM1QVX+,MN]8+K:PFB)HB:(FB)HB:(FB)HB:(FB*Q0?^3%Q_[U&O\
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MU;4_#+CJ?>L=\2W2I^44_ML?W1^DN@.7WEJ7P?/SLTK;"6$)F))&=@6+%AV
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M0#KVU'JJU.*H!Y[43<)=P#I*!PW 0'8VX;[AU_<[NVJC593X80H *G"GN/"
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MGEH7S>GOZ97/M#II*:^E0-S+T#Y.3X]( '[+7-A$?^D.H8E43''N5W+,/S%
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M-$31$T1-$31$T1-$31$T1-$31$T1-$7+W.+TX M_<_=$"/L3;'U^D=>7R/\
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M,PR'+?0ELB.KO#Y*//I^/FR2.0(%ZRD8NY,8-O-I5Z,LB3Z.145=MFB2SD2
M"PJ!Q ($@-N0\IRYGKT#42_7GT^7>MQ/N4[EZE'>;WLMBNJ2J_,DSBH_.GC)
MDH^1R8S@X@("'0LC1VX69J%CXC]B3[%-'A'8P;& HA.*ZFW F1('K8\=U>A:
M;A?1I\E\%4Y*B-\.EDZ?*S-/GG-?M=]RC=X]&0Q_,(6&E#%I7.\3PP3.M338
MCAJU8"V:)F* =D)0VU226?<N8Y:P!I$?5<;SNZ_T;EMFS\H'+C=6>76%KQ36
MIQMGN5@)O,2;PL@!;]+5>.BHF!?S/8OTA*M&Q\&T2("/9$X4 W >G4-0VY;\
M*T=3Q'K8\5T,A&M&[(D<BD0C--N#0C< 'LRMBD[($  3";LP3]KU[[=W1=.&
MY:;H'+7@_%U'L^-*'CBM0%!NE@MEIM=3*S/(PD_/7I\M)VZ0DV4JL^1<GGGR
MYE'!!#LC"/00 Z-5R5SA9M0!C&(TDDGI.*Y>H'HG?1^XPR'5LI4CESK\+<:+
M9T+E2%0M.1)"MTNSM5%%F4S4:'*7%]1*P]CEE3&;&8QJ'@YMA( #TBU$KC'D
MN6A+7& U N,:=%?(NN,:X1QAA9K<FN+*A%4QKD&^3>3[HWBBN1)8;[9&<6PG
M+,_\+=.# ^D6<&T3."8D3V1#8NXZAQ!7DVX6X B(Q+]:^6'+_P"A6Y:ZEDKF
M)RMS#TW&W,1;,M<T^1^8>BR-@JD@F-#C+S*GF&-2>MW<T[C[0:%>*"J1=PB9
M,5#"8J93=.KJ)VV[%X5KD;4)2E<$9R,B13!U]3K!@G%-IR#C?*L]2XB2R#B%
MK/LL;698KLCVH-;3'IQ5A1B4FSM!HF24CD@1.!DS%*7\D U."\PPB9"9'K!;
M<*'"4"]X #V VT6E.B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M19IJD7=Z
M:C49HSHL58+-5XY^+%4&[L&Z\VSXQ;KF(J5)0.'H$2F#?N:ZV;DK,Q<@VH=B
M]9[W]U<M[Y]WW/=W.:OJ]Q@=)8X[BQ\BT?\ P%,)]/[KO/U@9_AAQUY?WES&
M4>P^=?B/RJ^&?;YO]Y'Z"?P%,)^^[U]86?T-I]Y<QN$>P^=/RJ^&?;YO]X/H
M)_ 4PI[[O7UA9_0VI]Y<Q_)[/2GY5?#/M\W^\'T%'\!/"GOR]?6!C]"ZOWES
M'\GO\ZGY5?#/M\W^\C]!3_ 4PG[[O7UA9_0VGWES/\GL]*OY5?#/M\W^\'T%
MM;$_+O0L-2LI,5!>PJ.I=@2.=EF))!\EX.FX(Y+V1$V+44S]J3I'<=PUQO\
M-W>8B(W-+ O0+W_P_P#!ONGX:YBYS/N\WC=N0TG7(2#/JIZHJZWOKQ5^K31$
MT1-$31%A-E_?:/>[#;V%#:W'!8EBL= -^_[ CK;+!+*!Z-%4U$31%)2\7?\
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MGU+%-NFR0+%;JR'8B"HJ<*AM;,8D,6[UJU]8A&$Q*9E*$G=R':@R&_TU7,V
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MB:(FB)HB:(FB('6'KZ(<%88/_)>XA_VI-0_X=JNL%4?-/2OG)Z-=0H\R'/\
M@'6;,X][H_=TP.P[#T#K=V)TQ/!?G/</^_<[_M?E*^QBZ7;)B0=A 1 1 W24
M=NGA,'48H]0@/6&N2_3TWKQ)QY4N/LDTDA4,)C@E^Q\9AZ>,_" %.81 .L-_
M5[FBM&XK\RQI2%X4D&J15#F46*DF!"*'/TG.8A0*!CJ   (]>_3ZFB@HOT,R
M'C(8$T>@AB&[AMAX0 !V#8Y=@Z 'J^\:M<$'>OS7BD':8MW;=HY:&_*06134
M2Z#&4+NDH10AMC"&W>Z^O1M^]!2FY5$CB)$*1)) A2H@GV8%*"8@F&R1>$I
M#9,"@ =P Z@ZM,<4P%,55X$.P"!$0.E[5'8NP%+^2 ![7<H 33I3HP51FACE
M #E3-[?<0$=P#;;8P>UZ#  ='5TAH CE?H1J!   (F4  -BEW*4!V$-]B[!T
M;[!T!]W4PJ%:&FY8E;Z! 7BMVRKSK)(S"ZUF;J,ZX: 1O)J0M@BG$-(IH/\
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MVJG%?N9EQDV.FBH.^W"H G+P=.^XF >+B'O]0]_16F2J*Q(4"[)(AL<3\/"
ME*81VXB )1 !X0U*]2@94G8]J4.-) 3 78!,4#"3<1W*F(D'AV#;I[NBM-ZG
MP'<X&$J?M!*9/K'@$HB/0'5W=OO[ZI4(&Y?@ZB&[Y,Z+QNU=(G/Q&2<(D7)N
M'Y)A*J0Q1'UP'8 #4;-.JB]3-IX*!2D*DFD1,$R))% A2D+L"92@4"@!4R
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M%!J,$/0+54?Z^?\ QG4<HP7E5HE87,!EV"BA@#8!%_(AL'>#9WJZBII"_/\
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M+9WF4([,*T3C9SRT)U6128X_2QF%A2CBJ0TDLW3>HA&%=O'Z2CTSDY5>ST<
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M68Y25;+4BX/[$I=6$E)0L;$MC)I-6[X6;%<ZBYFJBB@B%,JEW[%XXLW(6X
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MFSUA9G*U*N.LH4AK.W>-BI6IQ+FP,$'T]'SA!4AGC!!54AU$9<"CX,(@7MS
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HMIHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm228243d1-tbl_cohort14clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm228243d1-tbl_cohort14clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ X@+  P$1  (1 0,1 ?_$ .\   (!!0$! 0
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M0EQI5HJUN?H6ER5E4U:Q5)F-:S=E);7QNXC0:(J&=K;D( B [9IU*=:F9TY
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M*4!5B<9&H3EE@T'%FZP*7<H_HM;7EG"7.TRN0K6?-V7[E8)/#LK,Y$M 5DL
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M ,R*@"92AN ^VO6E5C(1LISU(D&'VF\6=MBQ2C"E'3QF/W(:24)#^=Y9:F\
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MWEWX!GLHRE4"T8@N-4I$4/BLJ@Z,C7'PSU=5>>)]UVTP#L$,';. S32%"<9
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MSH+BF( ?@.S)FE*I!Y50+1>0!:> 0O" D0T#=V[EC)S])!R4Q4%CO*"TG8[
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MC+.W$:UMULGXQ"49E*+N&DB5^JO(6:9%$.R+N$F&R#I(/YM$-27U$[5J(&4
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M?3S92GW&\5X6:L?;+-%DCB'>R/CT:V=*)D43;J.&Z9Q)N772#QG*6PFY27S
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MQ'H'K#4B28AUQ-ZJU5D7JG<?#JK#E5:BZ*G<=:=<W*8:BHO1L'@T!6W*\EE
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MM\SCAN=K79>2F:]:*Y<XBHY"\6>LE)MV@ZCUHX$G2:A%"K%.EV1E&,*=6N(
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M $ ZN(</Y(:TYO"CL&"0@ B CQV'<-]QV];3,3>H;=Z-@XCP 1Z^GUM8RQ+
M[$?B53W1 'M &P@&W#<.&^_WPTG&,PTOI^!!]H=(_(<T?J"9$RI[@7H-N(AT
M\3;[C]W3*'?>3VDN>]!9=M3V =P$NX;[[#ZWJ<=]5K3B5;PQN2%,NW9VX '
M.OI =@]01#3* %&V*@J"90V O9 0VV 1]?;COPWU06N0BT[U41,J8;%WXB':
M];KV$1';6<L1+,+U8 1BVQ5"0HCT!PZ-MPUJ1S$$W@K.5KKD 0H;[!MOT^KM
M[.L9(O*6V1M702,2,MB0%V'<-PWX\-N @/N=M_!K1 -^P@\ P2%25-\CAT%(
M4@F,   G_"$!'CMT"(< U!&(E*8^J5YQ6;65?ZN&JB-%$M51B4:*I^MHF\7H
MU$2T($@QN1VMVJDQ"&V$P;B'KAI " RQN4E\ULKTP(3;;81+N [;[?=US%&
M.87K3N&V)F#<!#;?I >/ 0'UNK70@$,;E5Y"BF)RJ"78Q V 0X<=MM_ (CI(
M"0C&5HA=N4D\CFE?<J^R #P .L/!T^MI'Y!\MBC!]Z0I%$Q#<=R /8V#H$0$
M-Q$3=.P^#8=+XRA]L[]ZW*4IRC,FV-R92%*)A .)N.X](B(@([\>OKZ=QU@4
MXB8GM"F8,<2@2@/5ZO3^MT=&N@LLV%0$Y61W9=Q'CQ]7J\&L&G"<!3E](=NU
MG]BT)RC(R!O#'J3 A0$3!N)A*!1'J[(#N' .O<=:B&J2JCZY7J"9 R@ICH
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ME<O/W_2D =.=/%<O0Z'BEW)!A'F_^T3R_P#Y+EY'[_-)ISZF/<IZ'I_%)^Q
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ML(\X(AMZ1'+^/$!]SRO7DH\!WW ?2C'H'JVX]'#I!SIFQ^Y!^$H @YI6'BI
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M^\5KZ4UBS,,/:%8_&\S"V?'#QW=F,]'-LDVN4=?!V9'3A%KW10;ILP5;=LH
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M\==+3:;2LB(B21>2YZRL_HJC1$:(C1$:(C1$:(C1%YG2(H E.7<!Z>(A]T!
M=3*"03>"Z&VQ6BD:R62%!5 #HF3,D9,QCB4Z9B]@Q3^ZW,!B\!WZM<Y482!B
M19*.4]3NH!E9MA<*P@JQ 5F)904!%M(F&CD0;L(QBD#9DR;E$1!!L@GV2))
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M"_6MQA$GYB0D*0;_ .Z& O#B([=(@4.GPB8 #U1T=8,"#M94F*0O[,Q@#\(
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MR]!3)ON"ANSN(!L81WVX#OT[  Z/;O6\CW$LJ2D(.VRW;W !#L' P#OOV=A
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MZRA$7>]3$F7$58@J@P=UMG74IW)$U9(V,>LUG:+1^S.+J,WD%5USIIH 4R9
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M&1.825@)''F;LFU)YE].L8]B9EO5JM/)H-F+"&6@%JFP<*(?T.B(M'"Y>T4
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M^@7ZU!(FKUNQY49)E40AJHUKKUV_QLW>VYY,D08?'9E:83(+KQI9)!4&*$:
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M!) Z@26ZTAJJL(B,38'[P![(A;_#8&Q57W$,[B:=&L'4 >L*1"J*T@/B)Z7
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M=BM;:\3=8:R-L9OZM)MII9P][]-[2G<@^JRX($<D9[P[J47.F7N^P8R@]L#
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MI$&P ].K?AMM6ARWZ1:H5R\14%9:JO!P#ZJ4Z?75>2;8+B#J[8X:9%B2L*F
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M7DKOL !ON([<-]^(>$-A#AIUH0]BX9RMAC-LG9++E6&L]7G;/3:Y?BX)K#.
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MX ]K1$;!X ]K1$;!X ]K1$;!X ]K1$;!X ]K1$=DO@#V@T1&P> /:#1$;!X
M_5QT1&P> ./3P_5X-$1L ]( /L:(C8/ 'M:(C8/ 'M!HB-@\ >UHB>B);!X
M]K1$;!T;!MZW@XA[0Z(C8-MM@VX<-@VX='M;:(C8/ &B(V .H.'1P#1$;!X
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M?C?+];RP>G8GK-WE6#NC2.%[W'5UE'LW*.34)&S)/8:4IS,'+9!TBV47.7M
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M*/&YGU3PE3#PK07;948\<A7@PO995 BZ8(N74534DDCJI]X4"O3)B/:$Q=8
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M!W'HW 1+N&X;#[H"AOZVLF$9L97BY4QD",EVU>X)%*7W)2@(B(;[ &P"''H
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M1V0,)S"/6([@(AV>L2[![&@#R$ZELQ=N6FD 8PLIF_>GW "'9X=D-]@#AMN
M>$.DVW$=='$;(B^]8,3(6FS8D+=/<. E'<=@#]CN/[$>D!\'K:Q<J*<1UKU[
M ]H1 " / 3;?@[].Q0ZB@(CMOT;^'2]:((-K($#!ON'AX@.EERP8%U7V1WZM
MND1WZNOAZFFQU<A=K%2'K^WN'W=$$3M*!$=NH1\ #_*U%3$LKC"?!LX#B/[[
M;?N/@'QAQ[>O ?I/6OUWXP?]>*A*0C>8*"LUO/4:%B6QUZ;L:DS'2<_EZTU6
M4[I:*BF*C9Y"LL-VEJV42<1Y]C$>JE.0Q1]SQ .XJ9-CKSZ[\?/5U^=$@!NF
MU4^.<TXAL;$V"A#_ .X*Y[_]WK6O,6_277D]&K,QJ1Z=J ><TX^Y\TV"AV 0
MW](&Y[\0VZ0Y>>K4Y^Y!^&K>.+=7ZIF><T_#?$V"@VWX^D!<]_9'T>=!7)V/
MTZE?1JI^^/3M2\;YIND,38+#;A_G W/[WH\ZO/+ME*A_#5?''IVIB\YIN #B
M;!7Y0-S'?_\ 'G4Y[_:5?1:OCCT[4O'.:8=O[TF"NOB',!<PZ./V>=]7GM]I
M4]&J^./3M3\;YIQXCB7!0_Z0%S_-YWU/,$?:GHM7QQZ=J?CG-./'S2X)X>#F
M!N>X;;_]GGU=:Y_\I3T:MXX].U4B[YIQX^:;!6W7_E 7/CU!O_D\[ZG/+_2I
MZ+5_\D>G:EXWS3;_ .";!0<0';T@;F ?]WG3GDCZ2KZ-6=\\7Z;TQ><TW#?$
MV"NO@',#<^/K[<O.ISFV%/1ZWCCT[4%=\TW5B;!8]/\ &!N?YO.AK[D]&J[9
MQZ=J/&^:4!_P2X*_*!N?#K^SSJC4;E?1:OCCT[4O&N:8> 8FP6/^D#<_S>=.
M>7^E/1JOCCT[4>.<TH\/-)@L-_!S 7/[_H]:O/L^DJ>C5?\ R1Z=JJ\;YIPX
M^:;!?1U\P%R_-YWUD5P]R>C5?''IVI \YI]N&)L%#OP !Y@;GMP]3T>=4U_Y
M2@_#5?''IVH\<YJ '<<38*V'HVY@;F/K_P 7G3GGPE3T:KXX].U('G-*'^*;
M!?Y0-T_-YVT-;<J/PU7QQZ=J8/>:;@'FFP4.W1OS W/\WG4Y[;"GHU7QQX?J
MJ1=<T^XB.)<%;;]'I W0/O<O.KS[+ 5?1JFV<>G:JO'.:81#;$N"MR]7I W,
M _[O/5J"O_*5#^'J^./3M1X[S2[[^:;!?1Q_R@+GQ]?_ ">=7GGPE/1JOCCT
M[53XYS2_1/@L>CIY@;IU?Z/.G/W)Z-5\<>G:J@=\TH[ &)<%</\ M W3]?EY
MVT-=A=TX)Z-6\<>G:F+SFF#;^]+@H!VVW]("Y_F\]6H*S[">W]%3^'J^.+]7
MZJGQSFFX?WIL%[AT#Z0%T^]Z/.VJ:S?:5GT:MXX].U'C?--L']Z;!?$!#_.!
MN?6/$>/+SJ"L_P!JOHU7QQZ=J8N^:;I\TN"O7](&Y@/_ '>=]3G[CT[$/X:M
MXX].U+QSFFX &)L%].X?Y0-TZ?R>=:YYORE3T:K=GB_3>JO'>:?B/FEP5X!'
MT@+IT^K_ )/.G/V-:KZ-5\<>G:EX[S3=6)<% /J<P%S_ #>=#7L^DIZ+6\<>
MG:GXUS3[[^:7!>XA]H&Y]'Y/6GF/Y5/1:OCCT[4O&^:8.(XFP7OZO,!<QZ/]
M'G05RWTVIZ+5_P#)'IVH%[S3?1-@L/#_ )0%SX__ (\Z<\C[5?1JOCCT[4>.
M\TW7B;!8^OS W/[WH\ZSS[?I*OHU5OKCT[4>.<TW5B7!(?Z0%S_-YU><?"6Z
MU/1JOCCP_5,'O-/T!B7!7Y0%T_-YUKGXQ*>C5O''IVI^-\TX?XIL%A_I W/\
MWK4\Q_*5!^%JC[X].U+QSFFZ\3X*'_2!N7YO.ISR=A5]&J[9QZ=J7C?-+]$V
M"?R@;E^;UJ\XX%/1JOCCT[4RN^:8.C$N"AVZ_2!N>_\ W>M.=C$IZ-5\<7ZO
MU1XYS3ATXFP4/ >GF N?1['+SJ&MN*>C5O''IVJD'G-.40_O3X+';H_R@;IM
MQ#_[>=7G./I*#\/6!?/%^F],'7--T^:;!>X\=_2!N>_'_1YUDZC=TX)Z-5\<
M>G:CQKFG#CYIL&</^T#<^'_X\ZOF/Y>G!7T:KXX].U O.:8W#S38*X[</2!N
M8=''[//7IS]R>C5?''IVH%WS3AQ\TN"PZN',#=/UN7G3G[BA_#5=DX].U+QS
MFGZ\3X,_* N8?ZO :"M_*H/P]7QQZ=J ><TP?XIL%;=?^4!<]Q]3_-YZ-7GG
MPE/1JOCCP_5!GG-,(_X)L%AZ@<P-T]C^+SISR_TE/1ZING%NF]/QSFF'8/--
M@KAL/^<#<^K_ $>=.>?"IZ-5OSQ?IO1XYS3;C_>EP5X0WY@+H(^K_%YTYQ.P
MJ^CU1;GCT[4>.<TP#OYIL%]'V@+G^;SJ"M_*GHU;QQZ=J >\TW#^]+@KA_V@
M+I^;SJFN3>"@_#51]\>G:@7O-*.W]Z;!7Y0-T_-YU!6(V=."I_#5?''IVH\<
MYIOHFP4&W#AS W/I]7_)YTY^QK5/1JOCCT[4>.\T^P_WI\%=/V@;E^;SQU><
M1]IXH?P]4_?'A^J?CO-/]$N"?R@;F'1_H\Z<^UC%/1JOCCT[4_&^:<>G$N"A
MZ_\ .!N?YO.IY@8=.">C5=LQT[4@><T_T38*X] >D#<_S>=7GM8Q=3T:KXX]
M.U'C?-.'$<38,X>'F!N?YO.H=0_VE4?AJOCCT[4O'>:;A_>GP6.W_:!NGW@Y
M>=!6M^E#^&K-_DCT[4O'.:;JQ+@H1'P\P%T'_5YUKG_RJ>C5O''IVI^.<TV^
MWFEP5ZWI 7/;A_H\ZG/PBKZ+5>V<>G:CQWFG ..)<%!QX ',#=-O^[UJ\_\
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M!6P[\ Y@;GMQ'_[>=3S!\*>C5;L\6Z;T>.<U ;!YIL%]>W^4#<_S>>K5Y_\
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K/Q-IQ3@G^)^C]7L:G%."]F_^ZI_^K>@W]+_[K^";_<_4\/J;Z;-J#L7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm228243d1-tbl_cohort24clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm228243d1-tbl_cohort24clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ T *V P$1  (1 0,1 ?_$ /P   (!!0$! 0
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MZ3@Q 2.LW4(!A,0P!%%>0?M17[V!RV%?,Y>A!9,5LTRE.H'1<?'F0IP$>8!
M>4,/8KU*(23$2B?OUGP@CWR)^^$N$&V>7?&?'D" C]?GP]G%18&2Z,&I<5U;
M4L=5!9)I1S*MCU*K2L\E;Y>.?S!H1O%,Z_.R"E754BZ*)S1A'0O2M\E13X!X
ML%E[66>C(L@1*Y%XT!N<X)$7[X2Z$ZAC<)4RJ"<""H)@RRSS$<1WM#,M,I"^
M; H*(N6P+%SS2%4@*%R3Z4>)/CX@_0@$V[WNW=BIL40D6(IH+ ]9BBX4*D@K
MWPCT:ZIC<)4D3@IPJ*&', *41$1V8>U13!ZV,MWL#EN+@!. H=,GTV:8$,H
M) <3B)"*%$=FP# /*&(ZI"]>*HC!$8(C!$8(C!$8(C!%S/'?WM5#^_ZP'_\
ML2S'%=8%Y*YYOYITJ;4SIADJ*H>H(BG:]I>_LM=2@W-3-7$A2+VKK;7OF:IA
MX:KV#4Q7#FG)5=B*#GHP,HF!P.4!$N0\9TZE#,4:E ^"B&.VQEV!/#K4ZS8Z
M_<[&Q:6O!:3\H9J<LTM2UV**T]4/)T==:UM=(6TH"\ERG=*:@J-I):;4KNUU
MRZI&E8-]2U(5KWPR,FW2;2!#';"1V51(1*.YVSI5@6'3V+E _P!RF;F]RY6>
M_DK[Y5C"TLA<B1I*81A+6ZT6-)T,VN-6CB!LK5-[I6GIBP]LZ.J%X@A-3]"V
MB7AN%LZ< FFR611.W; ":0$E><3&9HV9V4*,1MX4I2<]ZW2IT3.G"O;D1F7E
MU,?M8K*87\GQK'"[=!575%7TK5$B1SI?GG=]Y.[-PAN=9)K:"@:4@+JVLH2D
M4VIJ<JRFKKS\(]<N7:KEF5^$DJJ_276*F(>NGF,N/J4LW4 E$3J2PZ/U PBU
MS0_T#KE4I5CE:M"D3$2C"(:\B$C*^\&W7LN7MF?R7M5+Z3XBEW%"VKN3J-I_
M5/%Z@I%.X]63TO2==4W3E\)JKFMN5ZHDXV;6I:(EK<31H]1%K'BU3.HHF9,X
M&,<?G9>7!ED84S;EXB3V6X:<HE];RD#:]R]%>6/CS \5:!B-GB&Z[0RZ=UQ6
M=UEWALE:NR%C;=6?;6]J:!AV&I2DG5VIVWSKP;AVD*L:SUNZIB**F!1H^<<M
MU8Z1?"R076AB&0322%P8Q.Q,CFXU]+6]:XQA&.6-%K68=.FM?3.AF\FTHVE6
MDS!1-,2K2GH=K(TY .S/X.!=MV""*\/#O3-60NXR-.044%.A2XDR /"7<'69
M>1-ZD P8K*L96T8(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8
M(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8(C!$8
M(C!$8(C!%J*_3*XTE9BY\;:#JT+J2=#U-&V[7F9%>*B658R,.\94_)2,@V;N
MG#5G%R3A-R<2)F,()<(;1QY,[*8H$0#B1C$_NS(C(]D23V+42 \OO1!D/WHV
MQWD#L7PS2_)U7DT:T=4UPJ-O+,W7@%=#-[;(7@BJH94S3$E#-&U-SMR*2JRC
ME*+IU@_K&H6MS7\J116677?F;3*QP<"?B VLWPHY3.9<DQRG#$87N].($.IX
MRD^T#8NF5XE6O0S1 /U UXF0L9JEM3=*,6&IUC.GO0/JEJ"A*>KZ,\!K74_5
MM+Z)7Y*)IV[=S*F0N2YMA=Z@KJ5Y>.N#58P(%.U^\H6)<Q"+-$BYW?2BDX<=
M$4G#]#,^'-4A4'ZE',"?8*<XMOD%\[+&>8R$\?\ <J43'_?$ON'>LJJW\F3J
M%AX&_=#69IZR%!4[.:G&5^Z<F86>5AG=[[>N)=:9>Z?[K4X6C7T/$TE!*O5>
M]4W(S,6\,0I5V@)'. >0C%#+T,1:E6F3U3Q'KTW'4O?.H^:JYK"'K4J<7U&&
M$$@7:+6 =[5RGJ[L?<_3I92TL'=NK(:MYR1T_P"HZUU V9JJX]XIYW1MV*YK
M>6JB@:XLE*VLMTC%5/7U-P<VSI>$B%VD.#*/$B#5P5HFN.,5#.IG1EZ-M3!2
M86Z)^(ZK@=+EK768PA#+2%4?YY6^P>[0NN;>?DYKX55;F_52S4_X'W=N-IVT
MTT=9:6>UU6#60HEW2=MH^&O+34XC .FXTB:XYVG4DC(,!7?=XJG.F<ITP*;U
M9VK3YB4J;2 S<JAI_,IX0!3V"1$NT!<J+RI4H2<0Y7"^F,C*7BZQ8O53?Y-Z
M]U2/:5;5Y&6_H>U#C4C#W-G-*]'W3KBI;=VXMU#62JJWTM&TQ/2+")<2SFX=
M</T)B2C44&; HG.)@.IQB?B<S5EE*53 951"J(D-9(CPPOMPZ]=UBYY>$:.9
MD8EH@498-$<,B92U>(%O:K? _DQM1E*VQ7IBB*RC:=K"I=)=36LN6\\:]?N6
M]P+B1EZ*7JZA8J9E.E-+-:<=VLB)&F#2C7@=Q3!^**"1DP  [2G&,+ >##@5
M&TRJ1<U8=1LZ]J[&'A%)_P!0SS !\M&JW!EUQ(.T+"&OY-#5*X/4TNXM182,
MA'VI"R]WX*P#>]]QGEOHRB:%LO7E!511257JTR2>C2R\]4B!RHM6I62J9U 4
M)T/$F>3E$RRAB6E YB1.L580 A_ Q/L4$C@S5.0Q"K&A  _=-.9)G_&X&NP.
MN^[761UFZ>="56V\M8XMM(ZCY6J*]G[>TS5%;U+*6LLG3U?5C(2T/0%-U7+1
MKZ=GH*U=.O\ HXTJS5%!54@)@FF@4I,<\Q"-:G"A3L8")(O8O;UL>M* C1XL
MZA+ $@;0+!;H>]<J4]HFUFTA26GVXM%4)9%MJ"M"SU(4/6U-5C=NI*D@+KL]
M2T72CNM+ZU'<1E0T=(&N8YKZGU9!\PZMZ%9LH9!)<@='P\\]3$H2R^6E(Y>>
M0%$Z#&49Q(;<^LEW6J52H)SG6B.(,S&K';$Q8^TKH&5_)X3SJT?Y.RQ4N\AJ
MVM[IF3D&5\F[V9EH-G6;!6QU6T<DG&QS 4UI2-&X$RV6!JNJF!62>9N,Q1(;
MEFP:N>GF:7QC(SI0&CB>'AD[<0#G:@B.#4I??G7-3LE*1(_W=RX>J[0->VQ.
ME6I7#^Y\?0$L727;^F[]58I<B[%0MJ^N1;J^E*U:LE4K^GFTM6"E.5#;!LYI
ME:58H&=M(UZ9$$1;$$N/7F9TI"56$!4I\;+S$?-. PU0?PF5^@@6JPIM5@(B
M3&EG(?\ M2/Z! TRC%R-(-UK+$M*M(5WJ!M;>:V%$6^?0-D]4^LBA(">EZ#D
M;BRML*7TZ6TL_1-0W;CZ6J2Y4334ZYI>MIVE0I! 2LD&3I:5= U(9%$XXS1$
MA2R]2H1&CS%2N0=($K ?WI86'EB="X3+&I++$\Q"C2HC86M(_@)<^9@2N\JK
MT07Q8:VI34K1CJC*@M4A-V<;1]@YN?>0E,/V%+T5*TH[N,=%K%+L$Z[M2JX*
M>G&;LCI@JBLL)1;+E34#EE@8'-&O_EK&I AG_MQBW42'/>N]<CATZ%,/.$@9
MOMD3?L=<"?D[*?J5#7A9NDXYQ"UX]LE0VI>+O_>*CJCOK-+UW5=42T"RHZK+
MSL[J4Y3L'3]?2ZK-PU;,62LD[!!LH;I"LBM0'T?3R.7J8C:<GEV?]Z3MIN#^
MU8S?]^)B& S!?JP2[+R!8OLS3.A&#I;6?4^KU&YUVG[JH+=QU*$HB4NE<&3@
M&TT6I:PF)(YXA_4:]/JT2FSJ1((R![U!C&/DU72)2J+G''&A.5&$H!GD0?8_
M0+=6/'E$G[H/LTKG%WH0N>MJ/E[^,G\6UJ61UKHW.0G$:YJ1%^AIG=61@*'G
MZ+3B2$+%HNY2LF"[E>/ G1.2$15.J)B%*7C2A..6J4*DO[G,.=0K?VMPW+54
MT:QQ.U4"BW_M&W>+UQS$?DY=<\G;^2HBXQJ"<,:5TLT/IYI0]#7YJ:&D:UDZ
M&OVVN.C5]0O)RW4U%1R-04\F"+N,=L9-F[23.S<B*2P\/MSF'-"L1X>+5R\^
MS+TC [[VN=B;5@3E3G"7EG5/_P":0VZU914WY.K636M+.8JHIJU,5(2>G6R]
ML9*/MW4TY1%,LIVC=33"YM3C!QL9&-D8<AK<(F;@Y8IM4U7PBFBBBB)0+O,9
MJ.9-.I$&W-Y:IHNA"H"'U%[M-]Z\L:1RHE3A:1E,Q3[:DZ9B;=6$VZ'L56ZG
MY-#4UU%5%.VIFZ46MLRU+WPK>A;+35?/D:;C+:72H&@(>DYF)>U+2];Q=/UC
M;ZJX69=1[7O)4C \FHZ9KI.!#/YE* A3IU"X-(58-KQ5B1V@%AI9EZS*4:E2
M)N>'LMZ>Q;<A/R=UUCEU0S]P963K>O[B6!L5:VS]0J7RJ^*J:,D:5LTA0-WI
M->JVD,+2GY^JI<B><R$4Y7?($_1$TTSJ)CZL_4A4HUQ3##F@VB^-*RXV> []
MJF489FC*I>*,MMOC_,.I<^U;^3>US5%;&T\4M.VJ2<4K%W0IEW;NC:AAK?15
M!J534#"3H^[=)3$?;![23:[\"Q:BDM*1$%$+H*Y*,S)"94#^G&(YV!B;!$:#
M[+?:VQ>=C+*RCI,KWZ6KHQ/0)?5"_,/?%E/-1K9CK0MA<B0JL]Q:DZR=:<X3
M3; VVN!1RS!%)&(7?5-<F*,_=,.]R(ORD1<*'*8B:9..2KTZ=5Q_;E7S@8C_
M !&<S3B+_AE;L;8E2,ZM*I&ZJ*.7-A_R";U.S W7I7W##=BKT(P1&"(P1&"(
MP1&"(P1<S1H#X,5"'+X_&'_F)9COQK0LCXBMA6:_O0D,]_C!NK_C*JH,)*A;
M6RQE5'" \@<^X-_/B,'?2B7"'( !GV P8*N4<)>8 SY<@['8[&# 7*7WJ6*B
M,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B
M,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B
M,0AT4#)@.0[A#/++L[^WLP8(F!0 ,@Y,^0.7:/)BH+$\@_-^;+$9%3%$AAS$
M.0 YL@#/+(0V[,\55RD1$A R#;L N8@&>0<^S$8/BTJ;-"GT9 -Q 4H"(9"(
M%+F._ERSY<46!A<EE^EF0!"@.8  #NW<G-GORVX;-")\(9@.S=EN#/!@B!*4
M0R$ ]0!['+V,-+ILT% %*&X ]3\V_!+T^$!W@ []X<@[P[6(R*F*)!'/=L$/
M<@ ;^YL'%ZD0")0/Q\O)L#, RR$ 'LX&T,;DVIG2*?+/=MS#(-OK9X)?>D"1
M0-Q9CL', [.7#[&( P8)?>JN6*P1+(-^6WGY<1@B,L\&1'" \@;LMP;L6ZP(
MCA#9LW=@,1@JZ7"7//(.;<'8^I@PN43X0RRR#+FRQ5&%R * ;@ -N>X-_/B,
M%4\5$8(C!$8(C!$8(C!$8(N9XX0\&ZAV;0OXP]0=1+,/:Q="R/B*T93DUJ<9
M'JM"B*VL-%4J2XUS"1#*J[0W$J&?12\/)]10)*7B+ZTS'OEQ74-D=%@T+P9
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ML;DN-ID[MA[J9>MJ1PY>>SIV*^NY3\6X?F3\)-8_+<?3'Y![J_C)8<O+9O\
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MRS8:B&6;HU)C7 U$,8/V$)P%,]O299D'@QNTKZ S4#EC7MP@_:-OV]JR&B
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MWL!S]K$M6A&)M8)< "/O2@':#VNQ@Y4PA[@@0(&S(@;.8 'V,+4:(T!("DS
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MW*D3AV\09[@#8([\59&U3R#/, _D0V;LOKO5Q%6"1\\N7?MSSWY<G8P4*D0
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M=>LU<OEJ%.I$$XY9J(/X8G$21L[=MMR]E":F?RE[]YJ3BYNBI@+B4A::]DQ
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M/L[L\$-J Y@+D =D-FS/< [=^"!4> ?Y+U 'U=NS!UED^#_1>H >R;!TPJJ
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M2<Q(M=9%AQ#XA=V7)B&?O\@ 1 =H ;,2[A[8>KS8R&8 7"P;.I4DE\6E/+,
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M&Q4="L6D7$,&$3%Q[=-G'1D<T;1["/9I$!-)HQ9-$TVK1JDF'"5-,I2%*&0
M&-&V^UR_;KZU)2E*6*7Q+W@!,N',NW,!#+8.>68!N#+9B%S?<%D,+-!3 #%$
M!((E,(9"(9@.0![G:&>[LXR(PL8"P,++AJ&Q;XE0%P2_65:24]")3*U1)P\2
MG/.&:,<XFTXUD29<1K8ZBK:.6E2(E?+,6ZRQSD1,<4R&.(E* B.>Q8) ?> ?
M:US]6A0R) !M$;MCZM78KMV,C#S>Y#9EN'/9NP62HB0PCGEZX=T=^"RQ3X1
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M*VZ90AZ;I>'AX2FFJ+1 A7"Z>2AC+J&4,.-?>,OO$N3K)().\#<%B,1$"(
M  &P"YM36V;5TLE15)H,J=CD*8IY&/I!5HO2C%&'CTF=,KLF*T8T6IYLFV*C
M#*-8URHW3,W*F*:"AB%R*80&$/(3E;,.QTAP0=X)!V6*L,)A]PD.-!8N'ZB
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M22G+4V7M/;.:EFB["2EJ"M_2M(R4BQ7>DD5F3U[ 1+!RX9K/TB+G3.8Q3+%
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MDM9?Y?0'PS#<G%I>8;TAUQZ/0^Z6LQ\O8'VG>&Y3BTO,-X1Y\6C[TEK+_+Z
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MWI+67^7T!\+P3BTO,.Y'GQ:/?26LO\OH#X7@IQ:7F"//CT>CNU+68'__ 'V
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MV5BXYE-/'32 >0R4BG%)1+TC@7BI$T"IE/Q&*)# $$XXA3!<\"57^&,HP/\
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MYIJDK%4 ]?)<#2G8Z%D'TP$;(MFD=7$'43QP68:-R"V?MFC-44%2)%S.4H"
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M<N%GX*HVSD46:2IXH&-1.013+P*)FX3"<W"(&\?!-/(T/I]-P*3N=;RE*_\
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M_5=7TQ6,Z5P]=TK3E;TLSCE3)*0[V)K].!0J!"3:*)',[XV\ 1-/]$ I2*J
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M8U9'W<E*2F*OIZJ&<=,4^X>T5 P-/P7>\:[;*)%(W1IMHXR4Z00=I](42CD
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M9'V>^Y.3M[PR#%L4PHX#CLS-MV9<(_4P5PV6H!-0!'>';((^QB6(()\*FT!
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MG*"C*1FGX.Y./K6LZ/HB$7A>]G:2LE6KPC.&>F4.NDD>*,90#F5(8_Z&(&*
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M:-</&L<+M@T01D%D5D%R@'%UQ#BU13!C3E4D8N7(@;1%]0N&R]USE;A,6!
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M>7DGKM+1&2.IM8?I=T8/WJT*'\,.'+2UIZ[3\I[O>GU-K"]+JC,__"M#>O\
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M4>7&Y "9 N"SALM%JNH"F8!]P7(/Y$ V[Q#8(B @&,VIAZE3**:G%P  @3@
MW"!!X>D$Y2 .P<N,Q!X1'WV6S/&15C(2(^[?V*\&; M8M>PEX+45%6DS;B!K
MVDYBOJ=[X&=I"/F6+JH8CO3H =!(1B2@N6HMQ<I@<#E 2\89[\;C*$J8J@O$
MAU32E&\,MB<:8&#/+(1SR$-G#D(]K+8(=L,L02$@XN6<#&U6BH9^"I6$DJCJ
M*18PD##MCO)25D5DFK*/:)F*"KEVY5'@112XO=&$0  P!TE;%,'1:KP;HR%
M3E F_/B  $IBY\139@ @8HAM[.+UIPQJM5GF:BI^GHLLS.R3*)BA<QK(L@\7
M10:F=3+UO&Q3<%CF @K/Y%VDBD7>=10H!GGB.W4LF%IT$*[B*8#EP;0$<P$
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M<27N0X=AMHCD CM'E$,^$-F"@CH50I $,P(4 YA HCS;<RCA:F%DA NW,A0
M!R'("Y^H(86H18EF0/K"CVP* ^L&#++LI@D3F[FSFW;,'6L(41*0HAF4,MH[
M  =@AEER86E1@$RE 0]X0.SD&?;VE'$L=46ZD\BDWE#;S 7D[A>?%2P7JG^A
MB/\ 0PW_ )MF+:L^'4@.CR',N8]K+M<N(EC7)AP;@3+MV<_^=BJAM2D)"%#,
M2 ': #?ZH,2U" $@*3ZTA1'(>0,P_E<N'!T %ZB'!]<0,NP!=_< N%JEFE2
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MZ];:F:>I!Q5UQI[4!0]8L[:Z=!H-"VS>B&5K5ZBG(RD6MWD+LH2I5W+2N#7
MD)-F5JJH@<K K4(LJKCIPQ:LYSSD\O0($N8IL/\ TY1<C8-&L2M^%2&7I'Z>
M*V$\3A5)$Z,49,'VV'O70NJ2A+Q5+>"DI:UU-7+I=FWC:?"=N[992E2U[)H,
M9U1RYHR;2KG4';*CW5.I-B#D24IFJ$R)N3G1*BL4H8XQB!FJPC_8G(W:KK"3
M[]FA<^)3EEH"! JX;7.G:%E% 4[7M):BY9.AD[NNK:U14%Q)^Z#&Z5"4M!T1
M3$I+<,I!REGJX81,;4U4&FJ@5,19JLXED$F(B)S-54B%/[:,8X948!Z$;!U7
MW]:Y9@Q-"F;JDK3M/3KL6M6\W>Z>OE5+FE)R_LB^I?52VI+JM1"FATVL['-H
MRC5Z[:3[@[8KSK]LUDW:C'B<%F!?F0[V1.S!4P^:F98&B;!]G3?8N\J=",8B
M42YE3<Z&D3B'6VZSMQ5JVU>F@:L,V/?IW74C:ZY);JQ=9M8,:!CKG]\QIK:M
M=-XH($3=Q2@B_*8&:SQKU>5(7AR/ (!O11Q&M,U?[$80UV2D6L/30M2Y>->
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MWY#OS_S\% %4R^KZV7L8+2@?<;M%]D?7V8(5 A0'/, $=F\1#V,"5D!3$I0
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MW[F0L3&1OC=[4P*GGF ;>SM <\^+,!'A'V<4!HB/W0&'8J_B)%Y/M4^ ! P
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ED>'"KO[W^_"PA#&Z3/H>D#AS^NQQ.A?=&7IBD:#' ?;_ *K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm228243d1-tbl_cohort34clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm228243d1-tbl_cohort34clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ W@*R P$1  (1 0,1 ?_$ .X   (!!0$! 0
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M3RA^6TO]2-,QVIE"?A MZ4\H?EE*'[]'U,Q3*$>$"WI3RA^64K]1]5RC!'A
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MS?NBH=TJB(=Z5?Y>OFZ#\D?MT:S-IZ'BL<DFEXGQ_-QV=2]=<PJ?6F((^I!
MW-4<-A8NR^?G N:,^80QOBO'&(GSZ=A"PUTIMF8<P_ASX*YIJT49KCNP6LJL
M9+>)]4ICV04=JI%3D3NG3-(?-CB8%B>@S)U0U-*^^_W+A2IQ&EY%6PLV-G7T
M=?2^E,[)'5"L1]PDFLS:F%>A65DF&3<6K26GFL8U0F9-LUV+YNWD))-59-/8
M.P0X!U:W6R&?Y=SK-'F" YOQ,LHUA=4:(C1$:(C1$:(@1VT1(! >@?<^'IX^
M31$"(!TZ(@! >C4<(D8P%#<1X< \O3T?'JHF!@,&X=']8!_#HB>B(T1&B(T1
M&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B+CSGDH&:<M<M^0L08(<-(FZ
MY<+$8TD[8\D&[!.BX]N4LVA\E7-J"SALI(2T)1'+\S%J@(KK/CI%#LE[1@\>
MHA&J>5)Q&9 _T^+ONW[5TIRRG,+POBKS/<MG-#RIX>YDZY%7)C;\19FLG*M;
M*Y<<=F)@">JN8FF3L>XIL]185^I3,W(5^(M&.Z]"J*3+0RNZZ:HJDWX&],JF
M>5&C,Y:'U$)1.PYB2:?:;<+5F!G*K4KTP#5EIZN=]PL[ENC'G(MS0K6W';"U
M?2*I<O*^;LR2[W#$OS&V[)-@Q[BZ]<MT[C=VQE;X$JUD[46X99>JSJ$>T=N
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MD?C/>+PDCJ!(<D"53-I[2=TQ5[LI%EI!Q6<^SYK^0L[5GD8HV483(+VD<NM
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MJYL%&LKU%[;IRR4"8H=-3-&H/HZLPZ<(D4PI"\*FFH;S2KB'[>)&V9%$8N;
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MG,:5)1,*<*?Q"4WLO!@ +>OWKB(F)J"J'IC2Y8_U&1D>J]G_ )KZ0>S2Y?\
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MA&Y5V39N'<3BBPVR&EYF)1\S37?.2M*FJLZ8IIG58N3BU$RIR@<^#6C&A3U
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ML6(V#D,J64*W<0SA:YNP7W*U>Y:8G*U@I:A*U!S$CRMW21O]$E:W"R"<VZ@
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MM_?^(=$9/1$:(C1$M_?^(?V-%61O[_Q#^QHC)Z*);^_\0Z(GHB-$1HB6_O\
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MUM1S(V2"E:W8!CAF*_8Z?9)>I66'>N(A])P[LT?.PBZ97#1RNU<$ %$U#%,
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MF[%Z\CEXQ%VHDL5N4FO+3J5J<*U+*"(ZJA'L-)CQ,5QI58U(1IF^>GKEV_\
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MPWV 0W'[W'J#4 :Y4VWI>7@ @([AP'\!1#2P6!+T  !N.P (AL(]':#CP'<
MWZ=0@2OZ='*H,A=M1V0VX;   .VVVWD\O4&J[$':#9NZE+6;%(0* <!+P
M-@ZO> =& L%R&WK4?D[=7'@("'5Q#I[/'@.J++D!(NL4M@#^P'?I_%WX\./3
MY \NH0'<J ,D(\=P >/XVY1W .CW0TO#;$VN$]B@/:^#H$ Z-A >'#5^Q!>^
MU ]DV_ -]A#B'#;CUB7W=3$XJ[4PV#8>  (B/DW'C[@  ZN[!$^U[GP[AM\(
M] :B.H"3I-N&P\>OK^#5<*95(FX /0/'RB'WPT)" ,H]GY0COT#OP 1Z]^/O
M:(UKJ6P=(] \=_E=(^]MP'3J59 #M\D/?VW-T_%T:;U+;D&#R;![NW';KVV
M=M1"CAN [<3;@([ .X;=8B #MJ"(#D7LW9AU(EV.CK .CAMP\FX>_JV,!]T(
MVU&Y=]QVWZQ^4 []>X;:(SH O'APX;"  (;AU].W$>&A#AMBH<%Q84M@W, [
M<>.VVY@$0]P..K:S*$;2I" !PVZMNUMT>^/N[:@ &Q$% -@#;?HZ V#AQX^4
M-& #"P!7K0)0'R#Y. B'N]/#?ITO#&Y+4;;#L \1W$>@!'?R#MPV'5M-J$N;
M;RC<>C<HAT#Y?+U;Z*6FS8EV!-TCMU='#X-]M'492'<0[/O!OQZO@VT6MB@
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M3Q5]*TN'M]Z?JL9C_GK9D^J_EE^Q?3F2Q/%/2=+@EZJ^8^GUULR_5ARS?8P
M:O,EB5/2-+A[?>CU6<R[[^NMF7R?O7\LH\/J:U,YQ/%/2=+A[?>GZK&9!_YZ
MV9-_XKN67[&!U>9+$\4])TN'3BEZK&9?YZ^8Q_DNY9?L9#3F'$\4])TN'3BC
MU6,R_P ]?,@;AMMX7<LWX,,ZF>6)XIZ3I</;[T_58S'_ #ULR?5?RR_8OIGE
MB>*>DZ;#IQ1ZK&8_YZV9/JOY9?L7U>9+$\4])TN'3BCU6,R?SULR#_)?RR_8
MN&IS)8GBGI.EPZ<4AY6,R&Z>=;,OU7\LOX,,:HJ2&TH?VC2G9[?>@.5C,O\
M/8S)]5W++]C'EU.9+$\4])TN'3B@>5C,@_\ /7S)\.+N64?]3&J*DAM/%/2=
M+A[?>CU6,R?SU\R!_)=RR_<_<8X:<R6)XIZ3I</;[TO58S+U<Z^9O)^]ARS=
M7O89+IS#O3TG2X>WWH#E8S+_ #U\R<?+B[EE'W_X&1'4SRQ*>DZ7#V^],.5?
M,H?\]C,GU7\LW5O_ *&/=U>9+:3Q3TG2X>WWI^JQF38?^6OF3?\ BOY9>/\
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ML>9&V1:)C[EV-3X)CE8S&O2UXC[W(^,AK5!MK$$%;5EZ0J"#H)3OVBJ)@.V
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M=,YCJ&*'83.?8-*<X1U,1.XPJ?\ ]<F[^]<-2)&CX7?F4^&>+]UZY4R=@OF
MB>;#&G,7,6;'UHQY5L@VJ9DI$U5GV,_B;"<9B*[L4JPW,:\GC7GG\M*KJ.7C
M2/\ .7DB[24<)^:M4DD\"I#3U:FJJME^GJ1?K,)=P@2-_6NM:,ZM*G1H_'SJ
M9[!F!P=W X'8M@4'&DO<N67.-\DH4)G)_,M#9&R=%QCYNT!_!I6^F2<)ARIM
M%'XIIQ;^O4%6-9J&,9 R;Q5P*@E$QQ'RZAZ7[9X+*O*E-]N:;RD'O.4G+$_*
M!L7JTY@=<#)N4*H!VA@UXWBTBVTLM@Y!QK=;[CGE^PR>,<-*9).Z>OG5^DY8
MD%O4,=U]K80IA1*[!PY/=[O$QL:Z!L58AXGSTIC 42]KZ$R1J,PQ/\%X*0S:
M4 _*%2SJ1S$9VP]-O&",C'V>@YAQ95#R+=\O!1>3;0RK<M7T)I1FD?S!G;HF
MMO&(KF%(H=@4@.!U2 ;@(D4M13'BG5$<L2[>%R;;Q9:PO9=).*U&I]R&;-O<
M!GV6&Y<A85H?,;@N$=V]+#>5LG3M%Y;(''T11+A9,1)H1&0XRU0JT?0L'.X2
M;9F+B*&0%=X\?3:SR3691<:F@X<N4E$M9@(RC,R,C(B,7-A\+OL&TWB_$A=
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MT^YC")G;I,Z@\1XFZ1Z=,PE6J$?#GLZF"[$, L@UI1&B+4^:/\C&?_IYB_\
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MPLW([!?[4OQ!^QJ,JD*9!Z2%'CON( (^_OMIE#OM=^YO98AMO2%,@_C$(/
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M@$6I<7231333!,B:9"@&W8(4"EVVV     -@ /)H8B0RRM#-V(+"XLM=5"E
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M8T?S=Q1XH<S_ %8RY=1][/&51_ZL^@T\RKZQI-DNX^Y'BAS0>C#EV^O?*O\
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MEWV+^P(;:6K.6-RB/9*(;@.WO%WWX[!L&P[&][IT=TR@=20]GM"0Q!()>D!
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MKV4R*F W9[*1CF#O3=' NX@ \0#<-%.78[+TE$FP#V0X^X&V_O\ 1U:AM4
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M7J:E,CPTK)"\$0>+'?*PX]BZPT\/5--2JV4I5!&6^)FTB;[0 &PV+4MCLK^
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M7G=A3F8+F3P)%LT&%EL4;"^9S63(9O)G?UZ,DVT+,+JLMT.]>MG(IHF,4@D
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M+#FC>K*4I B1)!5/Y12F*': INR E*)NR($ >SN7H$ [0Z8[T,I,SED 8X
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M1IE<E+9!WE]#M'EKK<;+0T!,NP.J[B(Z>,T--(QPJ'%-L:2"/0*N<I.\433
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M'Y1_J]R/6"B-MAQ-S/CY?^2YGGC_ .HNVG.@IZ5JKO#^+W)>L!$=6)N9T/\
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M[1@ >=6I"0 %[KT:7]MU%.M&=1LH.Q_M'VKZ1Z\R_2+4V&^R%0D#"&W[H.5
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M(' 3<?>']C1%4T1&B(T1&B(T1&B(T1&B* G(&X";B&^_3U  C[_ =$1WA V
M3=.^W >.WP>[HB.\)P^4''W]$1WA/[;[@_L:)N1WA!$ [7$>C@/'[FB([PG]
MM]P?V-$2[TG'Y71T\!_8Z]$3[PF^W:^_Y-_)Y-$4@$#!N'$/B^X/$-$3T1&B
M+4V:  ::RW_;[B[B'3^^/5^CW=:C>LRN6V=96EQ7:'.5&>#'RN)E9QK-!F2Z
M?2![5&U%>W..I@9;LY[*_J33)HC0G$TW9EXA(D5)YMWHI)G< B&LU9//FQ^#
M=O*4HM#ER^,>Y:3Y5^;2V95M["/R;*S4& 14;CN&CT*4A]%[ID<(1:]R%ED[
MS'1RT9$V*:J+ ZD5"M7*;):/0<2 "=-XP(GVRBX8/U>_XAPLN*XYI7N;VZ]_
MX9667[XMN*U<XWS#9)1@AB>VO*"A?9##D3E;YZJB4))YC:JN8Y&IFK!ICZ:L
MX96R,U8H9A1D#0CQ,3"'FVS@>5$C4^&E:7J#_MN_L/#>NE<_2EZU@:F>RHS?
M\0X[BM/<N^<LBU7E$3YD<OLLF72U9"LE5DC5)6V4:8%)QD"_0%!@HS'R4>TK
M-?JU90?V%( 9/%SJ)D0,=1<QC";61(PH0RM.7?;LWMV6+T&FVIG2NB#4WV1!
M;V<5LHO.P_\ G]7%JN"+VCS$)69K )X55M./^VZCG=3?7PEL1R,G85*'\R%J
M<:X6,F9R5Z#I$6W<=HQ3#!4@9F+C,'LZLI/#/'_4,%P&9@2+6'?_ "/#>M<T
M'G5R%E/+E'JU<PU+0]!M&,\UVFR2DW;*NC<*A.XCRK XRF-F#>0D8J1CXQW(
M*"9)+OS.CN$3)'%-)4BF:IA#-+,6%"G5'5.,NNY@?Y(,P,:9;.:\QV1,6-PL
MMNV*6/?:"U!_-X:QFUKF5+Y+6:H8*-;KJO",575>F,SU2O6.M+6EM6(=E"N'
M81%B9OIMPP1:QS CDQDDQ(F=-+O*&:J81(=I-L%D??=:H,T:(D;3S"-[.?Y+
MS9!Y][;%XSR1;*K@^PLY6.QCEZ]XC?VNS4\]>R"?"UC:UJ^ [9PLVO-UYK"*
MR;9\B1Z5LI)M>V1$2*!L/DA.1TL) N1"C*1V_F3R_9?M=:G95G2NF\@/[(N>
MIUNQ/FW>Q&1,+XLO.+Y*G67*]9:S:[^3ME;2K<2\=N9)JA 04RLN@UO%C*2/
M*Y<,&!@=(-G2 E(L8QB%]M6F8ZN5 ?<E(=H)"YTYOIHZ@ME(!XAU0R5S?+T:
MT6)C%X=O-UI=)NN/\<73($-/4J-BJ_=\BRM0C8J*"OS<XQM$JSC6UV9.'SQL
MU422*H!4^],53N^=,PJ2A 'Q5JQI#'-%_<E>I]/3-68L$(ROL:5@_DM)/N<7
MF.;T]E8 Y>(L'SOF^-R^-V_B3700=U[Q3FJ&9XF(N2G;SZ*48FW%501:^<JB
MOW7<D$FL:4 T*)D29&))>VX2OQNV+TY#*I6B 3&-$D,UI\+7W7WV;Q:MUO>;
MIXE:!B28:O#BE-\K5W"$ADQ*P48L,QR5+2D=#R46,"I8"7!Q#P<A( W5D4F7
M=++%'N0%,05THTYZB),;Y4I3O-F1WNMV7B_VRE"1D(D;-V#]O3>M41O/,2MP
MD:*U!RGD*OP50H5TR+DM](8VC5ZW7<G9%O-"@I"1@XYS6QG'L?*4]4Z[:'CS
M"FQ$BFQE0$JGIA2.IG&G$-.I].(M9;5IB8_C_-OG4J^72QK$G+DKFVT_E5&-
MMFPV;N^J?GA/3%[9%M*)E++CF 6YA;O87BLGBV /4,=8/R!%U:WKM"%4JZ,R
MTATYI,8IH0CF6>HI=E90ZH]L?'"O$T(U@Q$CM+69\GM%S;E[C$RG(#9(0[<F
M?V%;/EN<Q)I8P0@L0WJT8Y;9$Q;B:<RHSFZ5'1D1>\J.<?A%L3U65GVMR>Q<
M/'9'C5GKUNS.0%#F22*H)%3)^FJ!3J&,OBYA@V!!R^U<I2-+3PU)MISHBH-X
M):[L?NO5HNO-%D&G\RD9ANOX]\8ZW/GKQ)/Z 1]VCKCB5*6+V'%@O,O-5Y3$
MDO6Q Q7/8"PQ$L@AV@29/#B0#^;32YM6I R^&HVVP9'Z,N]2)IRB^"P+$6=<
MA8PL5K9<WMKS3%V1Y Y&O-7J<ECK&-EH[Z@TZ] R5EL9K<OU.FLAS,E"UZR0
MB;J-FUU910KGODVQP[PY>XCEI1-_A'%@2L5)1%4"-Q%W3H%G]IYY(UJZ?JX\
MQ'D7)58@<41V:[784"QV/'%<QRZD[(Q?R:M1RBM4+DZFXUO573@L8#$CIP4H
M%*!3&+VN6;\V<;/RA G?G$C]F*GQQCELSF0!N8P(&W>0%=B\Y49)SL>,1C>[
M/\3R-PJ&,O&Q!_5$89OD*^-*^I7(DE*?3"=Z5CE'MM8-%9#YN%ND[5V$HH$4
M6)VJ PJRIMX@*ECW<LD2[XD= N=*M&4(2!L,J8Z^9E;_ (AQLVK 8CG6^CU<
MJCEQC[)E\KS:GXCM.0,FR4ICJ/<5J+RY/OJK77\M 1J\"M-/V\PU+YZC#QP$
M(V-WQ2F$.P:T(2U%"C.-]7EQ'74C BVY_&%TJF-&6HE,L*7-D;V:E*8E9:6&
M0GV+.\&YZR?E"#YBY._4$<>M,59 R;2J](PEG@[ YDV--!4>V9HH+Y%O/120
MIG%54OF+HZP "8 F8!\L:].6B&L=HO)_[95(]5X"V1(:_E /3:'43*$)&R^\
MG^:PRJ<\2"+C'4"ZQSDFR5R1;<N\%9LNR$ECYJG&3O,' 0*]$<3E<C7D1(OW
M3V5FD$90\3&D9M%5>VF0$?DD]%241J*E ?%3J\L[+<G,]F]<J4)QH4ZDR3GI
M9^SF&G[1AL68(<X4R_HB^5&>"KTXQ_.V.@0&))A&TT C_+89'O$?2*T_CH-6
M>*_I[9VYE6SL"37F9RM%P%7NCE.4)"4)B.4OG ([1(_8M3SQD8R#921WQ_C[
M[598;GUJ,EF/P<=8]OS&6AGC>M7Z:;M%)R!H5Z&JM;=+UR3?0S)VR?1U>;.B
MMG,J@N+;OQ#NRG3'O YFM3CIY:DD<L9W_P#K.4]ZWED:T8Y?$<D6LOF''\]F
MU6Q7GW791C:<F^7;+<=#6;%%QS-CE=C)4JR2%WI%3E,<QIUTX6L6"5EJ_)O$
M<E,WQV[Q(AFC!-1101.0Z1.V7E&4)6F%^U<<W,$<K^(6=.GV*UR_M(<?1AL?
ML6-&M5QE+?5&-TG&U">M+PTK56D;-+U1H]:3-80DHRT2*[R"=J S;G27*5 R
M:G8<;(CS<U9#+8)2A'_N7'J&-S6K7^V#"3YHW]_N6ULZ\Q#?"=J8R+ME>+2W
M7QVWEFU%KY:HU82KV>S#B[&L4Y(YFD6$TE9$9"_()D(>0;QWF8KBJ0%@3.'2
MB.;K/IH.^6SK\7^-ZS6F8PC(8%[?Z1]OMW+"<F<TEP<<J/-+D6LUF:Q1E[!$
M+>(M]7K$O5;4O 7*%KC.PPKEL]CG,O4K#'OHR5:.DA[9DP!7NEB$.0X!XZ]0
M4:7U8),06(V?$(]-Z]6EIRKUSIC9(V@]AD&[%AV5^9S.$;/U>,0QE?<-,'F'
M.8>WJ2%S<8=LC>Q3]!H43,U@6?T1NEX?,%HB1>&<'(LFV;N"F["@J%#N]=]3
M#)2UIMSTXPRE[ <X!;&RPN%XA5)%*439*!/X7#NM:S64>;:IX=Q]8:U;,LSV
M4;[E#%T+!U[/M2Y=8B/L,6K!2EKM->KZF&Z]%)LV=R8QIV1'KY7SE@L9-1+L
M@!P/VU,Z5+6"E9DE&J6#O^7%SVV/V-N6]-+/IQ*=LS 6[Y"R[ _Q61PG.)D7
M,&>L.$P]_>[!]HJV5Z7(M[7!$;/K+G^OXX->G-<=.'C1&?@F&'G$86)DS("F
MF^E7KU 1$\;L/+(9T]14DX'(B:=M^8N^ZP]=O4W06B+71OZQBL"M',+GC'F$
M\O1EYR;E6"YJ8?'M0N),?V.@X5)&P(2ERB:M/3N#[%7JJ:D7JH#+OU&;(D])
M2<@S 6XR )'.)C9B)R^E$P6EJ:,9MA(L1?M7'4SY<-14B?AT\I 8$7%\>/O[
MCQU:<FXWPS?[]E=#.MVFJNUG[(C5KU$X'<Y$?1L'#^>%AZPQY?&D=3Y$90[8
MX-B+&.],N<2G,4G9 .ID(TGVV^U=6)F2/A>S^'1UAU0YSE\DQ=#'&F)9;(%I
MN3*>GY2MUG(N.?-*=4*[9VU4>S\I99::BXMT\-).TBEBD0&3(<3@LBD!.T*E
M(3RU/NF+XK,WC&46\3XKV&YQ&Z=E<$D<67B+QTYN.0\:U7*!YFG.8BSY$QC'
MW60L=="KM)Y:WP[-4,>S*320=M"-%U67RA3*L@97SRJ 436B783)ZH@].M=X
MTYFIRB&+QMO^(@;-\AUK5DG[22"K[/')9O"&3D+#D>C1>68VJ,/FRQSC+$T^
ML@VKML>!5SS+ LK.NC+D0A^]*\3\U/WPIF,F0WJJ0-+43T\OCA(@]A9<*=05
M*$*X^&40>(=?2EFZ3>M&SQ(JI4G2"+A,JR2B"Q2+)E4*55!4I%45 *;Y1# !
MBCP$ '4(8LM @APO3J*HT1&B(T1&B(T1<:<VLWFV!)0Y;&C[)\/1X@]LF<LS
M6(HO"4Y;F$/&13=:*,,3FR-EF+R(2.+E9P2);JRJ@HD(D0P&$!YYI0F-H*A!
M(87K6F6<\2<^XQW)8AR6W9T^GX/N',_D2URB"C6+E*HA29!CB".N;=O'(2+*
MN7.TKNY6019H(.A;5Y5,I4P. :T9&G*K,@2,890"6&:;L1O#!OZGMM"V!&0I
MB3Y3+-9MC!LP[00W:UJ\/*3FS+%C6R&UR_)7]VO%8BQ'E2(B\D52A5.R]_;8
MVY.+B-<2QRP:Q;ZBIO8-J@P\_!27:K@J5P8Q3IB.9B<-%.)LJTHL3O$7/;LL
MPW!8A*$]3EB^64G W2+1'8VWMM6O"9]S+%4K L%!R-_OF0<SP%BYG,F3E8BJ
M/)/J)A6*5@GS^G46,N;R(IZ!S.+)%Q#0I_/GGFQ'BR:*SQ5,Y=&M&%2,)CPT
MZ J'S;.LFU^Q9$)3HYXR+U:QI@_*SDG< WXMRSG*F4,F-\B\O^5Z9ES(</RQ
MY+:U1R_?-*QAN:I3^:NQ&S+&U/>Q<S2_&N";W^1F&RSV90>JI1H$(V*B@+A1
M=OJ-/D5:NGFY,R<I)^&5[?TL#VX6+!J<ZA3U$"(QB/$&^*-V/Q.W8"ZYZ;<V
MO,CC[(?A/F!_8FTJ_&HVBS2\32:3=K-0XR(976UY)@*16<8,I=M+URR5^K(!
M"NIXJDLPCDY%VX[]7S!);$*E.-6%$!X=INOSFS+V7CBNLR>6) M5>T"VRR[L
M7>F)KK)/L[WR&:WB3NF.;OC7'>;\<'?'3<$KS*UN9J$G8F.=>:-7?T<DBP["
M1CD77;604<NRE-W?9(GG3T)@:H&<I&%>D ]K"4)V1.V+Q-NWL5K51*M0(B(P
M-*J[;3$P8D8^*^SO77Q>@.O70668)8;0GJHC1$:(C1$:(C1$:(C1%H_F&6R<
MEB.^CAD9,N3C0)R4\T,G4UI8LLHZ:D%6+0O8&IBLD@Q,J= )0#,15*4%0[.O
M/6D0S'[\!QE;_%;@QD1+X1"9[0+.^Y<@O<W7)7EYMM8JMYR+(\Q;K(C3 <>.
M5X''<)>:EDVW*Q3@!<LL80D-C>6;TJC2JMC1=1Q5VKADR$3+*'[1=>F=.,ZE
M.E,F%.;DR!NC F4CP!CLV8KG3F8B9L+ &W%AE']TB'OVJPPV7,]5/F1Q]B6Y
M3V1%3VC)]NJE=ITA2*HICVPX(IE">2S++9\LMH@;(]R"H[:-5Y1M\Y$23D'G
MF1XQ$BB#@^*%6,C4-8 3C"<F'6,H[0;.U34 ^"=(^"4ALQM:WY6/=L(6?7N<
MY@;3-<T<CB6R60U@QZ7'V+\;4BN_0,G=OY-*F7/(%Y10R W&J/[<I#3YVL9\
M[G&.01:B7L;KG$<1-3Z>54CXZI$>J-CC<;UTD8<_+%\F5VZ[NU:TG.9K)[2K
MXSQ=CHN9[[FB:R!?8;*SVUU7#D?E'&]2Q;'PUIR"H>+BV]6P@_GRL;I ,81P
MW\Y8.$I9-WL],F=%7<XRA4A5D_)A2E.6W,+(QBU]LK7%H$6^\ZD82,)U 'C&
MI$'M![K%@>6N<G,E%>US-=9</)O!UV9$=8X@95C2XJNV.O&QK-3,A)V Q6JV
M9XV]UB\L"K22#1O\UIU]NN!43N3I=IEE2J&-9G$B7!.5IF(@QVBUR;PXL9!E
MJ4QRW+Q'=:>UAMW]G04'ER=>*\O=NCLDW>>78945Y?,Z5&V4Y*BO92SVRO+2
M;*2D*8K$-#UV:K<T,8]9G:'[E6">*%.=<QP6(%.?U<8R/@Y4SN)AB,7X=2YU
M)98>$7S!WM*X=6'>OHD'7[^I![7^8KH4];41HB-$1HB-$1HB-$7'G-5:<ITA
MYA&=HU\0K5=E\_8:H-PKI:E$2[RTPU[OD3 2K16P3"KP85B$8[4  9-$GG?"
M4Q71"@8AK2E^JITR'A*-1]V6G*43_J &V]>?4F<:!,+)9X<#.(/$6+0+;-^8
MWF0YN[FOWF=&@><YCRI!AE*N5H\?(UQZ6(A!O#FT+QZEX3NP3$V663*F_3B@
MAD.Z%D8YA<ZYTH2Y>GB'E*KSC,_+R^=(<>5 ?WW+M7E/-4Y;&,)TMEPGRP1V
M9^(=]BOLU?\ -%XHO-[EG'62G-"K]#6MU8Q6Z4K4);&SE/"U>LA+U9(>-G!^
M;0D)_(J2[!)X\1?M09Q11(W4!4#Z\U2G]-I:FJC,R-9ZH?[@R1C$# '+F;$N
MO52$)ZJG2-P(C(;S(OP=GW+T\P\[FDN)\/67&6=KU2<FY/)CFC5"FUZK8=EZ
M_9[Q;T$I>8L<XK><86Z8:QU7K#.3EW:31VS0,TCC)E ISE-KV5<WUHA3^"51
MSA&$093XQ! /S&*\-!Y:,3F2XB'.TDL(_B() V/L6\\@3MJD,[X:QM 6>5@(
M9&OWG*5P!CYD1S<&]4/7:_ U)RLNT6%"(<2]H%X^!OW)U :II@8$S'*;E1B:
MDZLI%I0 DSV R>,0V#1>^\KM,B$80%N<ENRT],%Q_6,G<U,-3+34KE,9J4YA
ME&-#MLE5YFD8 GD(#%B^0F,!D^Z8&1QA"?-]U?U^%D%@:QEB7D94%4FIA8K&
M6[M?=( "E3%HSC,26.60+/@!(#8[$[EFI4:4IM("5,Y0 _BBW?XA?9=L=:ZE
M>9'FD?X<M>3*99K2YH&.;WF&OM\BVBE8LJELM*%'3J;.I.,D56PQ\&RCJDXM
MQK#%20UV+8SB_P W-NX1174,4_)HR$*M4M3G%S:8@-48!Q:)&(! ND3@NAA4
M,JE*+BI$ALOB)&0$D V$.2"]P&-JV&WYI[1D?!F=;NPMEHI&4*57K5GNC4U:
MMJQ%8:4?$$N^BGE4)9Y*$3;Y&B9^7K*K"U'*L;S1Y(G28J)HI-G)_6:?,,*<
M21^93S$6$YR) #RY2S[;77 "I#- D9I.S6BPM?B[9@]FQ?4JK3"=@KT+.(HJ
MMT9J)C9=%NN&RZ"4FR1>I(K!V2_W5(BP%-PZ0URE9J*E-W$)-W+JQ MO60:J
M(T1:GS1O]#66W3]/<7;?6/5M:A>LS^%;8UE:7/\ 3JA W_$ULIMH8_.=>L=R
MRW%S,<+APU*^CG.2K41TS46:*H+E0<I;D4 IP[:9C%'<!$!LHALOW5(D_$#:
MKRWP-BYGD"/R>TJ+)I<8N':PS%ZV7>)1[9!@P/"L7J<$1T6#^?&4 J>/1?\
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M ''51^^$1[NF6& 3G5OFEQ2\"<(C_ WB?X,>5$?\$!J&,<$YU;YY<2CP*P@
M<<-XH =]OWNZCT;_ /BC3)!K@G/K7&<GZR@,%X.]#F*/JZJ(??B-7+' )SZO
MSRXIC@O!^^W@UBGW_#NG[!_^4;\-,L< G.K?-+B@<$X0#IPYBCR?O=5$/\$=
M6IEA@%>=6/WI<2EX%8/]#F*>'^CFH_?^:.O5RQ%C!3G5OGEQ3\"\']>&L5?5
MY4!^]#B.F2& 3GUS?*3=91X%8.]#>*>O^#NH]73_ .!]9, ]@"<ZK\TN)1X%
M8/Z\-8J#^3RG^_U1'DUK+' *<^MME+B@<%X- -QPWBH-_P#1W4O<_P#]/[NI
MDC@%KG5?FEQ*7@7@\>C#>*..VV^/*CY.O^\^KEC@ISJOS2XE'@5A#;CAO%'3
MMPQU4A_P/IEC@$YU;YI<2@<%8/Z?!S%'9Z_W.ZC]T?FCAQU,L, G.K/\<N)1
MX%8/[7[S>*MMNO'=1 -]_P#Q/Y-,D, G.K?/+B4_ K!WH;Q3M_%W4?<'_P#"
M.H-7)# )SZINE)NLI>!>#A#Y.',4?#CRHAP]S^\^F2. 0UJOSRXE/P*P?OMX
M-XI]S]SJH_?^:-,D, G.K?/+B4>!.#PZ<-XH^KRHA_@C3+$[ G.J_-+B4#@K
M!_5AK%(AY?#RG[?^:-],@P#*<^MLE+BEX%80#<1PUBKWO#NH?<'YHX[:@A#
M*\ZL/O2XE/P*P> @ X;Q3N/1^YW4>@=^&WS1OOPU<L=@"<ZK\TN)2\"<(;C^
MXWBD"AMQ\.ZB/3Y?[T<-,L!L"O-K.V:7$H\"L'[[>#F*?JZJ/1[_ ,T:F6+W
M!.=6^:7$H\"\'\!'#>*1Z>C'=0\NP=,1JF,< ISJWSRXI^!>#MM_!O%(>_CN
MH?HC3)# *\ZM\\N)2\"\'>AS%''<=_#NH[" ?^2.KKTR1P"G.K?/+B4_ G!_
M7AO%/P8[J/1[G]YQWTRPP"<ZM\\N)0."L']6&\4[]/''=2 /_,^H81P"<ZK\
MTN)0&"L'_P!EAO%._N8[J7D_\3^YH(0P"<ZK\TN)0."<'AQ\&\4[?Q=U#[XQ
M&VH(Q>X(:U4??EQ*7@9@[?CAO%0?R=U ?O1&MY(X!05ZNV<N)3\"<(#Q\&\4
M;#T#X=U$1^+YGU,D< KSZOS2XE'@3A#< \&\5#[V.J@ ;>[O#Z9(X!.=6?XI
M<4_ K!_3X-8JV\OAW3]O_,_1IDC@$Y]7YY<2H!@O!X[?N.8H 1ZO#JHC]WYH
MTR1P""O5^>7%3\"<(!TX;Q3]751_1&F6. 3G5OGEQ4? K"&P?N-XI-PZL=U
M./ >N(\@Z9(8!.=7^:7$I>!>#_0YB@!\@X\J/E -Q$(?8.(ZF2. X)SJU^:7
M% X+P@' <-XG#W\>5+]#ZN2& 3G5OFEQ*?@7A .G#6*>C?ACVG[;>7C$;[:9
M88)SJ_S2XH'!6#^K#>*.G;CCNI!Y=_\ P/[FF2-S!TYU;YI<2EX%81]#>)_J
M\J77_P"1],L, G-K?-+B4>!F#?0YB@>G@&.JB \.G_P1U:9(&U@G.K?/+BI^
M!.#^K#6*A_D[J&__ )H#;4R0P"<ZK\TN)1X$X/#^!O%(>Z..ZC^A]! 8!7G5
M?FEQ* P3@\>G#>*A_DZJ0?X'U<D< ISJOSRXE1#!>#Q$0\&\4 (#L'[G=1\O
MD^9],D< @KU?FEQ*/ K"&X!X-XHX\/WNZB/'APW^: \NF2. 4Y]9_CEQ*EX$
M80W_ 'F\4[?Q=5'[_P T:9(X!7G5OGEQ*/ G!X?P-8J'WL>5#]$:98X!.=5^
M:7$I>!6#Q_@:Q4 @/7CNHCT]'_@CKTR1P"<^K\TN)0."<)=6&\4_!CNH_H@-
M#&."&M6^:7$I>!6#PX#AS%(#T[>'-1WVX\?_ +HZ.&F2. 3G5F^.7%'@7@\-
M_P!QO%([?Z.Z@'WXCCTZ98X!.=6V2EQ2\#,'[;AAK%/U>4_]$:9!M 3G5G;-
M+BF&"\'B ?N.8HW$.U^]U4>C;?\ _"/=TR0P"<ZLWQRXE'@5@_CMAS%'#IWQ
MW40\F^_]Z/=TRPP"<ZMLE+B4>!>#^D<.8HV#B/[G51#A[@_-'EU!". 5YU;Y
MY<2D."L(!_ WB?;AMOCNI!TCL ?_ '/Q$1U<D, ISJWS2XE2\"L']6&L5"/D
M\.ZB'WX<-9$ ]P3G5=DI<2GX$X1'^!K%(>X..ZA]\(CAK66& 3G5OFEQ4? K
M!X\ PWBD?>QY4 $/@&'V'3)# *<^M\TN)1X$X0#^!O%7PXZJ!ONEA]M,D, K
MSJWS2XJ7@3A ?X&L4_5U4?O?-&F6. 3G5OFEQ*B."<(A_ WBGZNJC^B=,D,
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MDB/[.B%MJ6P!\KR;B >3?IT3>@INUOPVVVZ]^GX-"$!=8/D::GJ[3;)/5AO
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M ':W#6!".HH5S5&85LN=_O9 1%^H$@+M"K"E*B8C\VB)"!^43,92;^HQB3O
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M.2L<TR>SU1H-07:M4VJJ+9G0<DIY+9ND#K@)^_D)1,$%BC\D$N)0[0 .MFC
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MI*)I4:<!;&9,NT?S':NK0VZAW#Y7RMM@'HZNK7&E$0HBG]X%6M.-2J9P#0*
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MS >/%#<QN2+V2AL4>''H#<-QWX^36R3*R2D1E'AN3^3QW#A[O]81XB/O:P
M&BJYWH'L^YM[X\?@V\FM.4)*AV0,("( )@#\8P;;!Y $!XZC1?-8ZC$AK5+@
M  &Q1VZ^UM]_CJF1)M5%@8*0;!P 2@'N!M^'1RE]ZB<O7OOL !MUC^R.J^*A
MBH]D.LP?=W^$.K4=1E4+L4!#M /7Y-+UH6*'#M;[B [C_8[AQW]W?[FFQ1K4
M#\DP#OVNO@/]6VEZ,Q4>R(CT" #UB'5JJ-:JA0[.^QM_B#[^^HM 8*0CP$/<
MZ=P\GDX:B%1)L7?CT[>3\ CJJ"Q,.D>(#OMMN(B(?<_#J;[BKNV(, ^4.GR
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm228243d1_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm228243d1_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" /T# 2(  A$! Q$!_\0
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M1=HI@.:6MKF M%)11<!:*2BBXQ:*2BBX"T4E%%P%HI**+@+12447 6BDHHN
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M>PM****KH2MQ:***104444 %%%% !1110 4444 %%%% !1110 4444 %%%%
3!1110 4444 %%%% !1113 __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
